<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:43.5pt;left:507.5pt;line-height:9.5pt"><span style="font-family:RyfdclFrutiger,serif;font-size:9.5pt;color:#346eb7">Bio</span><span style="font-family:RyfdclFrutiger,serif;font-size:9.5pt;color:#007a83">Med</span><span style="font-family:Courier,serif;font-size:9.5pt;color:#007a83"> </span><span style="font-family:RcllhrFrutiger,serif;font-size:9.5pt">Central</span></p>
<img style="position:absolute;transform:matrix(.44174669,-.0008212745,.00080919617,.4354443,689.67117,8.280304)" src="data:image/png;base64,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">
<p style="top:757.4pt;left:502.1pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 1 of 33</span></p>
<p style="top:770.1pt;left:430.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:17.6pt;left:54.3pt;line-height:20.0pt"><span style="font-family:RyfdclFrutiger,serif;font-size:20.0pt">Journal of Experimental &amp; Clinical </span></p>
<p style="top:37.7pt;left:54.3pt;line-height:20.0pt"><span style="font-family:RyfdclFrutiger,serif;font-size:20.0pt">Cancer Research</span></p>
<p style="top:85.3pt;left:501.3pt;line-height:11.5pt"><b><span style="font-family:Arial,serif;font-size:11.5pt;color:#ffffff">Open Access</span></b></p>
<p style="top:85.2pt;left:54.1pt;line-height:14.0pt"><span style="font-family:QhjywcGillSans,serif;font-size:14.0pt">Review</span></p>
<p style="top:102.9pt;left:54.1pt;line-height:16.0pt"><b><i><span style="font-family:FslmpdGillSans,serif;font-size:16.0pt">Viscum album </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:16.0pt">L. extracts in breast and gynaecological cancers: a </span></b></p>
<p style="top:120.9pt;left:54.1pt;line-height:16.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:16.0pt">systematic review of clinical and preclinical research</span></b></p>
<p style="top:139.0pt;left:54.1pt;line-height:15.0pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:15.0pt">Gunver S Kienle*</span><sup><span style="font-family:BqvvhnGiovanni,serif;font-size:10.5pt">1</span></sup><span style="font-family:BqvvhnGiovanni,serif;font-size:15.0pt">, Anja Glockmann</span><sup><span style="font-family:BqvvhnGiovanni,serif;font-size:10.5pt">1</span></sup><span style="font-family:BqvvhnGiovanni,serif;font-size:15.0pt">, Michael Schink</span><sup><span style="font-family:BqvvhnGiovanni,serif;font-size:10.5pt">2</span></sup><span style="font-family:BqvvhnGiovanni,serif;font-size:15.0pt"> and Helmut Kiene</span><sup><span style="font-family:BqvvhnGiovanni,serif;font-size:10.5pt">1</span></sup></p>
<p style="top:175.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:8.0pt">Address: </span><sup><span style="font-family:BqvvhnGiovanni,serif;font-size:5.6pt">1</span></sup><span style="font-family:BqvvhnGiovanni,serif;font-size:8.0pt">Institute for Applied Epistemology and Medical Methodology, Zechenweg 6, D-79111 Freiburg, Germany and </span><sup><span style="font-family:BqvvhnGiovanni,serif;font-size:5.6pt">2</span></sup><span style="font-family:BqvvhnGiovanni,serif;font-size:8.0pt">Verein Filderklinik e.V, </span></p>
<p style="top:184.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:8.0pt">Research Department, Im Haberschlai 7, D-70794 Filderstadt, Germany</span></p>
<p style="top:199.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:8.0pt">Email: Gunver S Kienle* - gunver.kienle@ifaemm.de; Anja Glockmann - anja.glockmann@ifaemm.de; </span></p>
<p style="top:208.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:8.0pt">Michael Schink - m.schink@filderklinik.de; Helmut Kiene - helmut.kiene@ifaemm.de</span></p>
<p style="top:220.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:8.0pt">* Corresponding author    </span></p>
<p style="top:367.5pt;left:110.8pt;line-height:10.7pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:10.7pt">Abstract</span></b></p>
<p style="top:382.5pt;left:110.8pt;line-height:9.7pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:9.7pt">Background: </span></b><i><span style="font-family:TqhvmgGillSans,serif;font-size:9.7pt">Viscum album </span></i><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">L. extracts (VAE, European mistletoe) are a widely used medicinal</span></p>
<p style="top:394.3pt;left:110.8pt;line-height:9.7pt"><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">plant extract in gynaecological and breast-cancer treatment.</span></p>
<p style="top:411.0pt;left:110.8pt;line-height:9.7pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:9.7pt">Methods: </span></b><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">Systematic review to evaluate clinical studies and preclinical research on the therapeutic</span></p>
<p style="top:422.8pt;left:110.8pt;line-height:9.7pt"><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">effectiveness and biological effects of VAE on gynaecological and breast cancer. Search of databases,</span></p>
<p style="top:434.5pt;left:110.8pt;line-height:9.7pt"><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">reference lists and expert consultations. Criteria-based assessment of methodological study quality.</span></p>
<p style="top:451.3pt;left:110.8pt;line-height:9.7pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:9.7pt">Results: </span></b><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">19 randomized (RCT), 16 non-randomized (non-RCT) controlled studies, and 11 single-</span></p>
<p style="top:463.0pt;left:110.8pt;line-height:9.7pt"><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">arm cohort studies were identified that investigated VAE treatment of breast or gynaecological</span></p>
<p style="top:474.8pt;left:110.8pt;line-height:9.7pt"><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">cancer. They included 2420, 6399 and 1130 patients respectively. 8 RCTs and 8 non-RCTs were</span></p>
<p style="top:486.6pt;left:110.8pt;line-height:9.7pt"><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">embedded in the same large epidemiological cohort study. 9 RCTs and 13 non-RCTs assessed</span></p>
<p style="top:498.3pt;left:110.8pt;line-height:9.7pt"><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">survival; 12 reported a statistically significant benefit, the others either a trend or no difference. 3</span></p>
<p style="top:510.0pt;left:110.8pt;line-height:9.7pt"><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">RCTs and 6 non-RCTs assessed tumour behaviour (remission or time to relapse); 3 reported</span></p>
<p style="top:521.8pt;left:110.8pt;line-height:9.7pt"><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">statistically significant benefit, the others either a trend, no difference or mixed results. Quality of</span></p>
<p style="top:533.5pt;left:110.8pt;line-height:9.7pt"><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">life (QoL) and tolerability of chemotherapy, radiotherapy or surgery was assessed in 15 RCTs and</span></p>
<p style="top:545.3pt;left:110.8pt;line-height:9.7pt"><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">9 non-RCTs. 21 reported a statistically significant positive result, the others either a trend, no</span></p>
<p style="top:557.1pt;left:110.8pt;line-height:9.7pt"><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">difference, or mixed results. Methodological quality of the studies differed substantially; some had</span></p>
<p style="top:568.8pt;left:110.8pt;line-height:9.7pt"><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">major limitations, especially RCTs on survival and tumour behaviour had very small sample sizes.</span></p>
<p style="top:580.5pt;left:110.8pt;line-height:9.7pt"><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">Some recent studies, however, especially on QoL were reasonably well conducted. Single-arm</span></p>
<p style="top:592.3pt;left:110.8pt;line-height:9.7pt"><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">cohort studies investigated tumour behaviour, QoL, pharmacokinetics and safety of VAE. Tumour</span></p>
<p style="top:604.0pt;left:110.8pt;line-height:9.7pt"><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">remission was observed after high dosage and local application. VAE application was well tolerated.</span></p>
<p style="top:615.8pt;left:110.8pt;line-height:9.7pt"><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">34 animal experiments investigated VAE and isolated or recombinant compounds in various breast</span></p>
<p style="top:627.6pt;left:110.8pt;line-height:9.7pt"><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">and gynaecological cancer models in mice and rats. VAE showed increase of survival and tumour</span></p>
<p style="top:639.3pt;left:110.8pt;line-height:9.7pt"><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">remission especially in mice, while application in rats as well as application of VAE compounds had</span></p>
<p style="top:651.0pt;left:110.8pt;line-height:9.7pt"><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">mixed results. </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:9.7pt">In vitro </span></i><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">VAE and its compounds have strong cytotoxic effects on cancer cells.</span></p>
<p style="top:667.8pt;left:110.8pt;line-height:9.7pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:9.7pt">Conclusion: </span></b><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">VAE shows some positive effects in breast and gynaecological cancer. More research</span></p>
<p style="top:679.5pt;left:110.8pt;line-height:9.7pt"><span style="font-family:DdhngrGillSans,serif;font-size:9.7pt">into clinical efficacy is warranted.</span></p>
<p style="top:262.3pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Published: 11 June 2009</span></p>
<p style="top:276.6pt;left:54.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2009, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">28</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">:79</span></p>
<p style="top:276.6pt;left:257.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">doi:10.1186/1756-9966-28-79</span></p>
<p style="top:262.3pt;left:373.5pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Received: 6 March 2009</span></p>
<p style="top:271.8pt;left:373.5pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Accepted: 11 June 2009</span></p>
<p style="top:290.7pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">This article is available from: http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:305.1pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">&#xa9; 2009 Kienle et al; licensee BioMed Central Ltd. </span></p>
<p style="top:314.6pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), </span></p>
<p style="top:324.1pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</span></p>


<p style="top:41.9pt;left:54.1pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:41.9pt;left:405.7pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:757.4pt;left:502.1pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 2 of 33</span></p>
<p style="top:770.1pt;left:430.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:85.6pt;left:54.1pt;line-height:10.7pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:10.7pt">Background</span></b></p>
<p style="top:97.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Breast and gynaecological cancers (i.e. ovarian, endome-</span></p>
<p style="top:109.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">trial, cervical, vaginal, vulval, and fallopian cancers)</span></p>
<p style="top:121.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">account for a significant amount of morbidity and mortal-</span></p>
<p style="top:132.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ity in women. In Europe an estimated 429,900 cases were</span></p>
<p style="top:144.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">diagnosed as breast cancer in 2006 (13.5% of all cancer</span></p>
<p style="top:156.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">cases) and 131,900 died from it, despite substantially</span></p>
<p style="top:168.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">improved treatment options (surgery, chemotherapy,</span></p>
<p style="top:179.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">radiation, hormonal and targeted therapies) [1]. Of</span></p>
<p style="top:191.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">female cancer survivors more than half had suffered from</span></p>
<p style="top:203.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">breast or gynaecological cancer [2].</span></p>
<p style="top:226.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">40% to 80% of these patients use complementary thera-</span></p>
<p style="top:238.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">pies additionally to well-established treatments [3-8].</span></p>
<p style="top:250.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">This includes a variety of medicinal plants, but also acu-</span></p>
<p style="top:262.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">puncture, psychosocial support, yoga, art therapies and</span></p>
<p style="top:273.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">others. These are supportive measures to control symp-</span></p>
<p style="top:285.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">toms, improve quality of life, boost the immune system,</span></p>
<p style="top:297.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and possibly prolong life. Sufficient evaluation is often</span></p>
<p style="top:309.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">lacking, however, of the extent to which these therapeutic</span></p>
<p style="top:320.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">goals are achieved, as well as of issues relating to safety</span></p>
<p style="top:332.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and mode of action. Medicinal plants in particular have a</span></p>
<p style="top:344.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">long history in the treatment of cancer and other condi-</span></p>
<p style="top:356.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">tions connected with tumours, and also play a major role</span></p>
<p style="top:367.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">in the development of new drugs today. Over 60% of cur-</span></p>
<p style="top:379.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">rently used anti-cancer agents originally derive from natu-</span></p>
<p style="top:391.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ral sources such as plants, marine organisms and micro-</span></p>
<p style="top:403.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">organisms [9].</span></p>
<p style="top:426.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Across Europe, </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Viscum album </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">L. extracts (VAE or European</span></p>
<p style="top:438.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">mistletoe, not to be confused with the </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Phoradendron </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">spe-</span></p>
<p style="top:450.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">cies or &quot;American mistletoe&quot;) are among the most com-</span></p>
<p style="top:461.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">mon herbal extracts applied in cancer treatment</span></p>
<p style="top:473.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">[3,7,8,10]. </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Viscum album </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">is a hemi-parasitic shrub and</span></p>
<p style="top:485.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">contains a variety of biologically active compounds. Mis-</span></p>
<p style="top:497.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">tletoe lectins (ML I, II and III) have been most thoroughly</span></p>
<p style="top:508.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">investigated. MLs consist of two polypeptide chains: a car-</span></p>
<p style="top:520.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">bohydrate-binding B-chain that can bind on cell surface</span></p>
<p style="top:532.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">receptors, which enables the protein to enter the cell [11-</span></p>
<p style="top:544.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">13]; and the catalytic A-chain which can subsequently</span></p>
<p style="top:555.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">inhibit protein synthesis, due to its ribosome-inactivating</span></p>
<p style="top:567.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">properties, by removing an adenine residue from the 28S</span></p>
<p style="top:579.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">RNA of the 60S subunit of the ribosome [11]. Other phar-</span></p>
<p style="top:591.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">macologically relevant VAE compounds are viscotoxins</span></p>
<p style="top:602.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and other low molecular proteins, VisalbCBA (</span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Viscum</span></i></p>
<p style="top:614.5pt;left:54.1pt;line-height:9.7pt"><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">album </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">chitin-binding agglutinin) [14], oligo- and polysac-</span></p>
<p style="top:626.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">charids [15,16], flavonoids [17], vesicles [18], triterpene</span></p>
<p style="top:638.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">acids [19], and others [20,21]. Whole VAE as well as sev-</span></p>
<p style="top:649.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">eral of the compounds are cytotoxic and the MLs in partic-</span></p>
<p style="top:661.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ular have strong apoptosis-inducing effects [22-24]. MLs</span></p>
<p style="top:673.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">also display cytotoxic effects on multidrug-resistant cancer</span></p>
<p style="top:685.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">cells (e.g. </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">MDR</span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">+ colon cancer cells [25]) and enhance</span></p>
<p style="top:696.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">cytotoxicity of anticancer drugs [26,27]. In mononuclear</span></p>
<p style="top:708.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">cells VAE also possess DNA-stabilizing properties. VAE</span></p>
<p style="top:720.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and its compounds stimulate the immune system (</span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">in vivo</span></i></p>
<p style="top:85.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">in vitro </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">activation of monocytes/macrophages, granu-</span></p>
<p style="top:97.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">locytes, natural killer (NK) cells, T-cells, dendritic cells,</span></p>
<p style="top:109.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">induction of a variety of cytokines such as IL-1, IL-2, IL-4,</span></p>
<p style="top:121.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">IL-5, IL-6, IL-8, IL-10, IL-12, GM-CSF, TNF-</span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:9.7pt">&#x3b1;</span><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">, IFN-</span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:9.7pt">&#x3b3;</span><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt"> (over-</span></p>
<p style="top:132.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">view see [20,21]). The cytotoxicity of human natural and</span></p>
<p style="top:144.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">lymphokine-activated killer cells, for instance, can be</span></p>
<p style="top:156.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">markedly enhanced </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">in vitro </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">by VAE rhamnogalacturonans,</span></p>
<p style="top:168.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">which bridge these killer cells with NK-sensitive or insen-</span></p>
<p style="top:179.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">sitive tumour cells [28,29]. Furthermore, VAE seem to</span></p>
<p style="top:191.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">interfere with tumoural angiogenesis [30,31]. Injected</span></p>
<p style="top:203.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">into tumour-bearing animals, VAE and several of their</span></p>
<p style="top:215.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">compounds (MLs, a 5 kDa protein not specified further,</span></p>
<p style="top:226.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">protein complexes isolated by Vester and colleagues, oli-</span></p>
<p style="top:238.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">gosaccharids) display growth-inhibiting and tumour-</span></p>
<p style="top:250.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">reducing effects [20,21]. Despite extensive experimental</span></p>
<p style="top:262.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">analyses of their biological properties, many questions</span></p>
<p style="top:273.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">regarding the precise mode of action of VAE still remain.</span></p>
<p style="top:297.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">For clinical application VAE are made from mistletoes</span></p>
<p style="top:309.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">grown on different host trees [Host trees of VAE: Fir (</span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Abies</span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">,</span></p>
<p style="top:320.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">A); maple (</span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Acer</span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">, Ac); almond tree (</span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Amygdalus</span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">, Am); birch</span></p>
<p style="top:332.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(</span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Betula</span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">, B); whitethorn (</span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Crataegus</span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">, C); ash tree (</span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Fraxinus</span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">,</span></p>
<p style="top:344.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">F); appletree (</span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Malus</span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">, M); pine (</span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Pinus</span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">, P); poplar (</span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Populus</span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">,</span></p>
<p style="top:356.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Po); oak (</span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Quercus</span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">, Qu); willow (</span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Salix</span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">, S); lime (</span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Tilia</span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">, T),</span></p>
<p style="top:367.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">elm (</span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Ulmus</span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">, U)], either by aqueous extraction, partly com-</span></p>
<p style="top:379.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">bined with fermentation, or by pressing procedures.</span></p>
<p style="top:391.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Depending on host tree, harvesting time and extraction</span></p>
<p style="top:403.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">procedure, VAE vary in regard to their active compounds</span></p>
<p style="top:414.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and biological properties. Different commercial VAE</span></p>
<p style="top:426.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">preparations are available, and a recombinant ML (rML)</span></p>
<p style="top:438.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">drug is currently being developed and tested in clinical tri-</span></p>
<p style="top:450.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">als [32,33].</span></p>
<p style="top:473.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Clinical effects of VAE in cancer have been investigated in</span></p>
<p style="top:485.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">a variety of studies and assessed in systematic reviews [34-</span></p>
<p style="top:497.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">39]. These reviews, however, had inconsistent results, they</span></p>
<p style="top:508.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">are outdated, incomplete or concentrate on partial</span></p>
<p style="top:520.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">aspects. No review has yet assessed clinical and preclinical</span></p>
<p style="top:532.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">effects specifically and comprehensively for breast and</span></p>
<p style="top:544.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">gynaecological cancer, although there is widespread usage</span></p>
<p style="top:555.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">in these patients [3,7]. Our primary aim was therefore to</span></p>
<p style="top:567.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">assess the potential therapeutic effectiveness of VAE, and</span></p>
<p style="top:579.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">their potential biological effects on breast and gynaeco-</span></p>
<p style="top:591.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">logical cancer in clinical and preclinical studies.</span></p>
<p style="top:614.3pt;left:312.1pt;line-height:10.7pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:10.7pt">Methods</span></b></p>
<p style="top:626.3pt;left:312.1pt;line-height:9.5pt"><b><i><span style="font-family:FslmpdGillSans,serif;font-size:9.5pt">Design</span></i></b></p>
<p style="top:638.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Systematic review of clinical and preclinical studies inves-</span></p>
<p style="top:649.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">tigating the influence of VAE on breast or gynaecological</span></p>
<p style="top:661.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">cancer.</span></p>
<p style="top:685.1pt;left:312.1pt;line-height:9.5pt"><b><i><span style="font-family:FslmpdGillSans,serif;font-size:9.5pt">Search strategy</span></i></b></p>
<p style="top:696.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">We used a systematic process to search the following data-</span></p>
<p style="top:708.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">bases for clinical trials &#x2013; AMED, Biosis Previews, Cochrane</span></p>
<p style="top:720.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Library (Cochrane Database of Systematic Reviews,</span></p>


<p style="top:41.9pt;left:54.1pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:41.9pt;left:405.7pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:757.4pt;left:502.1pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 3 of 33</span></p>
<p style="top:770.1pt;left:430.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:85.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Cochrane Controlled Trials Register, The NHS Economic</span></p>
<p style="top:97.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Evaluation Database, Health Technology Assessment</span></p>
<p style="top:109.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Database), Embase, Medline/Premedline, NLM Gateway,</span></p>
<p style="top:121.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">private databases &#x2013; from inception of these databases to</span></p>
<p style="top:132.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">December 2008 using the terms (MISTLETOE OR VIS-</span></p>
<p style="top:144.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">CUM? OR MISTEL? OR ISCADOR? OR ISCAR OR</span></p>
<p style="top:156.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">HELIXOR OR ABNOBA? OR ISCUCIN OR ISOREL OR</span></p>
<p style="top:168.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">VISOREL OR ?SOREL OR WELEDA OR WALA OR</span></p>
<p style="top:179.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">EURIXOR OR LEKTINOL OR PLENOSOL OR AVISCU-</span></p>
<p style="top:191.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">MINE) AND (STUDY? OR STUDIE? OR TRIAL OR EVAL-</span></p>
<p style="top:203.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">UAT? OR RANDOM? OR INVESTIG? OR COHORT? OR</span></p>
<p style="top:215.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">KOHORT? OR OUTCOME?). The reference list from each</span></p>
<p style="top:226.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">potentially eligible study, relevant review article and text-</span></p>
<p style="top:238.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">book was checked, and experts in the field and manufac-</span></p>
<p style="top:250.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">turers of mistletoe preparations were contacted for</span></p>
<p style="top:262.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">additional reports.</span></p>
<p style="top:285.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Regarding </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">in vitro </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">or </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">in vivo </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(animal) experiments on anti-</span></p>
<p style="top:297.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">cancer effects, we checked title and abstract, and, where</span></p>
<p style="top:309.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">necessary, the whole article of each VAE-related reference</span></p>
<p style="top:320.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">in the databases (Medline/Pubmed and comprehensive</span></p>
<p style="top:332.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">private databases, using above mentioned terms but with-</span></p>
<p style="top:344.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">out restriction to clinical studies) and in major surveys.</span></p>
<p style="top:367.8pt;left:54.1pt;line-height:9.5pt"><b><i><span style="font-family:FslmpdGillSans,serif;font-size:9.5pt">Selection</span></i></b></p>
<p style="top:379.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">The following selection criteria were used for inclusion of</span></p>
<p style="top:391.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">studies in the analysis: (I) prospective randomized or</span></p>
<p style="top:403.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">non-randomized controlled clinical trial, or prospective</span></p>
<p style="top:414.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">single-arm cohort study (e.g. phase II trial) or pharmaco-</span></p>
<p style="top:426.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">epidemiological cohort study; (II) study population with</span></p>
<p style="top:438.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">breast or gynaecological cancer, i.e. ovary, uterus, cervix,</span></p>
<p style="top:450.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">genital cancer, or cervical intraepithelial neoplasm (CIN);</span></p>
<p style="top:461.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(III) intervention group treated with VAE preparation;</span></p>
<p style="top:473.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(IV) clinically relevant outcome (i.e. survival, disease-free</span></p>
<p style="top:485.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">interval, remission, relapse, QoL, or reduction of side</span></p>
<p style="top:497.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">effects or immune suppression during cytoreductive ther-</span></p>
<p style="top:508.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">apy); (V) completion of study; (VI) published or unpub-</span></p>
<p style="top:520.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">lished. Studies were excluded if they: only measured</span></p>
<p style="top:532.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">toxicity or tolerability (phase I trial), only measured stim-</span></p>
<p style="top:544.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ulation of immunological parameters, were not con-</span></p>
<p style="top:555.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ducted on cancer patients, or had a retrospective design</span></p>
<p style="top:567.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(except pharmaco-epidemiological cohort studies). There</span></p>
<p style="top:579.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">were no restrictions on language.</span></p>
<p style="top:602.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">For </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">in vitro </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and animal experiments the criteria were</span></p>
<p style="top:614.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">adapted accordingly; unpublished material was not</span></p>
<p style="top:626.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">included however. </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">In vitro </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">experiments were restricted to</span></p>
<p style="top:638.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">cancer cells originating from human tumours.</span></p>
<p style="top:661.5pt;left:54.1pt;line-height:9.5pt"><b><i><span style="font-family:FslmpdGillSans,serif;font-size:9.5pt">Validity assessment and data abstraction</span></i></b></p>
<p style="top:673.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Criteria-based analysis was performed on the selected</span></p>
<p style="top:685.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">clinical studies to assess their methodological quality.</span></p>
<p style="top:696.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Analyses were performed independently by two reviewers</span></p>
<p style="top:708.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(GK, HK). There were no major differences in study assess-</span></p>
<p style="top:720.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ment; disagreements were resolved by discussion. Criteria</span></p>
<p style="top:85.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">for assessing strength of evidence in controlled trials were</span></p>
<p style="top:97.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">adapted from the National Health Service Centre for</span></p>
<p style="top:109.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Reviews and Dissemination [40] and from criteria for</span></p>
<p style="top:121.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">good methodology as already applied in earlier reviews</span></p>
<p style="top:132.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">on VAE trials [34,36,41]. Quality criteria were adjusted for</span></p>
<p style="top:144.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">cohort studies [36]. Data were abstracted by one reviewer</span></p>
<p style="top:156.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(GK) and checked by a second reviewer (AG). When nec-</span></p>
<p style="top:168.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">essary, primary authors of the trials were contacted for</span></p>
<p style="top:179.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">additional information.</span></p>
<p style="top:203.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Regarding animal experiments we extracted data on study</span></p>
<p style="top:215.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">size, animal model, tumour type, tumour transfer, inter-</span></p>
<p style="top:226.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">vention, treatment schedule, outcome, physiological</span></p>
<p style="top:238.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">monitoring, side effects, dose-response, randomization,</span></p>
<p style="top:250.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">control treatment, blinding of outcome assessment, pub-</span></p>
<p style="top:262.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">lication in a peer-reviewed journal, and funding source.</span></p>
<p style="top:285.3pt;left:312.1pt;line-height:10.7pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:10.7pt">Results</span></b></p>
<p style="top:297.3pt;left:312.1pt;line-height:9.5pt"><b><i><span style="font-family:FslmpdGillSans,serif;font-size:9.5pt">Result of literature search</span></i></b></p>
<p style="top:309.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">The literature search identified 306 references describing</span></p>
<p style="top:320.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">potential clinical studies (after deletion of duplicates).</span></p>
<p style="top:332.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">After deleting references only describing studies on</span></p>
<p style="top:344.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">immune modulation or toxicity or tolerability (phase I</span></p>
<p style="top:356.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">trial), or only on cancer sites other than breast or gynaeco-</span></p>
<p style="top:367.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">logical, with retrospective evaluation, without quantifica-</span></p>
<p style="top:379.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">tion of results, or only investigating complex treatment</span></p>
<p style="top:391.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">regimes, or describing studies already published else-</span></p>
<p style="top:403.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">where, 48 potential studies were identified that met the</span></p>
<p style="top:414.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">inclusion criteria. Two trials [42,43], conducted in</span></p>
<p style="top:426.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Poland, were excluded because of severe validity concerns:</span></p>
<p style="top:438.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">a collaborating scientist questioned the alleged randomi-</span></p>
<p style="top:450.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">zation of treatment allocation, and no information could</span></p>
<p style="top:461.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">be obtained from the authors to clarify this question. One</span></p>
<p style="top:473.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">further RCT (on Lektinol</span><sup><span style="font-family:BqvvhnGiovanni,serif;font-size:6.8pt">&#xae; </span></sup><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and breast cancer by Schwiersch</span></p>
<p style="top:485.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">et al.) might have met the inclusion criteria but was</span></p>
<p style="top:497.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">unpublished and unavailable. Thus it was possible to</span></p>
<p style="top:508.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">include 46 studies in this review: 19 RCTs, 16 non-RCTs,</span></p>
<p style="top:520.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and 11 single-arm cohort studies. Of the 46 studies, 43</span></p>
<p style="top:532.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">were published (4 of these only as an abstract), 1 study</span></p>
<p style="top:544.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">was retrieved as a doctoral dissertation, and 2 were</span></p>
<p style="top:555.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">unpublished reports.</span></p>
<p style="top:579.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">1632 VAE-related references were checked by title, abstract</span></p>
<p style="top:591.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">or whole article, book chapter, or book regarding </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">in vitro</span></i></p>
<p style="top:602.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">or animal studies. Experiments meeting the inclusion cri-</span></p>
<p style="top:614.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">teria were excluded if they were described in another pub-</span></p>
<p style="top:626.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">lication, were not published in a scientific journal,</span></p>
<p style="top:638.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">scientific book or as a scientific dissertation, were unavail-</span></p>
<p style="top:649.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">able (some dissertations from the 1950s and 60s), or if</span></p>
<p style="top:661.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">they did not present sufficient information.</span></p>
<p style="top:685.1pt;left:312.1pt;line-height:9.5pt"><b><i><span style="font-family:FslmpdGillSans,serif;font-size:9.5pt">Characteristics of included clinical studies</span></i></b></p>
<p style="top:696.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Tables 1, 2, 3, 4, 5, and 6 show characteristics of the clin-</span></p>
<p style="top:708.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ical studies. Settings of the studies were mostly academic</span></p>
<p style="top:720.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">hospitals, large community hospitals, and specialized</span></p>


<p style="top:41.9pt;left:54.1pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:41.9pt;left:405.7pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:757.4pt;left:502.1pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 4 of 33</span></p>
<p style="top:770.1pt;left:430.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:532.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">cancer hospitals. The studies were mainly conducted in</span></p>
<p style="top:544.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Germany, but also in Austria, Switzerland, USA, Serbia,</span></p>
<p style="top:555.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Russia, Bulgaria, Ukraine, Italy, Egypt, Israel, China,</span></p>
<p style="top:567.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">South Korea. Most studies were conducted in more than</span></p>
<p style="top:579.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">one centre. In 31 of the 32 studies published since 2000,</span></p>
<p style="top:591.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">the funding source was identifiable: three studies had</span></p>
<p style="top:602.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">public funding [44-46], 17 a combination of public and</span></p>
<p style="top:614.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">industry funding, and 11 industry funding alone.</span></p>
<p style="top:638.0pt;left:54.1pt;line-height:9.5pt"><b><i><span style="font-family:FslmpdGillSans,serif;font-size:9.5pt">Controlled studies</span></i></b></p>
<p style="top:649.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">The 19 RCTs [47-63] (Table 1) encompassed 2420 partic-</span></p>
<p style="top:661.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ipants, 16 non-RCTs [49-53,59,64-72] (Table 2) encom-</span></p>
<p style="top:673.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">passed over 6399 participants (the sample size of one</span></p>
<p style="top:685.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">control group was not published). Cancer sites studied</span></p>
<p style="top:696.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">were breast (n = 20), uterus (n = 4), ovary (n = 6), cervix</span></p>
<p style="top:708.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(n = 4), and genital (n = 1). One RCT investigated malig-</span></p>
<p style="top:720.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">nant pleural infusion. 4 studies not only investigated</span></p>
<p style="top:532.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">gynaecological or breast cancer but other cancer types as</span></p>
<p style="top:544.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">well.</span></p>
<p style="top:567.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Stages ranged from early-detected to advanced disease. 33</span></p>
<p style="top:579.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">studies had two arms, one trial had three, and one four</span></p>
<p style="top:591.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">arms. Endpoints were: survival (22 studies), tumour</span></p>
<p style="top:602.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">remission, recurrence or time to recurrence or metastases</span></p>
<p style="top:614.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(8 studies), pleurodesis (1 study), QoL or coping with dis-</span></p>
<p style="top:626.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ease (11 studies), QoL or tolerability of concomitant</span></p>
<p style="top:638.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">chemotherapy, radiotherapy or surgery (13 studies).</span></p>
<p style="top:649.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Length of follow-up varied from three days in one trial to</span></p>
<p style="top:661.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">&#x2013; usually &#x2013; months or years.</span></p>
<p style="top:685.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">All treatment groups received conventional care when</span></p>
<p style="top:696.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">indicated, and most patients had undergone prior surgery.</span></p>
<p style="top:708.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">In 16 studies (9 RCTs and 7 non-RCTs) the combination</span></p>
<p style="top:720.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">of VAE treatment and concurrent chemotherapy, radio-</span></p>
<p style="top:86.0pt;left:54.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Table 1: Randomized Controlled Clinical VAE Trials on Breast and Gynaecological Cancer: Quality Assessment</span></b></p>
<p style="top:103.9pt;left:58.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Author, Year</span></b></p>
<p style="top:103.9pt;left:174.4pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Quality Criteria Fulfilled in Studies</span></b><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">I</span></sup></p>
<p style="top:103.9pt;left:441.7pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Participants</span></b></p>
<p style="top:103.9pt;left:511.7pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">AR</span></b><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">II</span></sup></p>
<p style="top:126.2pt;left:174.4pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">A)</span></b></p>
<p style="top:126.2pt;left:197.0pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">B)</span></b></p>
<p style="top:126.2pt;left:218.8pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">C)</span></b></p>
<p style="top:126.2pt;left:242.2pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">D)</span></b></p>
<p style="top:126.2pt;left:265.6pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">E)</span></b></p>
<p style="top:126.2pt;left:291.7pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">F)</span></b></p>
<p style="top:126.2pt;left:315.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">G)</span></b></p>
<p style="top:126.2pt;left:341.2pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">H)</span></b></p>
<p style="top:126.2pt;left:367.4pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">I)</span></b></p>
<p style="top:126.2pt;left:393.5pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">J)</span></b></p>
<p style="top:126.2pt;left:419.7pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">K)</span></b></p>
<p style="top:148.5pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Tr&#xf6;ger 2009 [47]</span></p>
<p style="top:148.5pt;left:174.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:148.5pt;left:197.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:148.5pt;left:218.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:148.5pt;left:242.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:148.5pt;left:265.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:148.5pt;left:291.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:148.5pt;left:315.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:148.5pt;left:341.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:148.5pt;left:367.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:148.5pt;left:393.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:148.5pt;left:419.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:148.5pt;left:441.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">95</span></p>
<p style="top:148.5pt;left:511.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">6%</span></p>
<p style="top:158.7pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">B&#xfc;ssing 2008 [48]</span></p>
<p style="top:158.7pt;left:174.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III</span></sup></p>
<p style="top:158.7pt;left:197.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III</span></sup></p>
<p style="top:158.7pt;left:218.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III</span></sup></p>
<p style="top:158.7pt;left:242.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III</span></sup></p>
<p style="top:158.7pt;left:265.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III</span></sup></p>
<p style="top:158.7pt;left:291.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III</span></sup></p>
<p style="top:158.7pt;left:315.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III</span></sup></p>
<p style="top:158.7pt;left:341.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III</span></sup></p>
<p style="top:158.7pt;left:367.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III</span></sup></p>
<p style="top:158.7pt;left:393.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III</span></sup></p>
<p style="top:158.7pt;left:419.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III</span></sup></p>
<p style="top:158.7pt;left:441.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">65</span></p>
<p style="top:158.7pt;left:511.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">No data</span></p>
<p style="top:168.9pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2008a [49]</span></p>
<p style="top:168.9pt;left:174.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:168.9pt;left:197.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:168.9pt;left:218.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:168.9pt;left:242.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:168.9pt;left:265.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:168.9pt;left:291.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:168.9pt;left:315.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:168.9pt;left:341.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:168.9pt;left:367.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:168.9pt;left:393.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:168.9pt;left:419.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:168.9pt;left:441.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">76</span></p>
<p style="top:168.9pt;left:511.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">21%</span></p>
<p style="top:179.2pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2008b [49]</span></p>
<p style="top:179.2pt;left:174.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:179.2pt;left:197.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:179.2pt;left:218.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:179.2pt;left:242.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:179.2pt;left:265.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:179.2pt;left:291.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:179.2pt;left:315.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:179.2pt;left:341.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:179.2pt;left:367.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:179.2pt;left:393.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:179.2pt;left:419.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:179.2pt;left:441.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">52</span></p>
<p style="top:179.2pt;left:511.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0%</span></p>
<p style="top:189.4pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2007a [50]</span></p>
<p style="top:189.4pt;left:174.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:189.4pt;left:197.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:189.4pt;left:218.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:189.4pt;left:242.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:189.4pt;left:265.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:189.4pt;left:291.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:189.4pt;left:315.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:189.4pt;left:341.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:189.4pt;left:367.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:189.4pt;left:393.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:189.4pt;left:419.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:189.4pt;left:441.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">50</span></p>
<p style="top:189.4pt;left:511.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">16%</span></p>
<p style="top:199.7pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2007b [50]</span></p>
<p style="top:199.7pt;left:174.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:199.7pt;left:197.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:199.7pt;left:218.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:199.7pt;left:242.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:199.7pt;left:265.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:199.7pt;left:291.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:199.7pt;left:315.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:199.7pt;left:341.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:199.7pt;left:367.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:199.7pt;left:393.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:199.7pt;left:419.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:199.7pt;left:441.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">48</span></p>
<p style="top:199.7pt;left:511.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">17%</span></p>
<p style="top:210.0pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2007c [51]</span></p>
<p style="top:210.0pt;left:174.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:210.0pt;left:197.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:210.0pt;left:218.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:210.0pt;left:242.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:210.0pt;left:265.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:210.0pt;left:291.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:210.0pt;left:315.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:210.0pt;left:341.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:210.0pt;left:367.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:210.0pt;left:393.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:210.0pt;left:419.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:210.0pt;left:441.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">38</span></p>
<p style="top:210.0pt;left:511.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0%</span></p>
<p style="top:220.2pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2006a [52,53]</span></p>
<p style="top:220.2pt;left:174.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:220.2pt;left:197.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:220.2pt;left:218.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:220.2pt;left:242.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:220.2pt;left:265.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:220.2pt;left:291.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:220.2pt;left:315.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:220.2pt;left:341.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:220.2pt;left:367.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:220.2pt;left:393.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:220.2pt;left:419.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:220.2pt;left:441.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">118</span></p>
<p style="top:220.2pt;left:511.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">36%</span></p>
<p style="top:230.4pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Semiglasov 2006 [54]</span></p>
<p style="top:230.4pt;left:174.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:230.4pt;left:197.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:230.4pt;left:218.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:230.4pt;left:242.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:230.4pt;left:265.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:230.4pt;left:291.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:230.4pt;left:315.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:230.4pt;left:341.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:230.4pt;left:367.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:230.4pt;left:393.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:230.4pt;left:419.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:230.4pt;left:441.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">352</span></p>
<p style="top:230.4pt;left:511.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">4%</span></p>
<p style="top:240.7pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Auerbach 2005 [55]</span></p>
<p style="top:240.7pt;left:174.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:240.7pt;left:197.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:240.7pt;left:218.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:240.7pt;left:242.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:240.7pt;left:265.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:240.7pt;left:291.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:240.7pt;left:315.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:240.7pt;left:341.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:240.7pt;left:367.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:240.7pt;left:393.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:240.7pt;left:419.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:240.7pt;left:441.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">23</span></p>
<p style="top:240.7pt;left:511.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">30%</span></p>
<p style="top:250.9pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Piao 2004 [56]</span></p>
<p style="top:250.9pt;left:174.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:250.9pt;left:197.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:250.9pt;left:218.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:250.9pt;left:242.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:250.9pt;left:265.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:250.9pt;left:291.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:250.9pt;left:315.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:250.9pt;left:341.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:250.9pt;left:367.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:250.9pt;left:393.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:250.9pt;left:419.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:250.9pt;left:441.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">233</span></p>
<p style="top:250.9pt;left:511.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">4%</span></p>
<p style="top:261.2pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Semiglasov 2004 [57]</span></p>
<p style="top:261.2pt;left:174.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:261.2pt;left:197.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:261.2pt;left:218.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:261.2pt;left:242.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:261.2pt;left:265.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:261.2pt;left:291.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:261.2pt;left:315.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:261.2pt;left:341.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:261.2pt;left:367.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:261.2pt;left:393.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:261.2pt;left:419.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:261.2pt;left:441.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">272</span></p>
<p style="top:261.2pt;left:511.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">4%</span></p>
<p style="top:271.5pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Borrelli 2001 [58]</span></p>
<p style="top:271.5pt;left:174.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:271.5pt;left:197.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:271.5pt;left:218.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:271.5pt;left:242.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:271.5pt;left:265.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:271.5pt;left:291.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:271.5pt;left:315.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:271.5pt;left:341.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:271.5pt;left:367.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:271.5pt;left:393.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:271.5pt;left:419.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:271.5pt;left:441.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">30</span></p>
<p style="top:271.5pt;left:511.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0%</span></p>
<p style="top:281.7pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2001a [59]</span></p>
<p style="top:281.7pt;left:174.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:281.7pt;left:197.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:281.7pt;left:218.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:281.7pt;left:242.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:281.7pt;left:265.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:281.7pt;left:291.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:281.7pt;left:315.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:281.7pt;left:341.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:281.7pt;left:367.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:281.7pt;left:393.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:281.7pt;left:419.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:281.7pt;left:441.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">34</span></p>
<p style="top:281.7pt;left:511.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0%</span></p>
<p style="top:291.9pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2001b [59]</span></p>
<p style="top:291.9pt;left:174.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:291.9pt;left:197.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:291.9pt;left:218.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:291.9pt;left:242.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:291.9pt;left:265.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:291.9pt;left:291.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:291.9pt;left:315.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:291.9pt;left:341.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:291.9pt;left:367.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:291.9pt;left:393.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:291.9pt;left:419.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:291.9pt;left:441.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">98</span></p>
<p style="top:291.9pt;left:511.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">20%</span></p>
<p style="top:302.2pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Kim 1999 [60]</span></p>
<p style="top:302.2pt;left:174.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:302.2pt;left:197.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:302.2pt;left:218.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:302.2pt;left:242.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:302.2pt;left:265.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:302.2pt;left:291.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:302.2pt;left:315.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:302.2pt;left:341.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:302.2pt;left:367.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:302.2pt;left:393.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:302.2pt;left:419.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:302.2pt;left:441.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">30</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">IV</span></sup></p>
<p style="top:302.2pt;left:511.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">13%</span></p>
<p style="top:312.4pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Heiny 1991 [61]</span></p>
<p style="top:312.4pt;left:174.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:312.4pt;left:197.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:312.4pt;left:218.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:312.4pt;left:242.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:312.4pt;left:265.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:312.4pt;left:291.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:312.4pt;left:315.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:312.4pt;left:341.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:312.4pt;left:367.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:312.4pt;left:393.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:312.4pt;left:419.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:312.4pt;left:441.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">46</span></p>
<p style="top:312.4pt;left:511.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">13%</span></p>
<p style="top:322.7pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Gutsch 1988 [62]</span></p>
<p style="top:322.7pt;left:174.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:322.7pt;left:197.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:322.7pt;left:218.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:322.7pt;left:242.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:322.7pt;left:265.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:322.7pt;left:291.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:322.7pt;left:315.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:322.7pt;left:341.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:322.7pt;left:367.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:322.7pt;left:393.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:322.7pt;left:419.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:322.7pt;left:441.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">692</span></p>
<p style="top:322.7pt;left:511.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">20%</span></p>
<p style="top:333.0pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Lange 1985 [63]</span></p>
<p style="top:333.0pt;left:174.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:333.0pt;left:197.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:333.0pt;left:218.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:333.0pt;left:242.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:333.0pt;left:265.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:333.0pt;left:291.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:333.0pt;left:315.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:333.0pt;left:341.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:333.0pt;left:367.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:333.0pt;left:393.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:333.0pt;left:419.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:333.0pt;left:441.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">68</span></p>
<p style="top:333.0pt;left:511.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">35%</span></p>
<p style="top:355.1pt;left:58.1pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">I </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">A) Protection against selection bias, especially by adequate randomization</span></p>
<p style="top:364.5pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">B) Minimization of heterogeneity by pre-stratification or matching</span></p>
<p style="top:373.7pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">C) Protection against observer bias by blinding of patient, care provider, and outcome assessor</span></p>
<p style="top:382.9pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">D) Protection against performance (treatment) bias by standardization of care protocol, documentation of all co-interventions, blinding of patients </span></p>
<p style="top:392.2pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">and care providers</span></p>
<p style="top:401.4pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">E) Protection against measurement (detection) bias by standardization of outcome assessment</span></p>
<p style="top:410.7pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">F) Protection against attrition (exclusion) bias, lost patients &lt;10% or by intention-to-treat analysis (including non-adherers as randomized) plus per-</span></p>
<p style="top:420.0pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">protocol analysis (excluding non-adherers) in combination with sensitivity analysis, and by comparison of prognostic characteristics of lost patients </span></p>
<p style="top:429.2pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">and compliers</span></p>
<p style="top:438.4pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">G) Effect measurement relevant and well described</span></p>
<p style="top:447.7pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">H) Well-described intervention, patient characteristics, disease (diagnosis, stage, duration), previous therapy</span></p>
<p style="top:456.9pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">I) Well-described study design</span></p>
<p style="top:466.2pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">J) Well-described results</span></p>
<p style="top:475.5pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">K) Data quality assured by ICH-GCP guidelines, especially by monitoring</span></p>
<p style="top:484.7pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+ = adequately fulfilled, (+) = partly fulfilled, (-) = little fulfilled, - = not fulfilled</span></p>
<p style="top:493.9pt;left:58.1pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">II </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">AR: attrition rate (dropouts, protocol deviations, withdrawals, patients did not receive treatment as allocated).</span></p>
<p style="top:503.1pt;left:58.1pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Assessment based only on an abstract</span></p>
<p style="top:512.4pt;left:58.1pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">IV </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Discrepancy in patient numbers in two presentations (30 and 33), with corresponding discrepancy of results</span></p>


<p style="top:41.9pt;left:54.1pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:41.9pt;left:405.7pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:757.4pt;left:502.1pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 5 of 33</span></p>
<p style="top:770.1pt;left:430.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:508.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">therapy or surgery was investigated. 13 of these studies</span></p>
<p style="top:520.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">assessed reduction of side effects from these cytoreductive</span></p>
<p style="top:532.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">therapies. Three trials directly compared VAE treatment</span></p>
<p style="top:544.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">versus chemotherapy treatment or versus radiation and</span></p>
<p style="top:555.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">hormones [60,62,66]. In most studies VAE therapy was</span></p>
<p style="top:567.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">used at least partly in an adjuvant setting after surgery or</span></p>
<p style="top:579.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">radiotherapy.</span></p>
<p style="top:602.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">The commercial VAE applied were Iscador</span><sup><span style="font-family:BqvvhnGiovanni,serif;font-size:6.8pt">&#xae;</span></sup><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">, Helixor</span><sup><span style="font-family:BqvvhnGiovanni,serif;font-size:6.8pt">&#xae;</span></sup><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">,</span></p>
<p style="top:614.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Eurixor</span><sup><span style="font-family:BqvvhnGiovanni,serif;font-size:6.8pt">&#xae; </span></sup><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">or Lektinol</span><sup><span style="font-family:BqvvhnGiovanni,serif;font-size:6.8pt">&#xae;</span></sup><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">. VAE dosage mostly followed general</span></p>
<p style="top:626.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">recommendations, starting with low doses and increasing</span></p>
<p style="top:638.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">to an individually still well-tolerated dosage, or treating</span></p>
<p style="top:649.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">according to lectin-content (in 6 trials) or leaving treat-</span></p>
<p style="top:661.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ment modalities to the physician&apos;s discretion, which, it</span></p>
<p style="top:673.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">can likewise be assumed, followed general recommenda-</span></p>
<p style="top:685.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">tions. VAE was injected subcutaneously except in three tri-</span></p>
<p style="top:696.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">als employing intravenous infusion or intrapleural</span></p>
<p style="top:708.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">instillation [48,60,65]. Treatment duration was often not</span></p>
<p style="top:720.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">specified and depended on primary endpoint and related</span></p>
<p style="top:508.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">follow-up, ranging from one single application (in one</span></p>
<p style="top:520.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">trial [65]) to repeated applications over months and years.</span></p>
<p style="top:532.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Control groups either received no further comparison</span></p>
<p style="top:544.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">treatment (n = 27), additional placebo application (n =</span></p>
<p style="top:555.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">5), doxycycline (n = 1), Lentinan (n = 1) or radiation and</span></p>
<p style="top:567.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">hormones (n = 1). 4 trials had double-blinded treatment</span></p>
<p style="top:579.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">application.</span></p>
<p style="top:602.8pt;left:312.1pt;line-height:9.5pt"><b><i><span style="font-family:FslmpdGillSans,serif;font-size:9.5pt">Single-arm studies</span></i></b></p>
<p style="top:614.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">11 prospective cohort studies [32,44-46,73-80] (Table 6)</span></p>
<p style="top:626.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">included 1,130 patients. Cancer sites studied were breast (n</span></p>
<p style="top:638.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">= 6), ovary (n = 1), CIN (n = 1), malignant pleural effusion</span></p>
<p style="top:649.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(n = 2) and malignant ascites (n = 2). 8 studies investigated</span></p>
<p style="top:661.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">several cancer types. Tumour stages were advanced or inop-</span></p>
<p style="top:673.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">erable except in three studies. In most studies patients had</span></p>
<p style="top:685.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">received conventional treatment some time previously.</span></p>
<p style="top:696.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Directly preceding or concurrent anti-cancer treatment had</span></p>
<p style="top:708.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">been applied in two studies (gemcitabine [44], surgery</span></p>
<p style="top:720.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">[45]). Nine studies assessed tumour remission; seven</span></p>
<p style="top:86.0pt;left:54.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Table 2: Non-Randomized Controlled Clinical VAE Studies on Breast and Gynaecological Cancer: Quality Assessment</span></b></p>
<p style="top:103.9pt;left:58.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Author, Year</span></b></p>
<p style="top:103.9pt;left:139.9pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Quality Criteria Fulfilled in Studies</span></b><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">I</span></sup></p>
<p style="top:103.9pt;left:333.7pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Participants</span></b></p>
<p style="top:103.9pt;left:388.0pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">AR</span></b><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">II</span></sup></p>
<p style="top:103.9pt;left:457.9pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Design/control for </span></b></p>
<p style="top:113.2pt;left:457.9pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">confounding</span></b></p>
<p style="top:135.4pt;left:139.9pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">A)</span></b></p>
<p style="top:135.4pt;left:158.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">B)</span></b></p>
<p style="top:135.4pt;left:176.3pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">C)</span></b></p>
<p style="top:135.4pt;left:193.8pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">D)</span></b></p>
<p style="top:135.4pt;left:211.5pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">E)</span></b></p>
<p style="top:135.4pt;left:227.9pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">F)</span></b></p>
<p style="top:135.4pt;left:244.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">G)</span></b></p>
<p style="top:135.4pt;left:262.2pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">H)</span></b></p>
<p style="top:135.4pt;left:280.4pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">I)</span></b></p>
<p style="top:135.4pt;left:298.5pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">J)</span></b></p>
<p style="top:135.4pt;left:316.7pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">K)</span></b></p>
<p style="top:157.7pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2008c [49]</span></p>
<p style="top:157.7pt;left:139.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:157.7pt;left:158.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:157.7pt;left:176.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:157.7pt;left:193.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:157.7pt;left:211.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:157.7pt;left:227.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:157.7pt;left:244.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:157.7pt;left:262.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:157.7pt;left:280.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:157.7pt;left:298.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:157.7pt;left:316.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:157.7pt;left:333.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">200</span></p>
<p style="top:157.7pt;left:387.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">5%</span></p>
<p style="top:157.7pt;left:457.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Prospective pair-matching</span></p>
<p style="top:168.0pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2008d [49]</span></p>
<p style="top:168.0pt;left:139.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:168.0pt;left:158.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:168.0pt;left:176.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:168.0pt;left:193.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:168.0pt;left:211.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:168.0pt;left:227.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:168.0pt;left:244.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:168.0pt;left:262.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:168.0pt;left:280.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:168.0pt;left:298.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:168.0pt;left:316.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:168.0pt;left:333.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">282</span></p>
<p style="top:168.0pt;left:387.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">27%</span></p>
<p style="top:168.0pt;left:457.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Prospective pair-matching</span></p>
<p style="top:178.2pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Loewe-Mesch 2008 </span></p>
<p style="top:187.5pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[64]</span></p>
<p style="top:178.2pt;left:139.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:178.2pt;left:158.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:178.2pt;left:176.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:178.2pt;left:193.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:178.2pt;left:211.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:178.2pt;left:227.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:178.2pt;left:244.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:178.2pt;left:262.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:178.2pt;left:280.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:178.2pt;left:298.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:178.2pt;left:316.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:178.2pt;left:333.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">82</span></p>
<p style="top:178.2pt;left:388.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">20%</span></p>
<p style="top:178.2pt;left:457.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Self-selected treatment </span></p>
<p style="top:187.5pt;left:457.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">allocation, no adjustment</span></p>
<p style="top:197.7pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2007d [50]</span></p>
<p style="top:197.7pt;left:139.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:197.7pt;left:158.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:197.7pt;left:176.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:197.7pt;left:193.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:197.7pt;left:211.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:197.7pt;left:227.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:197.7pt;left:244.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:197.7pt;left:262.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:197.7pt;left:280.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:197.7pt;left:298.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:197.7pt;left:316.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:197.7pt;left:333.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">198</span></p>
<p style="top:197.7pt;left:387.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">24%</span></p>
<p style="top:197.7pt;left:457.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Prospective pair-matching</span></p>
<p style="top:207.9pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2007e [50]</span></p>
<p style="top:207.9pt;left:139.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:207.9pt;left:158.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:207.9pt;left:176.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:207.9pt;left:193.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:207.9pt;left:211.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:207.9pt;left:227.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:207.9pt;left:244.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:207.9pt;left:262.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:207.9pt;left:280.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:207.9pt;left:298.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:207.9pt;left:316.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:207.9pt;left:333.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">132</span></p>
<p style="top:207.9pt;left:387.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">6%</span></p>
<p style="top:207.9pt;left:457.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Prospective pair-matching</span></p>
<p style="top:218.2pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2007f [51]</span></p>
<p style="top:218.2pt;left:139.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:218.2pt;left:158.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:218.2pt;left:176.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:218.2pt;left:193.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:218.2pt;left:211.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:218.2pt;left:227.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:218.2pt;left:244.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:218.2pt;left:262.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:218.2pt;left:280.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:218.2pt;left:298.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:218.2pt;left:316.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:218.2pt;left:333.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">212</span></p>
<p style="top:218.2pt;left:387.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">4%</span></p>
<p style="top:218.2pt;left:457.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Prospective pair-matching</span></p>
<p style="top:228.4pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2007g [51]</span></p>
<p style="top:228.4pt;left:139.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:228.4pt;left:157.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:228.4pt;left:176.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:228.4pt;left:193.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:228.4pt;left:211.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:228.4pt;left:227.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:228.4pt;left:244.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:228.4pt;left:262.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:228.4pt;left:280.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:228.4pt;left:298.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:228.4pt;left:316.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:228.4pt;left:333.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">140</span></p>
<p style="top:228.4pt;left:387.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">6%</span></p>
<p style="top:228.4pt;left:457.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Prospective pair-matching</span></p>
<p style="top:238.7pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2006b </span></p>
<p style="top:247.9pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[52,53]</span></p>
<p style="top:238.7pt;left:139.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:238.7pt;left:158.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:238.7pt;left:176.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:238.7pt;left:193.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:238.7pt;left:211.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:238.7pt;left:227.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:238.7pt;left:244.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:238.7pt;left:262.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:238.7pt;left:280.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:238.7pt;left:298.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:238.7pt;left:316.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:238.7pt;left:333.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">210</span></p>
<p style="top:238.7pt;left:388.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">20%</span></p>
<p style="top:238.7pt;left:458.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Prospective pair-matching</span></p>
<p style="top:258.2pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">B&#xfc;ssing 2005 [65]</span></p>
<p style="top:258.2pt;left:139.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:258.2pt;left:158.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:258.2pt;left:176.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:258.2pt;left:193.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:258.2pt;left:211.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:258.2pt;left:227.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:258.2pt;left:244.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:258.2pt;left:262.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:258.2pt;left:280.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:258.2pt;left:298.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:258.2pt;left:316.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:258.2pt;left:333.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">105</span></p>
<p style="top:258.2pt;left:388.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">7%</span></p>
<p style="top:258.2pt;left:457.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Comparison of two </span></p>
<p style="top:267.4pt;left:457.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">different hospitals. Pair-</span></p>
<p style="top:276.7pt;left:457.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">matching for analysis</span></p>
<p style="top:286.9pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2001c [59]</span></p>
<p style="top:286.9pt;left:139.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:286.9pt;left:158.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:286.9pt;left:176.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:286.9pt;left:193.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:286.9pt;left:211.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:286.9pt;left:227.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:286.9pt;left:244.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:286.9pt;left:262.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:286.9pt;left:280.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:286.9pt;left:298.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:286.9pt;left:316.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:286.9pt;left:333.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">792</span></p>
<p style="top:286.9pt;left:387.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">4%</span></p>
<p style="top:286.9pt;left:457.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Prospective pair-matching</span></p>
<p style="top:297.2pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Salzer 1987 [66]</span></p>
<p style="top:297.2pt;left:140.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:297.2pt;left:158.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:297.2pt;left:176.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:297.2pt;left:193.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:297.2pt;left:211.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:297.2pt;left:227.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:297.2pt;left:244.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:297.2pt;left:262.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:297.2pt;left:280.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:297.2pt;left:298.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:297.2pt;left:316.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:297.2pt;left:333.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">155</span></p>
<p style="top:297.2pt;left:388.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">not shown</span></p>
<p style="top:297.2pt;left:457.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Alternating treatment </span></p>
<p style="top:306.4pt;left:457.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">allocation</span></p>
<p style="top:316.7pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Fellmer 1966 [67]</span></p>
<p style="top:316.7pt;left:139.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:316.7pt;left:158.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:316.7pt;left:176.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:316.7pt;left:193.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:316.7pt;left:211.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:316.7pt;left:227.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:316.7pt;left:244.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:316.7pt;left:262.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:316.7pt;left:280.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:316.7pt;left:298.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:316.7pt;left:316.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:316.7pt;left:333.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">924</span></p>
<p style="top:316.7pt;left:388.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">15%</span></p>
<p style="top:316.7pt;left:457.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Treatment allocation by </span></p>
<p style="top:325.9pt;left:457.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">neutral attending physician</span></p>
<p style="top:336.2pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Majewski 1963 [68]</span></p>
<p style="top:336.2pt;left:140.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:336.2pt;left:158.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:336.2pt;left:176.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:336.2pt;left:193.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:336.2pt;left:211.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:336.2pt;left:227.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:336.2pt;left:244.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:336.2pt;left:262.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:336.2pt;left:280.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:336.2pt;left:298.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:336.2pt;left:316.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:336.1pt;left:333.7pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III</span></p>
<p style="top:336.2pt;left:388.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">not shown (15%)</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">IV</span></sup></p>
<p style="top:336.2pt;left:457.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Alternating treatment </span></p>
<p style="top:345.4pt;left:457.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">allocation</span></p>
<p style="top:367.7pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Retrolective pharmaco-epidemiological cohort studies</span></p>
<p style="top:390.0pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Beuth 2008 [69]</span></p>
<p style="top:390.0pt;left:140.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:390.0pt;left:158.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:390.0pt;left:176.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:390.0pt;left:193.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:390.0pt;left:211.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:390.0pt;left:227.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:390.0pt;left:244.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:390.0pt;left:262.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:390.0pt;left:280.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:390.0pt;left:298.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:390.0pt;left:316.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:390.0pt;left:333.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">681</span></p>
<p style="top:389.8pt;left:388.0pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">V</span></p>
<p style="top:390.0pt;left:457.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Multivariate adjustment </span></p>
<p style="top:399.2pt;left:457.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">only for one main outcome </span></p>
<p style="top:408.4pt;left:457.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(&quot;complaints&quot;)</span></p>
<p style="top:418.7pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Bock 2004 [70]</span></p>
<p style="top:418.7pt;left:139.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:418.7pt;left:158.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:418.7pt;left:176.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:418.7pt;left:193.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:418.7pt;left:211.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:418.7pt;left:227.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:418.7pt;left:244.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:418.7pt;left:262.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:418.7pt;left:280.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:418.7pt;left:298.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:418.7pt;left:316.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:418.7pt;left:333.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">1442</span></p>
<p style="top:418.6pt;left:388.0pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">V</span></p>
<p style="top:418.7pt;left:457.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Multivariate adjustment</span></p>
<p style="top:429.0pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Schumacher 2003 </span></p>
<p style="top:438.2pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[71,72]</span></p>
<p style="top:429.0pt;left:139.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:429.0pt;left:158.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:429.0pt;left:176.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:429.0pt;left:193.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:429.0pt;left:211.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:429.0pt;left:227.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:429.0pt;left:244.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:429.0pt;left:262.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:429.0pt;left:280.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:429.0pt;left:298.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:429.0pt;left:316.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:429.0pt;left:333.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">689</span></p>
<p style="top:428.8pt;left:388.0pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">V</span></p>
<p style="top:429.0pt;left:457.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Propensity score </span></p>
<p style="top:438.2pt;left:457.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">adjustment</span></p>
<p style="top:460.3pt;left:58.1pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">I&#x2013;II </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Abbreviations as in Table 1.</span></p>
<p style="top:469.6pt;left:58.1pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Number of study patients not indicated; mistletoe group included 155 patients.</span></p>
<p style="top:478.9pt;left:58.1pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">IV </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Numbers given only for mistletoe group.</span></p>
<p style="top:488.1pt;left:58.1pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">V </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Not applicable for retrolective studies.</span></p>


<p style="top:548.7pt;left:40.9pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:197.1pt;left:40.9pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:100.7pt;left:756.5pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 6 of 33</span></p>
<p style="top:173.7pt;left:769.3pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:64.1pt;left:87.0pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Table 3: Controlled Clinical Studies on VAE Treatment in Breast and Gynaecological Cancer: Survival</span></b></p>
<p style="top:81.1pt;left:91.0pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Site</span></b></p>
<p style="top:81.1pt;left:163.3pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Stage</span></b></p>
<p style="top:81.1pt;left:242.7pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Intervention </span></b></p>
<p style="top:90.4pt;left:242.6pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">(evaluable </span></b></p>
<p style="top:99.6pt;left:242.6pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">patients)</span></b></p>
<p style="top:81.1pt;left:322.6pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Survival Outcomes</span></b></p>
<p style="top:81.1pt;left:665.3pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Author, year, </span></b></p>
<p style="top:90.4pt;left:665.3pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">reference</span></b></p>
<p style="top:119.9pt;left:322.6pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Years (median)</span></b></p>
<p style="top:119.9pt;left:400.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Hazard ratio</span></b></p>
<p style="top:119.9pt;left:475.0pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">5-year survival and </span></b></p>
<p style="top:129.2pt;left:475.0pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">others</span></b></p>
<p style="top:119.9pt;left:555.3pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">P-value</span></b></p>
<p style="top:119.9pt;left:612.4pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">95% CI</span></b></p>
<p style="top:149.4pt;left:91.0pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Randomized controlled trials</span></b></p>
<p style="top:169.7pt;left:91.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Breast</span></p>
<p style="top:169.7pt;left:163.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">T1a-3, N0, M0</span></p>
<p style="top:169.7pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (38)</span></p>
<p style="top:169.7pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">14.8</span></p>
<p style="top:169.7pt;left:400.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.65</span></p>
<p style="top:169.7pt;left:555.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.2</span></p>
<p style="top:169.7pt;left:612.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.34&#x2013;1.25</span></p>
<p style="top:169.7pt;left:665.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2006a </span></p>
<p style="top:178.9pt;left:665.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[52,53,135]</span></p>
<p style="top:199.1pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (38)</span></p>
<p style="top:199.1pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">13.8</span></p>
<p style="top:219.4pt;left:163.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">IIIA&#x2013;IIIB</span></p>
<p style="top:219.4pt;left:242.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (17)</span></p>
<p style="top:219.4pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">6.3</span></p>
<p style="top:219.4pt;left:400.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.46</span></p>
<p style="top:219.4pt;left:555.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.13</span></p>
<p style="top:219.4pt;left:612.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.16&#x2013;1.31</span></p>
<p style="top:219.4pt;left:665.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2001a </span></p>
<p style="top:228.6pt;left:665.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[59,135,166]</span></p>
<p style="top:248.9pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (17)</span></p>
<p style="top:248.9pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2.3</span></p>
<p style="top:269.1pt;left:163.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">T1-3, N0-3, M0, local </span></p>
<p style="top:278.4pt;left:163.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">recurrence</span></p>
<p style="top:269.1pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Surgery, radiation</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">I</span></sup><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, </span></p>
<p style="top:278.4pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Helixor (192)</span></p>
<p style="top:269.1pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Not applicable</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">II</span></sup></p>
<p style="top:269.1pt;left:475.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">69.1% 5-year survival</span></p>
<p style="top:269.1pt;left:555.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.048</span></p>
<p style="top:269.1pt;left:665.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Gutsch 1988 [62]</span></p>
<p style="top:298.7pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Surgery, radiation</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">I</span></sup><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, </span></p>
<p style="top:307.9pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">CMF (177)</span></p>
<p style="top:298.7pt;left:475.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">67.7% 5-year survival</span></p>
<p style="top:298.7pt;left:555.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.025</span></p>
<p style="top:328.1pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Surgery, radiation</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">I </span></sup></p>
<p style="top:337.4pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(274)</span></p>
<p style="top:328.1pt;left:475.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">59.7% 5-year survival</span></p>
<p style="top:357.6pt;left:91.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Breast, others</span></p>
<p style="top:357.6pt;left:163.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">All stages</span></p>
<p style="top:357.6pt;left:242.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (39)</span></p>
<p style="top:357.6pt;left:322.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">3.5 (mean)</span></p>
<p style="top:357.6pt;left:555.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.04</span></p>
<p style="top:357.6pt;left:665.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2001b </span></p>
<p style="top:366.9pt;left:665.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[59]</span></p>
<p style="top:387.2pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (39)</span></p>
<p style="top:387.2pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2.5 (mean)</span></p>
<p style="top:407.4pt;left:91.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Cervix</span></p>
<p style="top:407.4pt;left:163.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">IVA-B</span></p>
<p style="top:407.4pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (19)</span></p>
<p style="top:407.4pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">1.83</span></p>
<p style="top:407.4pt;left:400.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.46</span></p>
<p style="top:407.4pt;left:555.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.12</span></p>
<p style="top:407.4pt;left:612.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.18&#x2013;1.21</span></p>
<p style="top:407.4pt;left:665.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2007c </span></p>
<p style="top:416.6pt;left:665.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[51]</span></p>
<p style="top:436.9pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (19)</span></p>
<p style="top:436.9pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">1.92</span></p>
<p style="top:457.1pt;left:91.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Uterus</span></p>
<p style="top:457.1pt;left:163.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">IA-C</span></p>
<p style="top:457.1pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (30)</span></p>
<p style="top:457.1pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">6.29</span></p>
<p style="top:457.1pt;left:400.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.36</span></p>
<p style="top:457.1pt;left:555.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.014</span></p>
<p style="top:457.1pt;left:612.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.16&#x2013;0.82</span></p>
<p style="top:457.1pt;left:665.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2008a </span></p>
<p style="top:466.4pt;left:665.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[49]</span></p>
<p style="top:486.6pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (30)</span></p>
<p style="top:486.6pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">5.17</span></p>
<p style="top:506.9pt;left:163.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">IVA-B</span></p>
<p style="top:506.9pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (26)</span></p>
<p style="top:506.9pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">1.5</span></p>
<p style="top:506.9pt;left:400.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">1</span></p>
<p style="top:506.9pt;left:555.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.99</span></p>
<p style="top:506.9pt;left:612.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.46&#x2013;2.16</span></p>
<p style="top:506.9pt;left:665.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2008b </span></p>
<p style="top:516.2pt;left:665.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[49]</span></p>
<p style="top:536.4pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (26)</span></p>
<p style="top:536.4pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2.0</span></p>
<p style="top:556.7pt;left:91.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Ovary</span></p>
<p style="top:556.7pt;left:163.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">IA&#x2013;IC</span></p>
<p style="top:556.7pt;left:242.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (21)</span></p>
<p style="top:556.7pt;left:322.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">6.75</span></p>
<p style="top:556.7pt;left:400.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.40</span></p>
<p style="top:556.7pt;left:555.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.058</span></p>
<p style="top:556.7pt;left:612.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.15&#x2013;1.03</span></p>
<p style="top:556.7pt;left:665.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2007a </span></p>
<p style="top:565.9pt;left:665.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[50]</span></p>


<p style="top:548.7pt;left:40.9pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:197.1pt;left:40.9pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:100.7pt;left:756.5pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 7 of 33</span></p>
<p style="top:173.7pt;left:769.3pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:81.9pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (21)</span></p>
<p style="top:81.9pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">5.58</span></p>
<p style="top:102.2pt;left:163.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">IV</span></p>
<p style="top:102.2pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (20)</span></p>
<p style="top:102.2pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2.75</span></p>
<p style="top:102.2pt;left:400.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.33</span></p>
<p style="top:102.2pt;left:555.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.033</span></p>
<p style="top:102.2pt;left:612.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.12&#x2013;0.92</span></p>
<p style="top:102.2pt;left:665.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2007b </span></p>
<p style="top:111.4pt;left:665.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[50]</span></p>
<p style="top:131.6pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (20)</span></p>
<p style="top:131.6pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">1.58</span></p>
<p style="top:151.9pt;left:91.0pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Non-randomized controlled studies</span></b></p>
<p style="top:172.1pt;left:91.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Breast</span></p>
<p style="top:172.1pt;left:163.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">T1-3, N0, M0</span></p>
<p style="top:172.1pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (84)</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III</span></sup></p>
<p style="top:172.1pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">11.75</span></p>
<p style="top:172.1pt;left:400.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.42</span></p>
<p style="top:172.1pt;left:555.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.0002</span></p>
<p style="top:172.1pt;left:612.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.27&#x2013;0.68</span></p>
<p style="top:172.1pt;left:665.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2006b </span></p>
<p style="top:181.4pt;left:665.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[52,53,135]</span></p>
<p style="top:201.6pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (84)</span></p>
<p style="top:201.6pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">10.13</span></p>
<p style="top:221.9pt;left:163.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Local recurrence, </span></p>
<p style="top:231.2pt;left:163.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">N0, M0</span></p>
<p style="top:221.9pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (29)</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">IV</span></sup></p>
<p style="top:221.9pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">5.17</span></p>
<p style="top:221.9pt;left:555.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.0025</span></p>
<p style="top:221.9pt;left:665.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2001b </span></p>
<p style="top:231.2pt;left:665.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[59,135]</span></p>
<p style="top:251.4pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (29)</span></p>
<p style="top:251.4pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">4.33</span></p>
<p style="top:271.7pt;left:163.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">T1-4, N&gt;1, M0</span></p>
<p style="top:271.7pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (38)</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">IV</span></sup></p>
<p style="top:271.7pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">4.04</span></p>
<p style="top:271.7pt;left:555.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.0516</span></p>
<p style="top:271.7pt;left:665.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">&#xd8; same study</span></p>
<p style="top:291.9pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (38)</span></p>
<p style="top:291.9pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">3.17</span></p>
<p style="top:312.2pt;left:163.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">TX, NX, M1</span></p>
<p style="top:312.2pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (53)</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">IV</span></sup></p>
<p style="top:312.2pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">3.08</span></p>
<p style="top:312.2pt;left:555.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.0056</span></p>
<p style="top:312.2pt;left:665.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">&#xd8; same study</span></p>
<p style="top:332.4pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (53)</span></p>
<p style="top:332.4pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2.17</span></p>
<p style="top:352.7pt;left:163.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">I&#x2013;III</span></p>
<p style="top:352.7pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador, (76)</span></p>
<p style="top:352.7pt;left:475.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">29% alive 1985, after </span></p>
<p style="top:361.9pt;left:475.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">11&#x2013;14 years</span></p>
<p style="top:352.7pt;left:555.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">not shown</span></p>
<p style="top:352.7pt;left:665.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Salzer 1987 [66]</span></p>
<p style="top:382.1pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Radiation, hormone </span></p>
<p style="top:391.4pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(79)</span></p>
<p style="top:382.1pt;left:475.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">24% alive 1985, after </span></p>
<p style="top:391.4pt;left:475.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">11&#x2013;14 years</span></p>
<p style="top:411.6pt;left:91.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Cervix</span></p>
<p style="top:411.6pt;left:163.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">IB-IVA</span></p>
<p style="top:411.6pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (102)</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III</span></sup></p>
<p style="top:411.6pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">7.17</span></p>
<p style="top:411.6pt;left:400.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.41</span></p>
<p style="top:411.6pt;left:555.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">&lt;0.0001</span></p>
<p style="top:411.6pt;left:612.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.27&#x2013;0.63</span></p>
<p style="top:411.6pt;left:665.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2007f [51]</span></p>
<p style="top:431.9pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (102)</span></p>
<p style="top:431.9pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">5.92</span></p>
<p style="top:452.1pt;left:163.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">IV</span></p>
<p style="top:452.1pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (66)</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III</span></sup></p>
<p style="top:452.1pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2.33</span></p>
<p style="top:452.1pt;left:400.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.54</span></p>
<p style="top:452.1pt;left:555.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.015</span></p>
<p style="top:452.1pt;left:612.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.32&#x2013;0.89</span></p>
<p style="top:452.1pt;left:665.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2007g </span></p>
<p style="top:461.4pt;left:665.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[51]</span></p>
<p style="top:481.7pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (66)</span></p>
<p style="top:481.7pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">1.83</span></p>
<p style="top:501.9pt;left:163.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">I&#x2013;III</span></p>
<p style="top:501.9pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Radiation, Iscador </span></p>
<p style="top:511.1pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(81)</span></p>
<p style="top:501.9pt;left:475.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">83% 5-year survival</span></p>
<p style="top:501.9pt;left:555.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.05</span></p>
<p style="top:501.9pt;left:665.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Fellmer 1966 [67]</span></p>
<p style="top:531.4pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Radiation (709)</span></p>
<p style="top:531.4pt;left:475.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">69% 5-year survival</span></p>
<p style="top:55.9pt;left:87.0pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Table 3: Controlled Clinical Studies on VAE Treatment in Breast and Gynaecological Cancer: Survival</span></b><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt"> (Continued)</span></i></p>


<p style="top:548.7pt;left:40.9pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:197.1pt;left:40.9pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:100.7pt;left:756.5pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 8 of 33</span></p>
<p style="top:173.7pt;left:769.3pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:69.9pt;left:91.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Uterus</span></p>
<p style="top:69.9pt;left:163.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">IIIA&#x2013;IVB</span></p>
<p style="top:69.9pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (95)</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III</span></sup></p>
<p style="top:69.9pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2.75</span></p>
<p style="top:69.9pt;left:400.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.61</span></p>
<p style="top:69.9pt;left:555.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.023</span></p>
<p style="top:69.9pt;left:612.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.39&#x2013;0.93</span></p>
<p style="top:69.9pt;left:665.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2008c </span></p>
<p style="top:79.1pt;left:665.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[49]</span></p>
<p style="top:99.4pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (95)</span></p>
<p style="top:99.4pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">1.67</span></p>
<p style="top:119.6pt;left:163.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">IA-C</span></p>
<p style="top:119.6pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (103)</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III</span></sup></p>
<p style="top:119.6pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">8.75</span></p>
<p style="top:119.6pt;left:400.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.41</span></p>
<p style="top:119.6pt;left:555.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">&lt;0.0001</span></p>
<p style="top:119.6pt;left:612.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.26&#x2013;0.63</span></p>
<p style="top:119.6pt;left:665.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2008d </span></p>
<p style="top:128.9pt;left:665.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[49]</span></p>
<p style="top:149.1pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (103)</span></p>
<p style="top:149.1pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">6.67</span></p>
<p style="top:169.4pt;left:91.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Ovary</span></p>
<p style="top:169.4pt;left:163.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">IA&#x2013;IC</span></p>
<p style="top:169.4pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (75)</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III</span></sup></p>
<p style="top:169.4pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">6.83</span></p>
<p style="top:169.4pt;left:400.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.47</span></p>
<p style="top:169.4pt;left:555.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.0002</span></p>
<p style="top:169.4pt;left:612.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.31&#x2013;0.69</span></p>
<p style="top:169.4pt;left:665.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2007d </span></p>
<p style="top:178.7pt;left:665.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[50]</span></p>
<p style="top:198.9pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (75)</span></p>
<p style="top:198.9pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">5.83</span></p>
<p style="top:219.2pt;left:163.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">IV</span></p>
<p style="top:219.2pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (62)</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III</span></sup></p>
<p style="top:219.2pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">1.79</span></p>
<p style="top:219.2pt;left:400.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.62</span></p>
<p style="top:219.2pt;left:555.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.077</span></p>
<p style="top:219.2pt;left:612.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.37&#x2013;1.05</span></p>
<p style="top:219.2pt;left:665.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2007e </span></p>
<p style="top:228.4pt;left:665.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[50]</span></p>
<p style="top:248.6pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (62)</span></p>
<p style="top:248.6pt;left:322.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">1.17</span></p>
<p style="top:268.9pt;left:91.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Genital</span></p>
<p style="top:268.9pt;left:163.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">All stages</span></p>
<p style="top:268.9pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Surgery</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">I</span></sup><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, radiation</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">I</span></sup><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, </span></p>
<p style="top:278.1pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (155)</span></p>
<p style="top:268.9pt;left:475.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Disease-specific </span></p>
<p style="top:278.1pt;left:475.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">survival partly </span></p>
<p style="top:287.4pt;left:475.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">improved</span></p>
<p style="top:268.9pt;left:555.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">not shown</span></p>
<p style="top:268.9pt;left:665.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Majewski 1963 [68]</span></p>
<p style="top:307.7pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Surgery</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">I</span></sup><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, radiation</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">I</span></sup><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">,</span></p>
<p style="top:316.9pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(not shown)</span></p>
<p style="top:337.1pt;left:91.0pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Retrolective pharmaco-epidemiological cohort studies</span></b></p>
<p style="top:357.4pt;left:91.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Breast</span></p>
<p style="top:357.4pt;left:163.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">I&#x2013;III</span></p>
<p style="top:357.4pt;left:242.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Conventional </span></p>
<p style="top:366.6pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">therapy, Iscador </span></p>
<p style="top:375.9pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(710)</span></p>
<p style="top:357.4pt;left:400.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.46</span></p>
<p style="top:357.4pt;left:555.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.038</span></p>
<p style="top:357.4pt;left:612.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.22&#x2013;0.96</span></p>
<p style="top:357.4pt;left:665.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Bock 2004 [70]</span></p>
<p style="top:396.2pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Conventional </span></p>
<p style="top:405.4pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">therapy (732)</span></p>
<p style="top:425.6pt;left:163.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">I&#x2013;IV</span></p>
<p style="top:425.6pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Conventional </span></p>
<p style="top:434.9pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">therapy, Eurixor </span></p>
<p style="top:444.2pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(219)</span></p>
<p style="top:425.6pt;left:475.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">No difference </span></p>
<p style="top:434.9pt;left:475.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">observed</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">V</span></sup></p>
<p style="top:425.6pt;left:665.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Schumacher 2003 </span></p>
<p style="top:434.9pt;left:665.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[71,72]</span></p>
<p style="top:464.4pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Conventional </span></p>
<p style="top:473.6pt;left:242.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">therapy (470)</span></p>
<p style="top:493.8pt;left:91.0pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">I </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Co-intervention (i.e. radiation) applied to part of the group</span></p>
<p style="top:503.1pt;left:91.0pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">II </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Not applicable since more than 50% alive at study termination</span></p>
<p style="top:512.3pt;left:91.0pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Data from complete set of patient pairs reported</span></p>
<p style="top:521.6pt;left:91.0pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">IV </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Data only from patient pairs with strict matching reported</span></p>
<p style="top:530.8pt;left:91.0pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">V </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">No difference could be found due to limited observation time (median &lt; 10 months)</span></p>
<p style="top:540.2pt;left:91.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">CMF: Cyclophosphamide, methotrexate, 5-fluorouracil</span></p>
<p style="top:549.4pt;left:91.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">P-value, 95% CI (confidence interval): Statistical significance of difference between mistletoe (or other verum) and control group.</span></p>
<p style="top:55.9pt;left:87.0pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Table 3: Controlled Clinical Studies on VAE Treatment in Breast and Gynaecological Cancer: Survival</span></b><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt"> (Continued)</span></i></p>


<p style="top:41.9pt;left:54.1pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:41.9pt;left:405.7pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:757.4pt;left:502.1pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 9 of 33</span></p>
<p style="top:770.1pt;left:430.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:86.0pt;left:54.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Table 4: Controlled Clinical Studies on VAE Treatment in Breast and Gynaecological Cancer: Tumour Behaviour or Pleurodesis</span></b></p>
<p style="top:103.9pt;left:58.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Site</span></b></p>
<p style="top:103.9pt;left:127.7pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Stage</span></b></p>
<p style="top:103.9pt;left:187.7pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Intervention </span></b></p>
<p style="top:113.2pt;left:187.7pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">(evaluable patients)</span></b></p>
<p style="top:103.9pt;left:286.2pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Outcome</span></b></p>
<p style="top:103.9pt;left:391.2pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">P-value</span></b></p>
<p style="top:103.9pt;left:427.5pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">95% CI</span></b></p>
<p style="top:103.9pt;left:468.0pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Author, year, </span></b></p>
<p style="top:113.2pt;left:468.0pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">reference</span></b></p>
<p style="top:135.4pt;left:58.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">R</span></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:6.2pt">EMISSION</span></b></p>
<p style="top:157.7pt;left:58.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Randomized controlled trials</span></b></p>
<p style="top:180.0pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Breast, ovary, lung</span></p>
<p style="top:180.0pt;left:127.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">T</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">1&#x2013;4</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, N</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">0&#x2013;3</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, M</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">0&#x2013;1</span></p>
<p style="top:180.0pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Chemotherapy</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">I</span></sup><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, Helixor A </span></p>
<p style="top:189.2pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(115)</span></p>
<p style="top:180.0pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Remission rate: no </span></p>
<p style="top:189.2pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">difference</span></p>
<p style="top:180.0pt;left:468.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Piao 2004 [56]</span></p>
<p style="top:211.5pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Chemotherapy</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">I</span></sup><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, Lentinan </span></p>
<p style="top:220.7pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(109)</span></p>
<p style="top:243.0pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Ovary, others</span></p>
<p style="top:243.0pt;left:127.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Inoperable</span></p>
<p style="top:243.0pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Radiation, cisplatin, </span></p>
<p style="top:252.2pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">holoxan, Helixor (23)</span></p>
<p style="top:243.0pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">10% complete remission</span></p>
<p style="top:252.2pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">48% partial remission</span></p>
<p style="top:261.4pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">5% progress</span></p>
<p style="top:243.0pt;left:468.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Lange 1985 [63]</span></p>
<p style="top:283.7pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Radiation, cisplatin, </span></p>
<p style="top:292.9pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">holoxan (21)</span></p>
<p style="top:283.7pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">17% complete remission</span></p>
<p style="top:292.9pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">48% partial remission</span></p>
<p style="top:302.2pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">4% progress</span></p>
<p style="top:324.4pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Pleural effusion</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">II</span></sup></p>
<p style="top:324.4pt;left:127.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Advanced</span></p>
<p style="top:324.4pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Helixor (11)</span></p>
<p style="top:324.4pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">82% complete remission</span></p>
<p style="top:333.7pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">9% partial remission</span></p>
<p style="top:324.4pt;left:391.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">&lt;0.05 </span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III</span></sup></p>
<p style="top:324.4pt;left:468.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Kim 1999 [60]</span></p>
<p style="top:355.9pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Doxycycline, meperidine, </span></p>
<p style="top:365.2pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">lidocaine (15)</span></p>
<p style="top:355.9pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">40% complete remission</span></p>
<p style="top:365.2pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">27% partial remission</span></p>
<p style="top:387.4pt;left:58.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">D</span></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:6.2pt">ISEASE-FREE INTERVAL, TIME TO EVENT, RECURRENCE</span></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt"> (H</span></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:6.2pt">AZARD RATIO</span></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">)</span></b></p>
<p style="top:409.7pt;left:58.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Randomized controlled trials</span></b></p>
<p style="top:432.0pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Breast</span></p>
<p style="top:432.0pt;left:127.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">T</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">1a-3</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, N</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">0</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, M</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">0</span></p>
<p style="top:432.0pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (38)</span></p>
<p style="top:432.0pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Time to local recurrences: </span></p>
<p style="top:441.2pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.44</span></p>
<p style="top:450.4pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">lymphatic metastases: 0.27</span></p>
<p style="top:459.7pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">distant metastases: 0.50</span></p>
<p style="top:468.9pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">all events (incl.death) 0.65</span></p>
<p style="top:432.0pt;left:391.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.18</span></p>
<p style="top:441.2pt;left:391.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.0048</span></p>
<p style="top:450.4pt;left:391.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.061</span></p>
<p style="top:459.7pt;left:391.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.012</span></p>
<p style="top:432.0pt;left:427.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.14&#x2013;1.44</span></p>
<p style="top:441.2pt;left:427.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.11&#x2013;0.67</span></p>
<p style="top:450.4pt;left:427.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.24&#x2013;1.03</span></p>
<p style="top:459.7pt;left:427.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.47&#x2013;0.91</span></p>
<p style="top:432.0pt;left:468.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2006a </span></p>
<p style="top:441.2pt;left:468.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[52,53]</span></p>
<p style="top:491.2pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (38)</span></p>
<p style="top:513.4pt;left:58.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Non-randomized controlled trials</span></b></p>
<p style="top:535.7pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Breast</span></p>
<p style="top:535.7pt;left:127.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">T</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">1&#x2013;3</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, N</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">0</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, M</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">0</span></p>
<p style="top:535.7pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (84)</span></p>
<p style="top:535.7pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Time to local recurrences: </span></p>
<p style="top:544.9pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.42</span></p>
<p style="top:554.2pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">lymphatic metastases: 0.22</span></p>
<p style="top:563.5pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">distant metastases: 0.36</span></p>
<p style="top:572.7pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">all event (incl.death) 0.66</span></p>
<p style="top:535.7pt;left:427.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.21&#x2013;0.83</span></p>
<p style="top:544.9pt;left:427.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.10&#x2013;0.47</span></p>
<p style="top:554.2pt;left:427.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.21&#x2013;0.62</span></p>
<p style="top:563.5pt;left:427.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.55&#x2013;0.79</span></p>
<p style="top:535.7pt;left:468.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2006b </span></p>
<p style="top:544.9pt;left:468.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[52,53]</span></p>
<p style="top:595.0pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (84)</span></p>
<p style="top:617.2pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Cervix</span></p>
<p style="top:617.2pt;left:127.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">IB-IVA</span></p>
<p style="top:617.2pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (102)</span></p>
<p style="top:617.2pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Time to local recurrences: </span></p>
<p style="top:626.5pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">1.42</span></p>
<p style="top:635.7pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">lymphatic metastases: None</span></p>
<p style="top:645.0pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">distant metast.:1 in Iscador </span></p>
<p style="top:654.2pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">group</span></p>
<p style="top:663.4pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">all event (incl.death) 0.32</span></p>
<p style="top:617.2pt;left:391.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.61</span></p>
<p style="top:626.5pt;left:391.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">n.a.</span></p>
<p style="top:635.7pt;left:391.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">n.a.</span></p>
<p style="top:645.0pt;left:391.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">&lt;0.0001</span></p>
<p style="top:617.2pt;left:427.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.37&#x2013;5.39</span></p>
<p style="top:626.5pt;left:427.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">n.a.</span></p>
<p style="top:635.7pt;left:427.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">n.a.</span></p>
<p style="top:645.0pt;left:427.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.22&#x2013;0.48</span></p>
<p style="top:617.2pt;left:468.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth 2007f [51]</span></p>
<p style="top:685.7pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (102)</span></p>


<p style="top:41.9pt;left:54.1pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:41.9pt;left:405.7pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:757.4pt;left:497.1pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 10 of 33</span></p>
<p style="top:770.1pt;left:430.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:367.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">reported QoL or symptomatic relief. Two studies primarily</span></p>
<p style="top:379.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">investigated the toxicity profile, pharmakokinetics and</span></p>
<p style="top:391.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">potential interactions of either the combination of gemcit-</span></p>
<p style="top:403.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">abine and VAE [44,73] or of rML [32], and secondarily</span></p>
<p style="top:414.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">assessed tumour behaviour. The commercial VAE remedies</span></p>
<p style="top:426.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">were Abnobaviscum</span><sup><span style="font-family:BqvvhnGiovanni,serif;font-size:6.8pt">&#xae;</span></sup><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">/Viscum fraxini, Iscador, Helixor,</span></p>
<p style="top:438.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Lektinol or Aviscumine</span><sup><span style="font-family:BqvvhnGiovanni,serif;font-size:6.8pt">&#xae; </span></sup><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(rML). VAE were applied subcuta-</span></p>
<p style="top:450.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">neously (n = 6), intratumourally (n = 1), intrapleurally (n</span></p>
<p style="top:461.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">= 2), intraperitoneally (n = 2) or as an intravenous infusion</span></p>
<p style="top:473.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(n = 1). Dosage depended on the preparation and mode of</span></p>
<p style="top:485.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">application; some treated according to lectin content, oth-</span></p>
<p style="top:497.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ers started with a low dosage and increased successively, or</span></p>
<p style="top:508.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">started with high dosage and applied it consistently once</span></p>
<p style="top:520.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">weekly. For intrapleural and intraperitoneal (repeated)</span></p>
<p style="top:532.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">application, VAE was diluted in 5 to 15 ml or 100 ml solu-</span></p>
<p style="top:544.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">tion. Treatment duration and follow-up ranged from weeks</span></p>
<p style="top:555.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">to, most commonly, months or years.</span></p>
<p style="top:579.3pt;left:54.1pt;line-height:9.5pt"><b><i><span style="font-family:FslmpdGillSans,serif;font-size:9.5pt">Quality assessment</span></i></b></p>
<p style="top:591.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Table 1, 2 and 6 summarize the validity assessment. Meth-</span></p>
<p style="top:602.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">odological quality differed substantially in the reviewed</span></p>
<p style="top:614.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">studies. 19 trials had randomized treatment allocation.</span></p>
<p style="top:626.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">The RCTs were mostly small (median sample size n = 60,</span></p>
<p style="top:638.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">range 23&#x2013;692), particularly when investigating survival</span></p>
<p style="top:649.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(median n = 52). Although RCTs investigating QoL were</span></p>
<p style="top:661.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">only slightly larger (median n = 68), they nevertheless</span></p>
<p style="top:673.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">encompass 4 trials that largely met modern standards of</span></p>
<p style="top:685.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">clinical trials and three of them had a sample size above</span></p>
<p style="top:696.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">200. In four of the RCTs the patients and physicians were</span></p>
<p style="top:708.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">blinded; three further RCTs had an active or a placebo</span></p>
<p style="top:367.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">control-treatment. &#x2013; 16 studies were non-randomized</span></p>
<p style="top:379.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(median sample size n = 203, range 82&#x2013;1442), 15 of them</span></p>
<p style="top:391.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">had controlled for confounding by close prospective (in</span></p>
<p style="top:403.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">one case retrospective) pair matching, by alternating treat-</span></p>
<p style="top:414.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ment allocation and by multivariate analysis or propen-</span></p>
<p style="top:426.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">sity score (though in one study only for the main outcome</span></p>
<p style="top:438.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">parameter [69]). &#x2013; Assurance of data quality according to</span></p>
<p style="top:450.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ICH-GCP (&quot;Good Clinical Practice&quot;) or GEP (&quot;Good Epi-</span></p>
<p style="top:461.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">demiological Practice&quot;) guidelines was reported in 5 RCTs</span></p>
<p style="top:473.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and 4 non-RCTs. Eight of the RCTs and 8 of the non-RCTs</span></p>
<p style="top:485.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">were embedded in the same large epidemiological cohort</span></p>
<p style="top:497.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">study. Most studies did not present a clear documentation</span></p>
<p style="top:508.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">of co-interventions. Regarding the other quality aspects,</span></p>
<p style="top:520.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">most studies &#x2013; especially the more recent ones &#x2013; were rea-</span></p>
<p style="top:532.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">sonably well designed and conducted.</span></p>
<p style="top:555.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">In the single-armed studies, study quality was reasonably</span></p>
<p style="top:567.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">good except in an unpublished report [80] and in an</span></p>
<p style="top:579.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">abstract publication [75] with too little information. Two</span></p>
<p style="top:591.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">studies had applied VAE in combination with or subse-</span></p>
<p style="top:602.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">quent to conventional cancer treatment and one study</span></p>
<p style="top:614.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">had explored CIN, which has high spontaneous remission</span></p>
<p style="top:626.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">rates.</span></p>
<p style="top:649.8pt;left:312.1pt;line-height:9.5pt"><b><i><span style="font-family:FslmpdGillSans,serif;font-size:9.5pt">Characteristics of the preclinical studies</span></i></b></p>
<p style="top:661.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">The </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">in vitro </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">cytotoxicity of different VAEs as well as iso-</span></p>
<p style="top:673.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">lated or recombinant lectins or their A-chain, viscotoxins,</span></p>
<p style="top:685.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">or other protein fractions were tested with different meth-</span></p>
<p style="top:696.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ods in a variety of human breast, ovarian, uterine, vulvar</span></p>
<p style="top:708.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and cervical cancer cells [12,20,22,81-110] (Table 7).</span></p>
<p style="top:92.7pt;left:58.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Retrolective pharmaco-epidemiological cohort study</span></b></p>
<p style="top:114.9pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Breast</span></p>
<p style="top:114.9pt;left:127.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">I&#x2013;III</span></p>
<p style="top:114.9pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Conventional therapy, </span></p>
<p style="top:124.2pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Helixor (167)</span></p>
<p style="top:114.9pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Recurrence, metastases, </span></p>
<p style="top:124.2pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">reoperation: no difference</span></p>
<p style="top:114.9pt;left:468.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Beuth 2008 [69]</span></p>
<p style="top:146.4pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Conventional therapy </span></p>
<p style="top:155.7pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(514)</span></p>
<p style="top:177.9pt;left:127.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">I&#x2013;III</span></p>
<p style="top:177.9pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Conventional therapy, </span></p>
<p style="top:187.2pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (710)</span></p>
<p style="top:177.9pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Recurrence: 0.98</span></p>
<p style="top:187.2pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Dist. metast. 0.65</span></p>
<p style="top:177.9pt;left:391.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.947</span></p>
<p style="top:187.2pt;left:391.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.172</span></p>
<p style="top:177.9pt;left:427.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.60&#x2013;1.62</span></p>
<p style="top:187.2pt;left:427.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.35&#x2013;1.21</span></p>
<p style="top:177.9pt;left:468.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Bock 2004 [70]</span></p>
<p style="top:209.4pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Conventional therapy </span></p>
<p style="top:218.7pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(732)</span></p>
<p style="top:240.9pt;left:127.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">I&#x2013;IV</span></p>
<p style="top:240.9pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Conventional therapy, </span></p>
<p style="top:250.2pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Eurixor (219)</span></p>
<p style="top:240.9pt;left:286.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Time to relapse: 0.28</span></p>
<p style="top:240.9pt;left:391.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.012</span></p>
<p style="top:240.9pt;left:427.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.10&#x2013;0.76</span></p>
<p style="top:240.9pt;left:468.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Schumacher 2003 </span></p>
<p style="top:250.2pt;left:468.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[71,72]</span></p>
<p style="top:272.4pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Conventional therapy </span></p>
<p style="top:281.7pt;left:187.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(470)</span></p>
<p style="top:303.9pt;left:58.1pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">I </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Chemotherapy: see table 5</span></p>
<p style="top:313.1pt;left:58.1pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">II </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Plural effusion indicates treatment site (primary cancer site: 4 &#xd7; breast, 1 &#xd7; cervix, 23 &#xd7; lung, 1 &#xd7; stomach, 1 &#xd7; unknown primary)</span></p>
<p style="top:322.3pt;left:58.1pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Side effects in Helixor and doxocycline group: pain in 6 and 14, fever in 3 and 6, burning sensation in 0 and 5 patients respectively; difference </span></p>
<p style="top:331.7pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">statistically significant (p &lt; 0.05)</span></p>
<p style="top:340.9pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">P-value, 95% CI (confidence interval): Statistical significance of difference between mistletoe (or other verum) and control group.</span></p>
<p style="top:77.7pt;left:54.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Table 4: Controlled Clinical Studies on VAE Treatment in Breast and Gynaecological Cancer: Tumour Behaviour or Pleurodesis</span></b><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt"> </span></i></p>


<p style="top:548.7pt;left:40.9pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:197.1pt;left:40.9pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:105.7pt;left:756.5pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 11 of 33</span></p>
<p style="top:173.7pt;left:769.3pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:64.1pt;left:87.0pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Table 5: Controlled Clinical Studies on VAE Treatment in Breast and Gynaecological Cancer: Reduction of side effects of chemotherapy, radiation or surgery; QoL</span></b></p>
<p style="top:82.1pt;left:89.0pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Site</span></b></p>
<p style="top:82.1pt;left:139.3pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Stage</span></b></p>
<p style="top:82.1pt;left:198.5pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Interventio</span></b></p>
<p style="top:91.4pt;left:198.5pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">n (evaluable </span></b></p>
<p style="top:100.7pt;left:198.5pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">patients)</span></b></p>
<p style="top:82.1pt;left:248.8pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Reduction of side effects of </span></b></p>
<p style="top:91.4pt;left:248.8pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">chemotherapy, radiation or surgery</span></b></p>
<p style="top:82.1pt;left:406.9pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">QoL (*during chemotherapy, radiation)</span></b></p>
<p style="top:82.1pt;left:694.4pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Author, </span></b></p>
<p style="top:91.4pt;left:694.4pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">year, </span></b></p>
<p style="top:100.7pt;left:694.4pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">reference</span></b></p>
<p style="top:121.9pt;left:248.8pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Outcome</span></b></p>
<p style="top:121.9pt;left:357.5pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">P-value</span></b></p>
<p style="top:121.9pt;left:407.0pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Measurement scale and outcome</span></b></p>
<p style="top:121.9pt;left:598.7pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">P-value</span></b></p>
<p style="top:121.9pt;left:646.6pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">95% CI</span></b></p>
<p style="top:143.1pt;left:89.0pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Randomized controlled trials</span></b></p>
<p style="top:164.4pt;left:89.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Breast</span></p>
<p style="top:164.4pt;left:139.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">T</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">1&#x2013;3</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, N</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">0&#x2013;2</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, M</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">0</span></p>
<p style="top:164.4pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">CAF, Iscador </span></p>
<p style="top:173.6pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">or Helixor </span></p>
<p style="top:182.9pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(59)</span></p>
<p style="top:164.4pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Neutropenia</span></p>
<p style="top:164.4pt;left:308.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">15%</span></p>
<p style="top:164.4pt;left:357.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.195</span></p>
<p style="top:164.4pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">EORTC QLQ-C30* </span></p>
<p style="top:173.6pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(Pain*, diarrhoea*, role*, insomnia*, nausea/vomiting*)</span></p>
<p style="top:164.4pt;left:598.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.0438 to</span></p>
<p style="top:173.6pt;left:598.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.0003</span></p>
<p style="top:164.4pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Tr&#xf6;ger 2009 </span></p>
<p style="top:173.6pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[47]</span></p>
<p style="top:204.2pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">CAF (30)</span></p>
<p style="top:204.2pt;left:308.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">27%</span></p>
<p style="top:225.4pt;left:139.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">No data</span></p>
<p style="top:225.4pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(F)EC, </span></p>
<p style="top:234.6pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador M </span></p>
<p style="top:243.9pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(32)</span></p>
<p style="top:225.4pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">EC-associated inhibition of </span></p>
<p style="top:234.6pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">granulocyte function: no </span></p>
<p style="top:243.9pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">difference.</span></p>
<p style="top:253.1pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Reduction of EC-related side </span></p>
<p style="top:262.4pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">effects (nausea, constipation, </span></p>
<p style="top:271.7pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">pain, stomatitis).</span></p>
<p style="top:280.9pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Lymphocytes, retching, emesis: </span></p>
<p style="top:290.1pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">no difference</span></p>
<p style="top:225.4pt;left:357.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">&gt;0.27</span></p>
<p style="top:225.4pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">EORTC QLQ-C30*, BR 23*, Rhodes Index*: no </span></p>
<p style="top:234.6pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">difference</span></p>
<p style="top:225.4pt;left:598.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">No data</span></p>
<p style="top:225.4pt;left:646.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">No data</span></p>
<p style="top:225.4pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">B&#xfc;ssing 2008 </span></p>
<p style="top:234.6pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[48]</span></p>
<p style="top:311.4pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(F)EC (33)</span></p>
<p style="top:311.4pt;left:357.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">&quot;significant&quot;</span></p>
<p style="top:332.6pt;left:139.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">T</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">1a-3</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, N</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">0</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, M</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">0</span></p>
<p style="top:332.6pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (38)</span></p>
<p style="top:332.6pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Self-regulation questionnaire,</span></p>
<p style="top:341.9pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Hazard-ratio</span></p>
<p style="top:332.6pt;left:550.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.35</span></p>
<p style="top:332.6pt;left:646.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.05&#x2013;0.60</span></p>
<p style="top:332.6pt;left:694.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth </span></p>
<p style="top:341.9pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2006a </span></p>
<p style="top:351.2pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[52,53]</span></p>
<p style="top:372.4pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (38)</span></p>
<p style="top:393.6pt;left:139.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">T</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">1&#x2013;3</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, N</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">0</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-N</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">+</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, M</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">0</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt"> CMF, </span></p>
<p style="top:402.9pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Lektinol 15 </span></p>
<p style="top:412.1pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ng ML (169)</span></p>
<p style="top:393.6pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Haematological parameters, hospitalization, </span></p>
<p style="top:402.9pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">paracetamol, metoclopramid: no difference.</span></p>
<p style="top:412.1pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Leucopenia </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2193;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt"> (trend)</span></p>
<p style="top:393.6pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">FACT-G*</span></p>
<p style="top:402.9pt;left:406.9pt;line-height:8.2pt"><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2191;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt"> 4.4</span></p>
<p style="top:393.6pt;left:454.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">GLQ-8* sum</span></p>
<p style="top:402.9pt;left:454.9pt;line-height:8.2pt"><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2193;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt"> 28.9</span></p>
<p style="top:393.6pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Spitzer </span></p>
<p style="top:402.9pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">uniscale*</span></p>
<p style="top:412.1pt;left:502.7pt;line-height:8.2pt"><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2193;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt"> 12.2</span></p>
<p style="top:393.6pt;left:550.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">KPS*</span></p>
<p style="top:402.9pt;left:550.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">No </span></p>
<p style="top:412.1pt;left:550.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">difference</span></p>
<p style="top:393.6pt;left:598.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">&lt;0.0001</span></p>
<p style="top:393.6pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Semiglasov </span></p>
<p style="top:402.9pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2006 [54]</span></p>
<p style="top:433.4pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">CMF, placebo </span></p>
<p style="top:442.7pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(168)</span></p>
<p style="top:433.4pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">FACT-G*</span></p>
<p style="top:442.7pt;left:406.9pt;line-height:8.2pt"><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2193;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt"> 5.11</span></p>
<p style="top:433.4pt;left:454.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">GLQ-8* sum</span></p>
<p style="top:442.7pt;left:454.9pt;line-height:8.2pt"><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2191;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt"> 94.8</span></p>
<p style="top:433.4pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Spitzer </span></p>
<p style="top:442.7pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">uniscale*</span></p>
<p style="top:451.9pt;left:502.7pt;line-height:8.2pt"><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2191;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt"> 10.8</span></p>
<p style="top:473.1pt;left:139.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">T</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">1&#x2013;2</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, N</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">0&#x2013;1</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, M</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">0</span></p>
<p style="top:473.1pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">CMF, </span></p>
<p style="top:482.4pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">radiation, </span></p>
<p style="top:491.6pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Helixor A </span></p>
<p style="top:500.9pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(11)</span></p>
<p style="top:473.1pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">CMF-induced </span></p>
<p style="top:482.4pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">NK-cell </span></p>
<p style="top:491.6pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">decrease </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2193;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt"> SCE-</span></p>
<p style="top:500.9pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">increase </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2193;</span></p>
<p style="top:510.2pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">other immune </span></p>
<p style="top:519.4pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">markers: no </span></p>
<p style="top:528.6pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">difference</span></p>
<p style="top:473.1pt;left:357.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.005</span></p>
<p style="top:482.4pt;left:357.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">n.s.</span></p>
<p style="top:473.1pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">EORTC </span></p>
<p style="top:482.4pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">QLQ-C30*</span></p>
<p style="top:473.1pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">No difference, data not </span></p>
<p style="top:482.4pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">shown</span></p>
<p style="top:473.1pt;left:598.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">not shown</span></p>
<p style="top:473.1pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Auerbach </span></p>
<p style="top:482.4pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2005 [55]</span></p>


<p style="top:548.7pt;left:40.9pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:197.1pt;left:40.9pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:105.7pt;left:756.5pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 12 of 33</span></p>
<p style="top:173.7pt;left:769.3pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:70.9pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">CMF, </span></p>
<p style="top:80.1pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">radiation, </span></p>
<p style="top:89.4pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">placebo (9)</span></p>
<p style="top:110.6pt;left:139.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">T</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">1&#x2013;3</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, N</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">0</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-N</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">+</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, M</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">0</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt"> CMF, </span></p>
<p style="top:119.9pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Lektinol 5 ng </span></p>
<p style="top:129.2pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ML (66)</span></p>
<p style="top:110.6pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Haematological </span></p>
<p style="top:119.9pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">parameters, </span></p>
<p style="top:129.2pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">hospitalization, </span></p>
<p style="top:138.4pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">paracetamol, </span></p>
<p style="top:147.6pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">metoclopramid: </span></p>
<p style="top:156.9pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">no difference. </span></p>
<p style="top:166.1pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">immune </span></p>
<p style="top:175.4pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">markerers: </span></p>
<p style="top:184.7pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">CD4, CD4/</span></p>
<p style="top:193.9pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">CD8, NK-cell-</span></p>
<p style="top:203.1pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">activity: </span></p>
<p style="top:212.4pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">significant </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2191;</span></p>
<p style="top:110.6pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">GLQ-8* sum</span></p>
<p style="top:119.9pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">No </span></p>
<p style="top:129.2pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">difference</span></p>
<p style="top:110.6pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Spitzer </span></p>
<p style="top:119.9pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">uniscale*</span></p>
<p style="top:129.2pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">No data</span></p>
<p style="top:110.6pt;left:550.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">QLQ C-30*</span></p>
<p style="top:119.9pt;left:550.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">No </span></p>
<p style="top:129.2pt;left:550.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">difference</span></p>
<p style="top:110.6pt;left:598.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">&lt;0.05</span></p>
<p style="top:110.6pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Semiglasov </span></p>
<p style="top:119.9pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2004 [57]</span></p>
<p style="top:233.6pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">CMF, </span></p>
<p style="top:242.9pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Lektinol 15 </span></p>
<p style="top:252.2pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ng ML (65)</span></p>
<p style="top:233.6pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">GLQ-8* sum</span></p>
<p style="top:242.9pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Superior </span></p>
<p style="top:252.2pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">60,8mm</span></p>
<p style="top:233.6pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Spitzer </span></p>
<p style="top:242.9pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">uniscale*</span></p>
<p style="top:252.2pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Superior </span></p>
<p style="top:261.4pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">16,4 mm</span></p>
<p style="top:282.6pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">CMF, </span></p>
<p style="top:291.9pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Lektinol 35 </span></p>
<p style="top:301.1pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ng ML (64)</span></p>
<p style="top:282.6pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">GLQ-8* sum</span></p>
<p style="top:291.9pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">No </span></p>
<p style="top:301.1pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">difference</span></p>
<p style="top:282.6pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Spitzer </span></p>
<p style="top:291.9pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">uniscale*</span></p>
<p style="top:301.1pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">No data</span></p>
<p style="top:322.4pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">CMF, placebo </span></p>
<p style="top:331.7pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(66)</span></p>
<p style="top:352.9pt;left:139.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">IIIA&#x2013;IIIB</span></p>
<p style="top:352.9pt;left:198.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (17)</span></p>
<p style="top:352.9pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Self-</span></p>
<p style="top:362.1pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">regulation </span></p>
<p style="top:380.6pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">e </span><sup><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">questionnair</span></sup></p>
<p style="top:389.9pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(score 1&#x2013;6)</span></p>
<p style="top:352.9pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2.92 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2192;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt"> 3.7</span></p>
<p style="top:352.9pt;left:598.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.13</span></p>
<p style="top:352.9pt;left:694.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth </span></p>
<p style="top:362.1pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2001a [59]</span></p>
<p style="top:411.2pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (17)</span></p>
<p style="top:411.2pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2.87 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2192;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt"> 2.99</span></p>
<p style="top:432.4pt;left:139.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">IV</span></p>
<p style="top:432.4pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador </span></p>
<p style="top:441.6pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">spezial (20)</span></p>
<p style="top:432.4pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Spitzer score </span></p>
<p style="top:441.6pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">questionnair</span></p>
<p style="top:450.9pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">e</span></p>
<p style="top:432.4pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">~5 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2192;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt"> 7.2</span></p>
<p style="top:432.4pt;left:598.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">&lt;0.05</span></p>
<p style="top:432.4pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Borrelli 2001 </span></p>
<p style="top:441.6pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[58]</span></p>
<p style="top:472.1pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Placebo (10)</span></p>
<p style="top:472.1pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">~5.2 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2192;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt"> 4.8</span></p>
<p style="top:493.4pt;left:139.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Advanced</span></p>
<p style="top:493.4pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">VEC, Eurixor </span></p>
<p style="top:502.7pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(21)</span></p>
<p style="top:493.4pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Leukopenia </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2193;</span></p>
<p style="top:502.7pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Platelets: no </span></p>
<p style="top:511.9pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">difference</span></p>
<p style="top:493.4pt;left:357.5pt;line-height:8.2pt"><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2264;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt"> 0.001</span></p>
<p style="top:493.4pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">QoL index* </span></p>
<p style="top:502.7pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(superior)</span></p>
<p style="top:493.4pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Anxienty </span></p>
<p style="top:502.7pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">scale* </span></p>
<p style="top:511.9pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(superior)</span></p>
<p style="top:493.4pt;left:598.6pt;line-height:8.2pt"><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2264;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt"> 0.01</span></p>
<p style="top:493.4pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Heiny 1991 </span></p>
<p style="top:502.7pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[61]</span></p>
<p style="top:533.1pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">VEC, placebo </span></p>
<p style="top:542.4pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(19)</span></p>
<p style="top:55.9pt;left:87.0pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Table 5: Controlled Clinical Studies on VAE Treatment in Breast and Gynaecological Cancer: Reduction of side effects of chemotherapy, radiation or surgery; QoL</span></b><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt"> (Continued)</span></i></p>


<p style="top:548.7pt;left:40.9pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:197.1pt;left:40.9pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:105.7pt;left:756.5pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 13 of 33</span></p>
<p style="top:173.7pt;left:769.3pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:70.9pt;left:89.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Breast, </span></p>
<p style="top:80.1pt;left:89.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">others</span></p>
<p style="top:70.9pt;left:139.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">All stages</span></p>
<p style="top:70.9pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (39)</span></p>
<p style="top:70.9pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Self-</span></p>
<p style="top:80.1pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">regulation </span></p>
<p style="top:89.4pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">questionnair</span></p>
<p style="top:98.6pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">e</span></p>
<p style="top:117.2pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(score 1&#x2013;6)</span></p>
<p style="top:70.9pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">3.41 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2192;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt"> 3.87</span></p>
<p style="top:70.9pt;left:598.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.02</span></p>
<p style="top:70.9pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth </span></p>
<p style="top:80.1pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2001b [59]</span></p>
<p style="top:138.4pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (39)</span></p>
<p style="top:138.4pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">3.85 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2192;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt"> 3.62</span></p>
<p style="top:159.6pt;left:89.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Breast, ovary, </span></p>
<p style="top:168.9pt;left:89.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">lung</span></p>
<p style="top:159.6pt;left:139.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">T</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">1&#x2013;4</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, N</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">0&#x2013;3</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, M</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">0&#x2013;1</span></p>
<p style="top:159.6pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Chemothera</span></p>
<p style="top:168.9pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">py</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">I</span></sup><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, Helixor A </span></p>
<p style="top:178.1pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(115)</span></p>
<p style="top:159.6pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Chemotherapy-related adverse </span></p>
<p style="top:168.9pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">events</span></p>
<p style="top:178.1pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">28</span></p>
<p style="top:159.6pt;left:357.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">not shown</span></p>
<p style="top:159.6pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">FLIC-score*</span></p>
<p style="top:168.9pt;left:406.9pt;line-height:8.2pt"><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2191;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt"> 9</span></p>
<p style="top:159.6pt;left:454.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">TCM-score*</span></p>
<p style="top:168.9pt;left:454.9pt;line-height:8.2pt"><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2191;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt"> -1</span></p>
<p style="top:159.6pt;left:550.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">KPS* </span></p>
<p style="top:168.9pt;left:550.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">increase in % </span></p>
<p style="top:178.1pt;left:550.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">of patients</span></p>
<p style="top:187.4pt;left:550.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">50%</span></p>
<p style="top:159.6pt;left:598.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">FLIC 0.014</span></p>
<p style="top:168.9pt;left:598.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">TCM 0.0007</span></p>
<p style="top:178.1pt;left:598.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">KPS 0.002</span></p>
<p style="top:159.6pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Piao 2004 </span></p>
<p style="top:168.9pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[56]</span></p>
<p style="top:208.7pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Chemothera</span></p>
<p style="top:217.9pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">py</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">I</span></sup><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, Lentinan </span></p>
<p style="top:227.1pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(109)</span></p>
<p style="top:208.7pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Chemotherapy-related adverse </span></p>
<p style="top:217.9pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">events</span></p>
<p style="top:227.1pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">77</span></p>
<p style="top:208.7pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">FLIC-score*</span></p>
<p style="top:217.9pt;left:406.9pt;line-height:8.2pt"><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2191;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt"> 4,7</span></p>
<p style="top:208.7pt;left:454.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">TCM-score*</span></p>
<p style="top:217.9pt;left:454.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0</span></p>
<p style="top:208.7pt;left:550.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">KPS* </span></p>
<p style="top:217.9pt;left:550.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">increase in % </span></p>
<p style="top:227.1pt;left:550.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">of patients</span></p>
<p style="top:236.4pt;left:550.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">32%</span></p>
<p style="top:257.6pt;left:89.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Ovary</span></p>
<p style="top:257.6pt;left:139.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">IA&#x2013;IC</span></p>
<p style="top:257.6pt;left:198.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (21)</span></p>
<p style="top:257.6pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Self-regulation </span></p>
<p style="top:266.9pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">questionnaire, (score 1&#x2013;6) </span></p>
<p style="top:276.2pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">median difference</span></p>
<p style="top:257.6pt;left:550.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.58</span></p>
<p style="top:257.6pt;left:598.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.0002</span></p>
<p style="top:257.6pt;left:646.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.30&#x2013;0.90</span></p>
<p style="top:257.6pt;left:694.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth </span></p>
<p style="top:266.9pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2007a [50]</span></p>
<p style="top:297.4pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (21)</span></p>
<p style="top:318.6pt;left:89.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Ovary, </span></p>
<p style="top:327.9pt;left:89.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">others</span></p>
<p style="top:318.6pt;left:139.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Inoperable</span></p>
<p style="top:318.6pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Radiation, </span></p>
<p style="top:327.9pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">cisplatin, </span></p>
<p style="top:337.1pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">holoxan, </span></p>
<p style="top:346.4pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Helixor (23)</span></p>
<p style="top:318.6pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Nausea </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2193;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">,</span></p>
<p style="top:327.9pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">vomiting </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2193;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">,</span></p>
<p style="top:337.1pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">depression of </span></p>
<p style="top:346.4pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">leucopoiesis </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2193;</span></p>
<p style="top:318.6pt;left:357.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.005, 0.08,</span></p>
<p style="top:327.9pt;left:357.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.003</span></p>
<p style="top:318.6pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">KPS*</span></p>
<p style="top:318.6pt;left:454.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">67% </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2192;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt"> 76% </span></p>
<p style="top:327.9pt;left:454.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(p = 0.0008</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">II</span></sup><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">)</span></p>
<p style="top:318.6pt;left:598.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">not shown</span></p>
<p style="top:318.6pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Lange 1985 </span></p>
<p style="top:327.9pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[63]</span></p>
<p style="top:367.7pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Radiation, </span></p>
<p style="top:376.9pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">cisplatin, </span></p>
<p style="top:386.1pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">holoxan (21)</span></p>
<p style="top:367.7pt;left:454.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">70% </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2192;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt"> 74% </span></p>
<p style="top:376.9pt;left:454.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(p = 0.12</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">II</span></sup><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">)</span></p>
<p style="top:407.4pt;left:89.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Cervix</span></p>
<p style="top:407.4pt;left:139.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">IVA-B</span></p>
<p style="top:407.4pt;left:198.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (19)</span></p>
<p style="top:407.4pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Self-regulation </span></p>
<p style="top:416.6pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">questionnaire, (score 1&#x2013;6) </span></p>
<p style="top:425.9pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">median difference</span></p>
<p style="top:407.4pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.7</span></p>
<p style="top:407.4pt;left:598.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.014</span></p>
<p style="top:407.4pt;left:646.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.15&#x2013;1.05</span></p>
<p style="top:407.4pt;left:694.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth </span></p>
<p style="top:416.6pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2007c [51]</span></p>
<p style="top:447.2pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (19)</span></p>
<p style="top:468.4pt;left:89.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Uterus</span></p>
<p style="top:468.4pt;left:139.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">IA-C</span></p>
<p style="top:468.4pt;left:198.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (30)</span></p>
<p style="top:468.4pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Self-regulation </span></p>
<p style="top:477.6pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">questionnaire, (score 1&#x2013;6) </span></p>
<p style="top:486.9pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">median difference</span></p>
<p style="top:468.4pt;left:502.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.4</span></p>
<p style="top:468.4pt;left:598.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.0012</span></p>
<p style="top:468.4pt;left:646.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.15&#x2013;0.70</span></p>
<p style="top:468.4pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth </span></p>
<p style="top:477.6pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2008a [49]</span></p>
<p style="top:508.1pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (30)</span></p>
<p style="top:55.9pt;left:87.0pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Table 5: Controlled Clinical Studies on VAE Treatment in Breast and Gynaecological Cancer: Reduction of side effects of chemotherapy, radiation or surgery; QoL</span></b><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt"> (Continued)</span></i></p>


<p style="top:548.7pt;left:40.9pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:197.1pt;left:40.9pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:105.7pt;left:756.5pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 14 of 33</span></p>
<p style="top:173.7pt;left:769.3pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:83.7pt;left:71.3pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Non-randomized controlled studies</span></b></p>
<p style="top:105.0pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Breast</span></p>
<p style="top:105.0pt;left:121.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">T</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">1&#x2013;3</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, N</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">0</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, M</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">0</span></p>
<p style="top:105.0pt;left:180.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (84)</span></p>
<p style="top:105.0pt;left:389.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Self-regulation </span></p>
<p style="top:114.2pt;left:389.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">questionnaire</span></p>
<p style="top:123.5pt;left:389.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Hazard-ratio</span></p>
<p style="top:105.0pt;left:485.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.20</span></p>
<p style="top:105.0pt;left:580.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.031</span></p>
<p style="top:105.0pt;left:628.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.00&#x2013;0.35</span></p>
<p style="top:105.0pt;left:676.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth </span></p>
<p style="top:114.2pt;left:676.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2006b </span></p>
<p style="top:123.5pt;left:676.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[52,53]</span></p>
<p style="top:144.7pt;left:180.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (84)</span></p>
<p style="top:165.9pt;left:121.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">I&#x2013;II</span></p>
<p style="top:165.9pt;left:180.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Surgery, </span></p>
<p style="top:175.2pt;left:180.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">CMF/EC, </span></p>
<p style="top:184.5pt;left:180.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (33)</span></p>
<p style="top:165.9pt;left:231.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">CMF/EC-induced lymphocyte </span></p>
<p style="top:175.2pt;left:231.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">decrease </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2191;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">,</span></p>
<p style="top:184.5pt;left:231.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">platelet decrease </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2193;</span></p>
<p style="top:165.9pt;left:339.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">n.s,</span></p>
<p style="top:175.2pt;left:339.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.01</span></p>
<p style="top:165.9pt;left:389.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">EORTC QLQ-C30*, BR </span></p>
<p style="top:175.2pt;left:389.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">23*</span></p>
<p style="top:165.9pt;left:485.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Reduced </span></p>
<p style="top:175.2pt;left:485.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">increase of </span></p>
<p style="top:184.5pt;left:485.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">nausea/</span></p>
<p style="top:193.7pt;left:485.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">vomiting, </span></p>
<p style="top:203.0pt;left:485.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">general side </span></p>
<p style="top:212.2pt;left:485.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">effects of </span></p>
<p style="top:221.4pt;left:485.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">CMF/EC</span></p>
<p style="top:165.9pt;left:580.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.02</span></p>
<p style="top:175.2pt;left:580.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.02</span></p>
<p style="top:165.9pt;left:676.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Loewe-</span></p>
<p style="top:175.2pt;left:676.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mesch [64]</span></p>
<p style="top:242.7pt;left:180.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Surgery, </span></p>
<p style="top:252.0pt;left:180.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">CMF/EC (33)</span></p>
<p style="top:273.2pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Breast </span></p>
<p style="top:282.5pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(suspected)</span></p>
<p style="top:273.2pt;left:180.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Surgery, </span></p>
<p style="top:282.5pt;left:180.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador M </span></p>
<p style="top:291.7pt;left:180.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">spezial (47)</span></p>
<p style="top:273.2pt;left:231.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Prevention of surgery-</span></p>
<p style="top:282.5pt;left:231.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">associated inhibition of </span></p>
<p style="top:291.7pt;left:231.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">granulocyte function (PMA- </span></p>
<p style="top:301.0pt;left:231.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">and E.coli-stimulated oxidative </span></p>
<p style="top:310.2pt;left:231.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">burst)</span></p>
<p style="top:273.2pt;left:339.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">&lt;0.0001,&lt;0.0</span></p>
<p style="top:282.5pt;left:339.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">01</span></p>
<p style="top:273.2pt;left:676.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">B&#xfc;ssing 2005 </span></p>
<p style="top:282.5pt;left:676.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[65]</span></p>
<p style="top:331.5pt;left:180.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Surgery (51)</span></p>
<p style="top:352.7pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Ovary</span></p>
<p style="top:352.7pt;left:121.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">IA&#x2013;IC</span></p>
<p style="top:352.7pt;left:180.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (75)</span></p>
<p style="top:352.7pt;left:389.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Self-regulation </span></p>
<p style="top:362.0pt;left:389.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">questionnaire, (score 1&#x2013;6) </span></p>
<p style="top:371.2pt;left:389.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">median difference</span></p>
<p style="top:352.7pt;left:485.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.30</span></p>
<p style="top:352.7pt;left:580.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">&lt;0.026</span></p>
<p style="top:352.7pt;left:628.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.10&#x2013;0.60</span></p>
<p style="top:352.7pt;left:676.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth </span></p>
<p style="top:362.0pt;left:676.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2007d [50]</span></p>
<p style="top:392.5pt;left:180.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (75)</span></p>
<p style="top:413.7pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Cervix</span></p>
<p style="top:413.7pt;left:121.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">IB-IVA</span></p>
<p style="top:413.7pt;left:180.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (102)</span></p>
<p style="top:413.7pt;left:389.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Self-regulation </span></p>
<p style="top:423.0pt;left:389.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">questionnaire, (score 1&#x2013;6) </span></p>
<p style="top:432.2pt;left:389.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">median difference</span></p>
<p style="top:413.7pt;left:485.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.25</span></p>
<p style="top:413.7pt;left:580.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">&lt;0.0005</span></p>
<p style="top:413.7pt;left:628.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.15&#x2013;0.35</span></p>
<p style="top:413.7pt;left:676.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth </span></p>
<p style="top:423.0pt;left:676.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2007f [51]</span></p>
<p style="top:453.5pt;left:180.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (102)</span></p>
<p style="top:474.7pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Uterus</span></p>
<p style="top:474.7pt;left:121.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">IA-C</span></p>
<p style="top:474.7pt;left:180.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (103)</span></p>
<p style="top:474.7pt;left:389.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Self-regulation </span></p>
<p style="top:484.0pt;left:389.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">questionnaire, (score 1&#x2013;6) </span></p>
<p style="top:493.2pt;left:389.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">median difference</span></p>
<p style="top:474.7pt;left:485.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.65</span></p>
<p style="top:474.7pt;left:580.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">&lt;0.0005</span></p>
<p style="top:474.7pt;left:628.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.4&#x2013;0.95</span></p>
<p style="top:474.7pt;left:676.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Grossarth </span></p>
<p style="top:484.0pt;left:676.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2008d [49]</span></p>
<p style="top:514.5pt;left:180.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">None (103)</span></p>
<p style="top:68.8pt;left:69.3pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Table 5: Controlled Clinical Studies on VAE Treatment in Breast and Gynaecological Cancer: Reduction of side effects of chemotherapy, radiation or surgery; QoL</span></b><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt"> (Continued)</span></i></p>


<p style="top:548.7pt;left:40.9pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:197.1pt;left:40.9pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:105.7pt;left:756.5pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 15 of 33</span></p>
<p style="top:173.7pt;left:769.3pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:165.5pt;left:89.0pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Retrolective pharmaco-epidemiological cohort study</span></b></p>
<p style="top:186.7pt;left:89.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Breast</span></p>
<p style="top:186.7pt;left:139.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">I&#x2013;III</span></p>
<p style="top:186.7pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Conventional </span></p>
<p style="top:195.9pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">therapy, </span></p>
<p style="top:205.2pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Helixor (167)</span></p>
<p style="top:186.7pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Odds ratio for occurrence of disease- or treatment </span></p>
<p style="top:195.9pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">associated symptoms: 0.508</span></p>
<p style="top:186.7pt;left:646.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.319&#x2013;0.811</span></p>
<p style="top:186.7pt;left:694.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Beuth 2008 </span></p>
<p style="top:195.9pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[69]</span></p>
<p style="top:226.5pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Conventional </span></p>
<p style="top:235.7pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">therapy (514)</span></p>
<p style="top:257.0pt;left:139.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">I&#x2013;III</span></p>
<p style="top:257.0pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Conventional </span></p>
<p style="top:266.2pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">therapy, </span></p>
<p style="top:275.5pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador (710)</span></p>
<p style="top:257.0pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Adverse drug reactions </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2193;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, </span></p>
<p style="top:266.2pt;left:248.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Odds ratio: 0.47</span></p>
<p style="top:257.0pt;left:357.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">95% CI 0.32&#x2013;</span></p>
<p style="top:266.2pt;left:357.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.67</span></p>
<p style="top:257.0pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Odds ratio for being symptom-free 3.56 (vomiting, </span></p>
<p style="top:266.2pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">headache, exhaustion, depression, concentration, sleep, </span></p>
<p style="top:275.5pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">dizziness, irritability) </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2191;</span></p>
<p style="top:257.0pt;left:646.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2.03&#x2013;6.27</span></p>
<p style="top:257.0pt;left:694.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Bock 2004 </span></p>
<p style="top:266.2pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[70]</span></p>
<p style="top:296.7pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Conventional </span></p>
<p style="top:306.0pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">therapy (732)</span></p>
<p style="top:327.2pt;left:139.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">I&#x2013;IV</span></p>
<p style="top:327.2pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Conventional </span></p>
<p style="top:336.5pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">therapy, </span></p>
<p style="top:345.7pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Eurixor (219)</span></p>
<p style="top:327.2pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Symptom mean score improved (nausea, appetite, </span></p>
<p style="top:336.5pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">stomach pain, tiredness, depression, concentration, </span></p>
<p style="top:345.7pt;left:406.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">irritability, sleep)</span></p>
<p style="top:327.2pt;left:598.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">&lt;0.0001</span></p>
<p style="top:327.2pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Schumacher </span></p>
<p style="top:336.5pt;left:694.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2003 [71,72]</span></p>
<p style="top:367.0pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Conventional </span></p>
<p style="top:376.2pt;left:198.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">therapy (470)</span></p>
<p style="top:397.4pt;left:89.0pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">I </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Chemotherapy (referring to the study by Piao et al.) &#x2013; breast cancer: CAP, CAF (CAP: Cyclophosphamide, doxorubicin, cisplatin; CAF: Cyclophosphamide, doxorubicin, 5-fluorouracil); ovarian </span></p>
<p style="top:406.7pt;left:89.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">cancer: CP, IcP (CP: Cyclophosphamide, cisplatin, IcP: Ifosfamid, carboplatin); non-small cell-lung cancer: VP, MViP (VP: Vinorelbine, cisplatin; MViP: Mitomycin, vindesine, cisplatin).</span></p>
<p style="top:415.9pt;left:89.0pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">II </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Statistical significance of pre-post difference within each group</span></p>
<p style="top:425.2pt;left:89.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">QoL: Quality of life; KPS: Karnofsky Performance Status Scale SCE: Sister chromatid exchange; </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2191;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">: increase; </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x2193;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">: decrease. P-value, 95% CI: Statistical significance of difference between mistletoe (or </span></p>
<p style="top:434.5pt;left:89.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">other verum) and control group; n.s.: not statistically significant; EC: Epirubicin, cyclophosphamide (F: 5-fluorouracil); VEC: Vindesine, epirubicin, cyclophosphamide; CMF: Cyclophosphamide, </span></p>
<p style="top:443.7pt;left:89.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">methotrexate 5-fluorouracil; CAF: Cyclophosphamide, doxorubicin, 5-fluorouracil.</span></p>
<p style="top:150.5pt;left:87.0pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Table 5: Controlled Clinical Studies on VAE Treatment in Breast and Gynaecological Cancer: Reduction of side effects of chemotherapy, radiation or surgery; QoL</span></b><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt"> (Continued)</span></i></p>


<p style="top:548.7pt;left:40.9pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:197.1pt;left:40.9pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:105.7pt;left:756.5pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 16 of 33</span></p>
<p style="top:173.7pt;left:769.3pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:154.6pt;left:69.3pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Table 6: Single-Arm Cohort Studies (e.g. Phase II Trials) on VAE Treatment in Breast and Gynaecological Cancer</span></b></p>
<p style="top:172.6pt;left:71.3pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Author, Year</span></b></p>
<p style="top:172.6pt;left:138.6pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Treatment</span></b><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">I</span></sup></p>
<p style="top:172.6pt;left:395.5pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Site</span></b><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">II</span></sup></p>
<p style="top:172.6pt;left:440.7pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Outcome</span></b><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III</span></sup></p>
<p style="top:172.6pt;left:598.4pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">N</span></b><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">IV</span></sup></p>
<p style="top:172.6pt;left:619.9pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Quality Criteria Fulfilled</span></b><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">VI</span></sup></p>
<p style="top:194.9pt;left:138.6pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Preparation</span></b></p>
<p style="top:194.9pt;left:214.8pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Injection </span></b></p>
<p style="top:204.1pt;left:214.8pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">site</span></b></p>
<p style="top:194.9pt;left:256.4pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Dosage</span></b></p>
<p style="top:194.9pt;left:316.0pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Escalatin</span></b></p>
<p style="top:204.1pt;left:316.0pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">g dosage</span></b></p>
<p style="top:194.9pt;left:355.7pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Duration</span></b></p>
<p style="top:194.9pt;left:440.7pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">CR</span></b></p>
<p style="top:194.9pt;left:500.8pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">PR</span></b></p>
<p style="top:194.9pt;left:523.8pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">NC</span></b></p>
<p style="top:194.9pt;left:546.8pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">PD</span></b></p>
<p style="top:194.9pt;left:569.9pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">QoL</span></b></p>
<p style="top:194.9pt;left:619.9pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">L</span></b></p>
<p style="top:194.9pt;left:639.0pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">M</span></b></p>
<p style="top:194.9pt;left:658.0pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">N</span></b></p>
<p style="top:194.9pt;left:677.2pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">O</span></b></p>
<p style="top:194.9pt;left:699.9pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">P</span></b></p>
<p style="top:194.9pt;left:719.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Q</span></b></p>
<p style="top:226.4pt;left:71.3pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Breast, Ovary, CIN</span></b></p>
<p style="top:248.6pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mansky 2008 </span></p>
<p style="top:257.9pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[44,73]</span></p>
<p style="top:248.6pt;left:138.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Helixor</span></p>
<p style="top:257.9pt;left:138.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(&amp; gemcitabine)</span></p>
<p style="top:248.6pt;left:214.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">sc</span></p>
<p style="top:248.6pt;left:256.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Up to 250 mg, </span></p>
<p style="top:257.9pt;left:256.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">daily</span></p>
<p style="top:248.6pt;left:316.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Yes</span></p>
<p style="top:248.6pt;left:355.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">9 w</span></p>
<p style="top:248.6pt;left:395.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Breast, </span></p>
<p style="top:257.9pt;left:395.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">others</span></p>
<p style="top:248.6pt;left:440.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0%</span></p>
<p style="top:248.6pt;left:500.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">10%</span></p>
<p style="top:248.6pt;left:523.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">47%</span></p>
<p style="top:248.6pt;left:546.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">43%</span></p>
<p style="top:248.6pt;left:598.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">27</span></p>
<p style="top:248.6pt;left:619.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:248.6pt;left:638.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:248.6pt;left:658.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:248.6pt;left:677.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">V</span></sup></p>
<p style="top:248.6pt;left:699.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:248.6pt;left:719.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:280.1pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Schink 2006 [45]</span></p>
<p style="top:280.1pt;left:138.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Helixor</span></p>
<p style="top:289.4pt;left:138.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(&amp; surgery)</span></p>
<p style="top:280.1pt;left:214.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">sc</span></p>
<p style="top:280.1pt;left:256.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">3/week, varying </span></p>
<p style="top:289.4pt;left:256.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">individually</span></p>
<p style="top:280.1pt;left:316.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Yes</span></p>
<p style="top:280.1pt;left:355.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Up to 2 </span></p>
<p style="top:289.4pt;left:355.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">years</span></p>
<p style="top:280.1pt;left:395.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Breast, </span></p>
<p style="top:289.4pt;left:395.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">colon</span></p>
<p style="top:280.1pt;left:440.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:280.1pt;left:500.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:280.1pt;left:523.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:280.1pt;left:546.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:280.1pt;left:569.8pt;line-height:8.2pt"><span style="font-family:Times New Roman,serif;font-size:8.2pt">&#xe2;</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">IIIa</span></sup></p>
<p style="top:280.1pt;left:598.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">40</span></p>
<p style="top:280.1pt;left:619.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:280.1pt;left:638.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:280.1pt;left:658.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:280.1pt;left:677.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">V</span></sup></p>
<p style="top:280.1pt;left:699.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:280.1pt;left:719.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:311.6pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Sch&#xf6;ffski 2004 </span></p>
<p style="top:320.9pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[32]</span></p>
<p style="top:311.6pt;left:138.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Aviscumine</span></p>
<p style="top:311.6pt;left:214.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">iv</span></p>
<p style="top:311.6pt;left:256.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">10 &#x2013; 6400 ng/kg, </span></p>
<p style="top:320.9pt;left:256.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2/w</span></p>
<p style="top:311.6pt;left:316.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Yes</span></p>
<p style="top:311.6pt;left:355.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">3&#x2013;24 w, </span></p>
<p style="top:320.9pt;left:355.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">median 6 </span></p>
<p style="top:330.1pt;left:355.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">w</span></p>
<p style="top:311.6pt;left:395.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Ovary, </span></p>
<p style="top:320.9pt;left:395.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">breast, </span></p>
<p style="top:330.1pt;left:395.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">others</span></p>
<p style="top:311.6pt;left:440.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0%</span></p>
<p style="top:311.6pt;left:500.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0%</span></p>
<p style="top:311.6pt;left:523.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">30%</span></p>
<p style="top:311.6pt;left:546.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">70%</span></p>
<p style="top:311.6pt;left:598.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">37</span></p>
<p style="top:311.6pt;left:619.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:311.6pt;left:639.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:311.6pt;left:658.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:311.6pt;left:677.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:311.6pt;left:699.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:311.6pt;left:719.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:352.4pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mahfouz 1999 [74] Viscum fraxini</span></p>
<p style="top:352.4pt;left:214.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">sc or it</span></p>
<p style="top:352.4pt;left:256.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">1 &#xd7; 45 mg/w</span></p>
<p style="top:352.4pt;left:316.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">No</span></p>
<p style="top:352.4pt;left:355.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">16&#x2013;136 w</span></p>
<p style="top:352.4pt;left:395.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Breast</span></p>
<p style="top:352.4pt;left:440.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">8%</span></p>
<p style="top:352.4pt;left:500.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">54%</span></p>
<p style="top:352.4pt;left:523.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">35%</span></p>
<p style="top:352.4pt;left:546.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">4%</span></p>
<p style="top:352.4pt;left:569.8pt;line-height:8.2pt"><span style="font-family:Times New Roman,serif;font-size:8.2pt">&#xe2;</span></p>
<p style="top:352.4pt;left:598.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">26</span></p>
<p style="top:352.4pt;left:619.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:352.4pt;left:638.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:352.4pt;left:658.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:352.4pt;left:677.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:352.4pt;left:699.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:352.4pt;left:719.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:374.6pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mahfouz 1998 [75] Abnobaviscum Fr</span></p>
<p style="top:374.6pt;left:214.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">sc</span></p>
<p style="top:374.6pt;left:256.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">1 &#xd7; 45 mg/w</span></p>
<p style="top:374.6pt;left:316.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">No</span></p>
<p style="top:374.6pt;left:355.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">17 w</span></p>
<p style="top:374.6pt;left:395.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Breast</span></p>
<p style="top:374.6pt;left:440.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0%</span></p>
<p style="top:374.6pt;left:500.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">44%</span></p>
<p style="top:374.6pt;left:523.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">33%</span></p>
<p style="top:374.6pt;left:546.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">22%</span></p>
<p style="top:374.6pt;left:569.8pt;line-height:8.2pt"><span style="font-family:Times New Roman,serif;font-size:8.2pt">&#xe2;</span></p>
<p style="top:374.6pt;left:598.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">9</span></p>
<p style="top:374.6pt;left:619.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:374.6pt;left:638.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:374.6pt;left:658.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:374.6pt;left:677.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:374.6pt;left:699.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:374.6pt;left:719.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:396.9pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Finelli 1998 [76]</span></p>
<p style="top:396.9pt;left:138.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Lektinol</span></p>
<p style="top:396.9pt;left:214.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">sc</span></p>
<p style="top:396.9pt;left:256.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2,5 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">l/kg, 2/w</span></p>
<p style="top:396.9pt;left:316.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">No</span></p>
<p style="top:396.9pt;left:355.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Up to 12 </span></p>
<p style="top:406.1pt;left:355.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">w</span></p>
<p style="top:396.9pt;left:395.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Breast, </span></p>
<p style="top:406.1pt;left:395.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">others</span></p>
<p style="top:396.9pt;left:440.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:396.9pt;left:500.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:396.9pt;left:523.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:396.9pt;left:546.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:396.9pt;left:569.8pt;line-height:8.2pt"><span style="font-family:Times New Roman,serif;font-size:8.2pt">&#xe2;</span></p>
<p style="top:396.9pt;left:598.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">884</span></p>
<p style="top:396.9pt;left:619.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:396.9pt;left:638.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:396.9pt;left:658.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:396.9pt;left:677.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:396.9pt;left:699.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:396.9pt;left:719.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:428.4pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Portalupi 1995 </span></p>
<p style="top:437.6pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[77]</span></p>
<p style="top:428.4pt;left:138.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador M</span></p>
<p style="top:428.4pt;left:214.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">sc</span></p>
<p style="top:428.4pt;left:256.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2 &#xd7; 1 ng MLI/kg </span></p>
<p style="top:437.6pt;left:256.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">bw &#xd7; w</span></p>
<p style="top:428.4pt;left:316.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">No</span></p>
<p style="top:428.4pt;left:355.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">16 w</span></p>
<p style="top:428.4pt;left:395.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">CIN I&#x2013;III</span></p>
<p style="top:428.4pt;left:440.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">41%</span></p>
<p style="top:428.4pt;left:500.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">27%</span></p>
<p style="top:428.4pt;left:523.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">27%</span></p>
<p style="top:428.4pt;left:546.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">5%</span></p>
<p style="top:428.4pt;left:598.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">22</span></p>
<p style="top:428.4pt;left:619.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:428.4pt;left:639.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:428.4pt;left:658.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:428.4pt;left:677.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:428.4pt;left:699.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:428.4pt;left:719.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>


<p style="top:548.7pt;left:40.9pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:197.1pt;left:40.9pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:105.7pt;left:756.5pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 17 of 33</span></p>
<p style="top:173.7pt;left:769.3pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:120.5pt;left:71.3pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Malignant effusion</span></b></p>
<p style="top:142.7pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Bar-Sela 2006 [46] Iscador M</span></p>
<p style="top:142.7pt;left:214.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ip</span></p>
<p style="top:142.7pt;left:256.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">10 mg</span></p>
<p style="top:142.7pt;left:316.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">No</span></p>
<p style="top:142.7pt;left:355.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">repeatedly Ascites </span></p>
<p style="top:152.0pt;left:395.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(ovary, </span></p>
<p style="top:161.2pt;left:395.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">others)</span></p>
<p style="top:142.7pt;left:440.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Increase of </span></p>
<p style="top:152.0pt;left:440.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">interval between </span></p>
<p style="top:161.2pt;left:440.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">two successive </span></p>
<p style="top:170.4pt;left:440.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">paracenteses </span></p>
<p style="top:179.7pt;left:440.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">from 7 to 12 </span></p>
<p style="top:189.0pt;left:440.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">days, p = </span></p>
<p style="top:198.2pt;left:440.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.001</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">IIIb</span></sup></p>
<p style="top:142.7pt;left:569.8pt;line-height:8.2pt"><span style="font-family:Times New Roman,serif;font-size:8.2pt">&#xe2;</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">IIIc</span></sup></p>
<p style="top:142.7pt;left:598.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">23</span></p>
<p style="top:142.7pt;left:619.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:142.7pt;left:638.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:142.7pt;left:658.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:142.7pt;left:677.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:142.7pt;left:699.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:142.7pt;left:719.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:220.5pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Werner 1999 [78] Abnobaviscum Fr</span></p>
<p style="top:220.5pt;left:214.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ipl</span></p>
<p style="top:220.5pt;left:256.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">1 &#xd7; 75 mg/w</span></p>
<p style="top:220.5pt;left:316.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">No</span></p>
<p style="top:220.5pt;left:355.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">3&#x2013;8 w</span></p>
<p style="top:220.5pt;left:395.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Pleural </span></p>
<p style="top:229.7pt;left:395.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">effusion </span></p>
<p style="top:239.0pt;left:395.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(breast, </span></p>
<p style="top:248.2pt;left:395.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">others)</span></p>
<p style="top:220.5pt;left:440.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">88%</span></p>
<p style="top:220.5pt;left:569.8pt;line-height:8.2pt"><span style="font-family:Times New Roman,serif;font-size:8.2pt">&#xe2;</span></p>
<p style="top:220.5pt;left:598.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">32</span></p>
<p style="top:220.5pt;left:619.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:220.5pt;left:638.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:220.5pt;left:658.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:220.5pt;left:677.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:220.5pt;left:699.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:220.5pt;left:719.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:270.5pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Stumpf 1994 [79]</span></p>
<p style="top:270.5pt;left:138.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Helixor A, M or P</span></p>
<p style="top:270.5pt;left:214.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ipl</span></p>
<p style="top:270.5pt;left:256.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">100&#x2013;1000 mg</span></p>
<p style="top:270.5pt;left:316.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Yes</span></p>
<p style="top:270.5pt;left:355.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">repeatedly Pleural </span></p>
<p style="top:279.7pt;left:395.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">effusion </span></p>
<p style="top:289.0pt;left:395.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(breast, </span></p>
<p style="top:298.2pt;left:395.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">others)</span></p>
<p style="top:270.5pt;left:440.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">61%</span></p>
<p style="top:270.5pt;left:500.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">11%</span></p>
<p style="top:270.5pt;left:523.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">22%</span></p>
<p style="top:270.5pt;left:598.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">18</span></p>
<p style="top:270.5pt;left:619.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:270.5pt;left:638.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:270.5pt;left:658.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:270.5pt;left:677.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:270.5pt;left:699.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:270.5pt;left:719.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:320.5pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Friedrichson 1995 </span></p>
<p style="top:329.7pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[80]</span></p>
<p style="top:320.5pt;left:138.6pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Helixor A, M</span></p>
<p style="top:320.5pt;left:214.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ip</span></p>
<p style="top:320.5pt;left:256.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">100&#x2013;1000 mg, 2/</span></p>
<p style="top:329.7pt;left:256.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">w</span></p>
<p style="top:320.5pt;left:316.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Yes</span></p>
<p style="top:320.5pt;left:355.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">repeatedly Ascites </span></p>
<p style="top:329.7pt;left:395.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(ovary, </span></p>
<p style="top:339.0pt;left:395.5pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">others)</span></p>
<p style="top:320.5pt;left:440.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">70%</span></p>
<p style="top:320.5pt;left:569.8pt;line-height:8.2pt"><span style="font-family:Times New Roman,serif;font-size:8.2pt">&#xe2;</span></p>
<p style="top:320.5pt;left:598.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">12</span></p>
<p style="top:320.5pt;left:619.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(+)</span></p>
<p style="top:320.5pt;left:638.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:320.5pt;left:658.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:320.5pt;left:677.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-</span></p>
<p style="top:320.5pt;left:699.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(-)</span></p>
<p style="top:320.5pt;left:719.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+</span></p>
<p style="top:361.1pt;left:71.3pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">I </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">sc: subcutaneous, it: intratumoural, ipl: intrapleural, ip: intraperitoneal; iv: intravenous infusion; bw; body weight; w: week</span></p>
<p style="top:370.4pt;left:71.3pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">II </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">CIN: cervical intraepithelial neoplasia. Stage: advanced, except in Portalupi 1995, and partly Schink 2006 and Finelly 1998; plural effusion and ascites indicates treatment site</span></p>
<p style="top:379.7pt;left:71.3pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">III </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">CR: complete, PR: partial remission, NC: no change, PD: progredient disease, QoL: quality of life, </span><span style="font-family:Times New Roman,serif;font-size:8.2pt">&#xe2;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">: improved, </span><span style="font-family:Times New Roman,serif;font-size:8.2pt">&#xe4;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt"> impaired</span></p>
<p style="top:388.9pt;left:71.3pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">IIIa </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Especially physical functioning, role, fatigue, appetite</span></p>
<p style="top:398.1pt;left:71.3pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">IIIb </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Median values, comparable abdominal circumference and symptom score or drained fluid before or during each paracentesis respectively</span></p>
<p style="top:407.4pt;left:71.3pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">IIIc</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Trend improvement in symptom score, especially abdominal pain, abdominal pressure, and waking up at night due to shortness of breath</span></p>
<p style="top:416.6pt;left:71.3pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">IV </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">N: Number of participants</span></p>
<p style="top:425.9pt;left:71.3pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">V </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Concomitant conventional oncological cytoreductive therapies in some of the patients</span></p>
<p style="top:435.2pt;left:71.3pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">VI </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">L Well-described patient characteristic and disease (diagnosis, stage, duration), prognostic factors</span></p>
<p style="top:444.5pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">M Outcome parameter relevant and well described</span></p>
<p style="top:453.7pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">N Well-described intervention</span></p>
<p style="top:463.0pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">O Concomitant therapies well described</span></p>
<p style="top:472.2pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">P Outcome clearly described, temporal relationship between applied therapy and observed outcome precisely described</span></p>
<p style="top:481.5pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Q Selection of patients excluded</span></p>
<p style="top:490.7pt;left:71.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">+ = adequately fulfilled, (+) = partly fulfilled, (-) = little fulfilled, - = not fulfilled</span></p>
<p style="top:105.5pt;left:69.3pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Table 6: Single-Arm Cohort Studies (e.g. Phase II Trials) on VAE Treatment in Breast and Gynaecological Cancer</span></b><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt"> (Continued)</span></i></p>


<p style="top:41.9pt;left:54.1pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:41.9pt;left:405.7pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:757.4pt;left:497.1pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 18 of 33</span></p>
<p style="top:770.1pt;left:430.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:85.8pt;left:54.1pt;line-height:9.5pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:9.5pt">Animal studies</span></i></p>
<p style="top:97.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">43 studies were found. 9 of these were excluded as they</span></p>
<p style="top:109.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">investigated: tumour-bearing eggs [111], pre-incubation</span></p>
<p style="top:121.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">of tumour cells with VAE [112,113], different cancer types</span></p>
<p style="top:132.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">without differentiating the results accordingly [114], or</span></p>
<p style="top:144.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">isolated VAE proteins that were unstable [115]. Of the</span></p>
<p style="top:156.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">remaining 34 experiments [96,111,116-134] (Tables 8</span></p>
<p style="top:168.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and 9), 28 had been conducted in mice and 6 in rats. 22</span></p>
<p style="top:179.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">experiments had included 788 animals, (5&#x2013;20 per treat-</span></p>
<p style="top:191.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ment group), one included 282 VAE-treated animals</span></p>
<p style="top:203.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(number of control animals were not reported), the other</span></p>
<p style="top:215.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">reports gave no details. 32 experiments investigated breast</span></p>
<p style="top:226.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">tumours (15 of these Ehrlich carcinoma, ECa), one uterus</span></p>
<p style="top:238.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">epithelioma and one ovarian cancer. 28 had used murine</span></p>
<p style="top:250.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">tumour models, 5 were of human origin and 1 an autoch-</span></p>
<p style="top:262.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">thonous model (methylnitrosurea-induced tumourigene-</span></p>
<p style="top:273.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">sis). 24 experiments investigated whole VAE (two of these</span></p>
<p style="top:285.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">VAE-activated macrophages), two investigated isolated</span></p>
<p style="top:297.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">MLs, two rMLs, two investigated other isolated proteins,</span></p>
<p style="top:309.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and four investigated polysaccharides (&quot;Viscums&#xe4;ure&quot;).</span></p>
<p style="top:320.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">VAE were applied systemically in 17 experiments (subcu-</span></p>
<p style="top:332.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">taneous, intraperitoneal, intratumoural on opposite site,</span></p>
<p style="top:344.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">intramuscular), local at the tumour site in 15 experiments</span></p>
<p style="top:356.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(intraperitoneal, intratumoural, intramuscular), and</span></p>
<p style="top:367.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">without specification in two studies.</span></p>
<p style="top:391.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">These experiments had been conducted in Germany, Swit-</span></p>
<p style="top:403.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">zerland, Austria, USA, India, Croatia and Serbia. 9 of the</span></p>
<p style="top:414.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">34 experiments reported the funding source, 8 of these</span></p>
<p style="top:426.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">had public funding and one a combination of public and</span></p>
<p style="top:438.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">industry funding. 19 had been published since 1990 and</span></p>
<p style="top:450.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">15 before (1938&#x2013;1989). 21 were published in peer-</span></p>
<p style="top:461.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">reviewed and 2 in other journals, 6 were published in sci-</span></p>
<p style="top:473.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">entific reference books, 1 as a conference abstract, and 4</span></p>
<p style="top:485.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">in a patent specification. Published information was often</span></p>
<p style="top:497.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">insufficient and sometimes extremely sparse. 6 experi-</span></p>
<p style="top:508.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ments reported randomized treatment allocation. Regard-</span></p>
<p style="top:520.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ing the control group, placebo treatment was described in</span></p>
<p style="top:532.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">13 experiments &#x2013; five of these with identical application</span></p>
<p style="top:544.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">schedule to the verum treatment -, no treatment in 11</span></p>
<p style="top:555.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">experiments, and 9 experiments gave no information.</span></p>
<p style="top:567.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">None of the experiments reported a blinded outcome</span></p>
<p style="top:579.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">assessment (but randomized treatment allocation and</span></p>
<p style="top:591.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">blinded outcome assessment are generally routine prac-</span></p>
<p style="top:602.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">tice).</span></p>
<p style="top:626.3pt;left:54.1pt;line-height:9.5pt"><b><i><span style="font-family:FslmpdGillSans,serif;font-size:9.5pt">Outcome</span></i></b></p>
<p style="top:638.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">We found substantial heterogeneity of the studies in terms</span></p>
<p style="top:649.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">of intervention, patient characteristics, clinical diagnosis,</span></p>
<p style="top:661.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">measured outcomes, design, methodological quality and</span></p>
<p style="top:673.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">potential positive and negative biases. We therefore</span></p>
<p style="top:685.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">regarded quantification of effect size by combining results</span></p>
<p style="top:696.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">as unreliable and decided on a non-quantitative synthesis</span></p>
<p style="top:708.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and discussion. A subgroup of studies (2 RCTs, 2 non-</span></p>
<p style="top:720.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">RCTs on breast cancer), with a comparable design (all</span></p>
<p style="top:85.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">originating in the same epidemiological cohort study)</span></p>
<p style="top:97.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">had already been analysed in a quantitative meta-analysis</span></p>
<p style="top:109.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">[135].</span></p>
<p style="top:132.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Results of controlled clinical studies are shown in Table 3</span></p>
<p style="top:144.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(survival), Table 4 (tumour behaviour) and Table 5 (QoL</span></p>
<p style="top:156.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and tolerability of conventional cancer treatment); results</span></p>
<p style="top:168.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">of single-arm studies are shown in Table 6.</span></p>
<p style="top:191.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Results of the preclinical studies are presented in Tables 7,</span></p>
<p style="top:203.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">8 and 9.</span></p>
<p style="top:226.8pt;left:312.1pt;line-height:9.5pt"><b><i><span style="font-family:FslmpdGillSans,serif;font-size:9.5pt">Breast cancer</span></i></b></p>
<p style="top:238.5pt;left:312.1pt;line-height:9.5pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:9.5pt">Clinical studies</span></i></p>
<p style="top:250.2pt;left:312.1pt;line-height:9.7pt"><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Survival </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(Table 3) was investigated by 4 RCTs and 3 non-</span></p>
<p style="top:262.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">RCTs (one of these is shown with three subgroups in Table</span></p>
<p style="top:273.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">3): Two RCTs reported a statistically significant benefit of</span></p>
<p style="top:285.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">VAE (of these one also included other tumour sites, and</span></p>
<p style="top:297.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">the other suffered from a major attrition rate without pre-</span></p>
<p style="top:309.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">venting bias by an intention-to-treat analysis), and two</span></p>
<p style="top:320.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">RCTs reported a small positive trend. The results of the lat-</span></p>
<p style="top:332.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ter two RCTs were also combined in an individual patient</span></p>
<p style="top:344.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">data meta-analysis; the result just missed significance</span></p>
<p style="top:356.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(HR: 0.59, 95% CI: 0.34&#x2013;1.02, p = 0.057) [135]. Two non-</span></p>
<p style="top:367.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">RCTs had observed a statistically significant benefit, and</span></p>
<p style="top:379.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">one a small positive trend. The results of two non-RCTs</span></p>
<p style="top:391.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">were additionally combined in an individual patient data</span></p>
<p style="top:403.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">meta-analysis, and showed highly significant results (HR:</span></p>
<p style="top:414.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">0.43, 95% CI: 0.34&#x2013;0.56, p &lt; 0.0005) [135]. </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Tumour</span></i></p>
<p style="top:426.5pt;left:312.1pt;line-height:9.7pt"><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">behaviour </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(Tables 4 and 6) was investigated by two RCTs,</span></p>
<p style="top:438.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">four non-RCTs and 4 single-arm studies. Four of the con-</span></p>
<p style="top:450.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">trolled studies combined VAE and conventional cancer</span></p>
<p style="top:461.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">treatment. These studies partly reported a benefit regard-</span></p>
<p style="top:473.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ing disease recurrence and time to disease relapse and</span></p>
<p style="top:485.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">partly no difference; none found a disadvantage. Two sin-</span></p>
<p style="top:497.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">gle-arm studies reported tumour remission in 44&#x2013;62% of</span></p>
<p style="top:508.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">patients after local application of high dosage VAE.</span></p>
<p style="top:520.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Another study found no remission after the application of</span></p>
<p style="top:532.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">rML. </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">QoL </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and the </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">reduction of side effects of chemotherapy,</span></i></p>
<p style="top:544.0pt;left:312.1pt;line-height:9.7pt"><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">radiation and surgery </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(Tables 5 and 6) were assessed by 11</span></p>
<p style="top:555.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">RCTs, 6 non-RCTs and 4 single-arm studies: 19 of these 21</span></p>
<p style="top:567.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">studies reported a benefit, mostly statistically significant,</span></p>
<p style="top:579.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">one study reported no QoL-benefit but a reduction of side</span></p>
<p style="top:591.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">effects, and the smallest of these studies found no differ-</span></p>
<p style="top:602.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ence. Three major pharmaco-epidemiological studies</span></p>
<p style="top:614.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">investigated patient charts and found reduced disease-</span></p>
<p style="top:626.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and therapy-associated symptoms in VAE-treated groups.</span></p>
<p style="top:649.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">In </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">preclinical studies </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(Tables 7, 8, and 9) VAE and VAE com-</span></p>
<p style="top:661.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">pounds showed cytotoxic effects in cancer cells. VAE also</span></p>
<p style="top:673.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">counteracted growth factor-induced proliferation and</span></p>
<p style="top:685.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">migration in breast cancer cells [95]. In mice, VAE inhib-</span></p>
<p style="top:696.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ited tumour growth in most cases, especially when</span></p>
<p style="top:708.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">applied locally and in high dosage. Survival was pro-</span></p>
<p style="top:720.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">longed in most cases, and numbers of metastases and</span></p>


<p style="top:41.9pt;left:54.1pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:41.9pt;left:405.7pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:757.4pt;left:497.1pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 19 of 33</span></p>
<p style="top:770.1pt;left:430.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:86.0pt;left:54.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Table 7: </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">In-vitro </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Studies on Cytotoxicity of VAE in Human Breast or Gynecological Cancer Cells</span></b></p>
<p style="top:102.9pt;left:56.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Tumour cell</span></b></p>
<p style="top:102.9pt;left:159.9pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">VAE</span></b></p>
<p style="top:102.9pt;left:274.7pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Result</span></b></p>
<p style="top:102.9pt;left:508.2pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Reference</span></b></p>
<p style="top:123.2pt;left:56.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Breast cancer</span></b></p>
<p style="top:143.4pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">MFM-223</span></p>
<p style="top:143.4pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador Qu, M, A</span></p>
<p style="top:151.5pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador P</span></p>
<p style="top:159.5pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I</span></p>
<p style="top:143.4pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:143.4pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.05&#x2013;0.12 mg/ml</span></p>
<p style="top:151.5pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1.89 mg/ml</span></p>
<p style="top:159.5pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">38 ng/ml</span></p>
<p style="top:143.4pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[22]</span></p>
<p style="top:179.4pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador M, Qu,</span></p>
<p style="top:187.5pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Abnobaviscum Fr</span></p>
<p style="top:179.4pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Inhibition of proliferation</span></p>
<p style="top:179.4pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.1&#x2013;1 mg/ml</span></p>
<p style="top:187.5pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.01&#x2013;1 mg/ml</span></p>
<p style="top:179.4pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[81]</span></p>
<p style="top:207.5pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">KPL-1</span></p>
<p style="top:207.5pt;left:159.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador Qu, M, A</span></p>
<p style="top:215.4pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador P</span></p>
<p style="top:223.5pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I</span></p>
<p style="top:207.5pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:207.5pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.1&#x2013;0.3 mg/ml</span></p>
<p style="top:215.4pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1.94 mg/ml</span></p>
<p style="top:223.5pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">141 ng/ml</span></p>
<p style="top:207.4pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[22]</span></p>
<p style="top:243.5pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador M, Qu,</span></p>
<p style="top:251.5pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Abnobaviscum Fr</span></p>
<p style="top:243.5pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Inhibition of proliferation</span></p>
<p style="top:243.5pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1 mg/ml</span></p>
<p style="top:251.5pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0,1&#x2013;1 mg/ml</span></p>
<p style="top:243.4pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[81]</span></p>
<p style="top:271.5pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscucin</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">&#xae; </span></sup><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">A, M, P, C, Po, T, Qu, S</span></p>
<p style="top:271.5pt;left:274.7pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Cytotoxicity</span></p>
<p style="top:271.5pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.1 mg/ml</span></p>
<p style="top:271.5pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[82]</span></p>
<p style="top:291.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador M</span></p>
<p style="top:299.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I</span></p>
<p style="top:291.7pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">No stimulation of cell proliferation</span></p>
<p style="top:291.7pt;left:393.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.05&#x2013;5 ng ML/ml</span></p>
<p style="top:299.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.01&#x2013;5 ng/ml</span></p>
<p style="top:291.7pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[83]</span></p>
<p style="top:319.7pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">MCF-7</span></p>
<p style="top:319.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador Qu, M, A</span></p>
<p style="top:327.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador P</span></p>
<p style="top:335.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I</span></p>
<p style="top:319.7pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:319.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.09&#x2013;0.12 mg/ml</span></p>
<p style="top:327.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1.61 mg/ml</span></p>
<p style="top:335.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">410 ng/ml</span></p>
<p style="top:319.7pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[22]</span></p>
<p style="top:355.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Lektinol</span></p>
<p style="top:355.7pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:355.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">&gt;10 ng ML I/ml</span></p>
<p style="top:355.7pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[84]</span></p>
<p style="top:376.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador Qu, M, P</span></p>
<p style="top:384.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">(max. 1 or 1.5 mg/ml)</span></p>
<p style="top:376.0pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Inhibition of S-phase progression</span></p>
<p style="top:384.0pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Induction of apoptosis</span></p>
<p style="top:375.9pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[85-87]</span></p>
<p style="top:404.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador M</span></p>
<p style="top:412.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador P</span></p>
<p style="top:420.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I</span></p>
<p style="top:428.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador Qu</span></p>
<p style="top:404.0pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:412.0pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">No influence</span></p>
<p style="top:404.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">185 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:412.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">no activity</span></p>
<p style="top:420.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.003 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:428.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.0015&#x2013;15 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:403.9pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[88,89]</span></p>
<p style="top:448.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Viscotoxin isoforms </span></p>
<p style="top:456.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">(A1, A2, A3, B, 1-PS)</span></p>
<p style="top:464.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Viscotoxin isoform U-PS</span></p>
<p style="top:448.0pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">GI</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:456.0pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">LC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:448.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.02&#x2013;0.8 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:456.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.6 to &gt;1 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:464.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">no activity</span></p>
<p style="top:447.9pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[90]</span></p>
<p style="top:484.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I A chain</span></p>
<p style="top:484.0pt;left:274.7pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Inhibition of proliferation</span></p>
<p style="top:484.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.5 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:483.9pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[91]</span></p>
<p style="top:504.2pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I, ML II, ML III</span></p>
<p style="top:504.2pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Inhibition of proliferation</span></p>
<p style="top:504.2pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1&#x2013;10 ng/ml</span></p>
<p style="top:504.2pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[91]</span></p>
<p style="top:524.5pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">TNF &amp; ML I (100 ng/ml)</span></p>
<p style="top:524.5pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Potentiation of TNF-cytotoxicity</span></p>
<p style="top:524.4pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[92]</span></p>
<p style="top:544.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Lektinol</span></p>
<p style="top:544.7pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:544.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.003 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:544.7pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[93]</span></p>
<p style="top:565.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Helixor P</span></p>
<p style="top:573.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I</span></p>
<p style="top:565.0pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:565.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">&gt; 150 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:573.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.086 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:564.9pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[94]</span></p>
<p style="top:593.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscucin M, P, C, Po, T, Qu, S</span></p>
<p style="top:601.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscucin A, Pi</span></p>
<p style="top:593.0pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Cytotoxicity</span></p>
<p style="top:593.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.1 mg/ml</span></p>
<p style="top:601.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">no activity</span></p>
<p style="top:592.9pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[82]</span></p>
<p style="top:621.0pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">MCF-7/ADR</span></p>
<p style="top:621.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Lektinol</span></p>
<p style="top:621.0pt;left:274.7pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50 </span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">(SRB assay)</span></p>
<p style="top:621.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.3 E-4 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:621.0pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[93]</span></p>
<p style="top:641.3pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">MAXF 401NL</span></p>
<p style="top:641.3pt;left:159.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Helixor P</span></p>
<p style="top:649.2pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I</span></p>
<p style="top:641.3pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:641.3pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.66 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:649.2pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.003 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:641.2pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[94]</span></p>
<p style="top:669.2pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador M</span></p>
<p style="top:677.3pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador P</span></p>
<p style="top:685.2pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I</span></p>
<p style="top:693.2pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador Qu</span></p>
<p style="top:669.2pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:677.3pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">&gt;70% growth inhibition</span></p>
<p style="top:669.2pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">&lt; 3 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:677.3pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">no activity</span></p>
<p style="top:685.2pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.353 E-4 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:693.2pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">10 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:669.2pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[88,89]</span></p>
<p style="top:713.3pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">MAXF 401</span></p>
<p style="top:713.3pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Lektinol</span></p>
<p style="top:713.3pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:713.3pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">&lt; 0.1 E-4 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:713.2pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[93]</span></p>


<p style="top:41.9pt;left:54.1pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:41.9pt;left:405.7pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:757.4pt;left:497.1pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 20 of 33</span></p>
<p style="top:770.1pt;left:430.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:91.7pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">MAXF 1162</span></p>
<p style="top:91.7pt;left:159.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Lektinol</span></p>
<p style="top:91.7pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:91.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">&lt; 0.1 E-4 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:91.7pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[93]</span></p>
<p style="top:111.9pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">MAXF 449</span></p>
<p style="top:111.9pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Lektinol</span></p>
<p style="top:111.9pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:111.9pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.2 E-4 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:111.9pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[93]</span></p>
<p style="top:132.2pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">MAXF MX1</span></p>
<p style="top:132.2pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Lektinol</span></p>
<p style="top:132.2pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:132.2pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">&lt; 0.1 E-4 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:132.2pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[93]</span></p>
<p style="top:152.4pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">MDA-MB-231</span></p>
<p style="top:152.4pt;left:159.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Lektinol</span></p>
<p style="top:152.4pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:152.4pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.7 E-4 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:152.4pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[93]</span></p>
<p style="top:172.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Helixor P</span></p>
<p style="top:180.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I</span></p>
<p style="top:172.7pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:172.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">135 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:180.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.041 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:172.7pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[94]</span></p>
<p style="top:200.7pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">MDA-MB-468</span></p>
<p style="top:200.7pt;left:159.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Helixor P</span></p>
<p style="top:208.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML 1</span></p>
<p style="top:200.7pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:200.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">47 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:208.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.006 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:200.7pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[94]</span></p>
<p style="top:228.7pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">MDA-MB-486-HER2</span></p>
<p style="top:228.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador M</span></p>
<p style="top:228.7pt;left:274.7pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Inhibition of epidermal growth </span></p>
<p style="top:236.7pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">factor-induced proliferation</span></p>
<p style="top:228.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.5 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:228.7pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[95]</span></p>
<p style="top:256.7pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Colo-824</span></p>
<p style="top:256.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador M</span></p>
<p style="top:264.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I</span></p>
<p style="top:256.7pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">No stimulation of cell proliferation</span></p>
<p style="top:256.7pt;left:393.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.05&#x2013;5 ng ML/ml</span></p>
<p style="top:264.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.01&#x2013;5 ng/ml</span></p>
<p style="top:256.7pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[83]</span></p>
<p style="top:284.7pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">HCC-1937</span></p>
<p style="top:284.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador Qu, M, A</span></p>
<p style="top:292.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador P</span></p>
<p style="top:300.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I</span></p>
<p style="top:284.7pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:284.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.1 to 0.3 mg/ml</span></p>
<p style="top:292.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">2.14 mg/ml</span></p>
<p style="top:300.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">320 ng/ml</span></p>
<p style="top:284.7pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[22]</span></p>
<p style="top:320.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscucin A, M, P, C, Po, T, Qu, S</span></p>
<p style="top:320.7pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Cytotoxicity</span></p>
<p style="top:320.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.1 mg/ml</span></p>
<p style="top:320.7pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[82]</span></p>
<p style="top:341.0pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">BT474</span></p>
<p style="top:341.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Helixor M, A</span></p>
<p style="top:341.0pt;left:274.7pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Cytotoxicity (WST-1)</span></p>
<p style="top:341.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Maximum (80 and 100%) with 25 </span></p>
<p style="top:349.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">mg/ml</span></p>
<p style="top:340.9pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[96]</span></p>
<p style="top:369.0pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Primary breast cancer</span></p>
<p style="top:369.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador M, Qu</span></p>
<p style="top:377.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Abnobaviscum Fr</span></p>
<p style="top:369.0pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Mitochondrial activity (MTT)</span></p>
<p style="top:369.0pt;left:393.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">50&#x2013;80% with 0.1&#x2013;0.001 mg/ml</span></p>
<p style="top:369.0pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[81]</span></p>
<p style="top:397.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Abnobaviscum M</span></p>
<p style="top:397.0pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Inhibition of proliferation</span></p>
<p style="top:397.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.5&#x2013;50 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:396.9pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[97]</span></p>
<p style="top:417.2pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I</span></p>
<p style="top:417.2pt;left:274.7pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Inhibition of proliferation</span></p>
<p style="top:417.2pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1&#x2013;50 ng/ml</span></p>
<p style="top:417.2pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[20,98]</span></p>
<p style="top:437.5pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">T47D</span></p>
<p style="top:437.5pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I, II, III</span></p>
<p style="top:437.5pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:437.5pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">&gt; 0.1 &#x2013; 1 ng/ml</span></p>
<p style="top:437.4pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[99]</span></p>
<p style="top:457.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I A-chain</span></p>
<p style="top:457.7pt;left:274.7pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Inhibition of proliferation</span></p>
<p style="top:457.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">10 ng/ml</span></p>
<p style="top:457.7pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[91]</span></p>
<p style="top:478.0pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">BT549</span></p>
<p style="top:478.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I A-chain</span></p>
<p style="top:478.0pt;left:274.7pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Inhibition of proliferation</span></p>
<p style="top:478.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">500 ng/ml</span></p>
<p style="top:477.9pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[91]</span></p>
<p style="top:498.2pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">HBL100</span></p>
<p style="top:498.2pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I A-chain</span></p>
<p style="top:498.2pt;left:274.7pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Inhibition of proliferation</span></p>
<p style="top:498.2pt;left:393.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">100 ng/ml</span></p>
<p style="top:498.2pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[91]</span></p>
<p style="top:518.5pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Breast cancer cells</span></p>
<p style="top:518.5pt;left:159.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML II, ML III, viscotoxins</span></p>
<p style="top:518.5pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Cytotoxicity</span></p>
<p style="top:518.4pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[100]</span></p>
<p style="top:538.7pt;left:56.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Ovarian cancer</span></b></p>
<p style="top:558.8pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">OVXF 1619L</span></p>
<p style="top:558.8pt;left:159.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Helixor P</span></p>
<p style="top:566.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I</span></p>
<p style="top:558.8pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:558.8pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">119 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:566.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.100 E-3 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:558.7pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[94]</span></p>
<p style="top:586.7pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">OVXF 899L</span></p>
<p style="top:586.7pt;left:159.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Helixor P</span></p>
<p style="top:594.8pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I</span></p>
<p style="top:586.7pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:586.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">&gt;150 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:594.8pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.229 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:586.7pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[94]</span></p>
<p style="top:614.7pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">SKOV-3 (HER-2 expression)</span></p>
<p style="top:614.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Recombinant ML I</span></p>
<p style="top:614.7pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:622.7pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Induction of apoptosis</span></p>
<p style="top:614.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.033 ng/ml</span></p>
<p style="top:614.7pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[101]</span></p>
<p style="top:642.8pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">OVCAR3</span></p>
<p style="top:642.8pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador Qu, M</span></p>
<p style="top:650.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">(max. 1 or 1.5 mg/ml)</span></p>
<p style="top:642.8pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Inhibition of S-phase progression,</span></p>
<p style="top:650.7pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Induction of apoptosis</span></p>
<p style="top:642.8pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">No clear effect</span></p>
<p style="top:642.7pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[87]</span></p>
<p style="top:670.7pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">OVXF 899</span></p>
<p style="top:670.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Lektinol</span></p>
<p style="top:670.7pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:670.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.3 E-3 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:670.7pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[93]</span></p>
<p style="top:691.0pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">OVXF 1353</span></p>
<p style="top:691.0pt;left:159.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Lektinol</span></p>
<p style="top:691.0pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:691.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.01 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:691.0pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[93]</span></p>
<p style="top:711.2pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">OVXF 1023</span></p>
<p style="top:711.2pt;left:159.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Lektinol</span></p>
<p style="top:711.2pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:711.2pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">&lt; 0.1 E-4 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:711.2pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[93]</span></p>
<p style="top:731.5pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">SKOV3</span></p>
<p style="top:731.5pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Lektinol</span></p>
<p style="top:731.5pt;left:274.7pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:731.5pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">&lt; 0.1 E-4 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:731.5pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[93]</span></p>
<p style="top:77.7pt;left:54.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Table 7: </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">In-vitro </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Studies on Cytotoxicity of VAE in Human Breast or Gynecological Cancer Cells</span></b><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt"> (Continued)</span></i></p>


<p style="top:41.9pt;left:54.1pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:41.9pt;left:405.7pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:757.4pt;left:497.1pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 21 of 33</span></p>
<p style="top:770.1pt;left:430.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:91.7pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Primary ovarian cancer</span></p>
<p style="top:91.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Abnobaviscum M</span></p>
<p style="top:91.7pt;left:274.7pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Inhibition of proliferation</span></p>
<p style="top:91.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">5 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:91.7pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[97]</span></p>
<p style="top:111.9pt;left:56.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Uterine cancer</span></b></p>
<p style="top:132.0pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">UXF 1138L</span></p>
<p style="top:132.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador M</span></p>
<p style="top:140.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador P</span></p>
<p style="top:147.9pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I</span></p>
<p style="top:156.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador Qu</span></p>
<p style="top:132.0pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:140.0pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Growth inhibition &gt;30%</span></p>
<p style="top:132.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">6.8 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:140.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">No activity</span></p>
<p style="top:147.9pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.16 E-4 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:156.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">15 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:132.0pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[88,89]</span></p>
<p style="top:176.0pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">UCL SK-UT-1B</span></p>
<p style="top:176.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Helixor P</span></p>
<p style="top:183.9pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I</span></p>
<p style="top:176.0pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:176.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">&gt; 150 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:183.9pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.038 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:175.9pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[94]</span></p>
<p style="top:204.0pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">SK-UT-1B</span></p>
<p style="top:204.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Lektinol</span></p>
<p style="top:204.0pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:204.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.6&#x2013;5.5 ng ML I/ml</span></p>
<p style="top:204.0pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[84]</span></p>
<p style="top:224.2pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I</span></p>
<p style="top:224.2pt;left:274.7pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Inhibition of proliferation</span></p>
<p style="top:224.2pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.5&#x2013;500 ng/ml</span></p>
<p style="top:224.2pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[98,102]</span></p>
<p style="top:244.5pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador M</span></p>
<p style="top:252.5pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I</span></p>
<p style="top:244.5pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">No stimulation of cell proliferation</span></p>
<p style="top:244.5pt;left:393.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.05&#x2013;5 ng ML/ml</span></p>
<p style="top:252.5pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.01&#x2013;5 ng/ml</span></p>
<p style="top:244.5pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[83]</span></p>
<p style="top:272.5pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">SK-UT-1</span></p>
<p style="top:272.5pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I</span></p>
<p style="top:272.5pt;left:274.7pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Inhibition of proliferation</span></p>
<p style="top:272.5pt;left:393.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.5&#x2013;500 ng/ml</span></p>
<p style="top:272.4pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[98,102]</span></p>
<p style="top:292.7pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">MES-SA</span></p>
<p style="top:292.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I</span></p>
<p style="top:292.7pt;left:274.7pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Inhibition of proliferation</span></p>
<p style="top:292.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.5&#x2013;500 ng/ml</span></p>
<p style="top:292.7pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[98,102]</span></p>
<p style="top:313.0pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Primary uterus cancer</span></p>
<p style="top:313.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Abnobaviscum M</span></p>
<p style="top:313.0pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Inhibition of proliferation</span></p>
<p style="top:313.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">5&#x2013;50 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:312.9pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[97]</span></p>
<p style="top:333.2pt;left:56.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Vulvar cancer</span></b></p>
<p style="top:353.2pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">SK-MLS-1</span></p>
<p style="top:353.2pt;left:159.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Lektinol</span></p>
<p style="top:353.2pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:353.2pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">2 to &gt;5 ng ML I/ml</span></p>
<p style="top:353.2pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[84]</span></p>
<p style="top:373.5pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I</span></p>
<p style="top:373.5pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Inhibition of proliferation:</span></p>
<p style="top:373.5pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.5&#x2013;500 ng/ml</span></p>
<p style="top:373.5pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[98,102]</span></p>
<p style="top:393.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador M</span></p>
<p style="top:401.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I</span></p>
<p style="top:393.7pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">No stimulation of cell proliferation</span></p>
<p style="top:393.7pt;left:393.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.05&#x2013;5 ng ML/ml</span></p>
<p style="top:401.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.01&#x2013;5 ng/ml</span></p>
<p style="top:393.7pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[83]</span></p>
<p style="top:421.7pt;left:56.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Cervical cancer</span></b></p>
<p style="top:441.7pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">HeLa</span></p>
<p style="top:441.7pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">TNF &amp; ML I (100 ng/ml)</span></p>
<p style="top:441.7pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Potentiation of TNF-cytotoxicity</span></p>
<p style="top:441.7pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[92]</span></p>
<p style="top:462.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I</span></p>
<p style="top:462.0pt;left:274.7pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Inhibition of protein synthesis</span></p>
<p style="top:462.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">100 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:462.0pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[12,103]</span></p>
<p style="top:482.3pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Protein fractions</span></p>
<p style="top:482.3pt;left:274.7pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Complete inhibition of DNA-, </span></p>
<p style="top:490.2pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">RNA-synthesis</span></p>
<p style="top:498.2pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Proliferation</span></p>
<p style="top:482.3pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:490.2pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">no effect</span></p>
<p style="top:482.2pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[104]</span></p>
<p style="top:518.3pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Viscotoxins</span></p>
<p style="top:518.3pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:518.3pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.2&#x2013;1.7 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:518.2pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[105]</span></p>
<p style="top:538.5pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Helixor M</span></p>
<p style="top:538.5pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Growth inhibition</span></p>
<p style="top:538.5pt;left:393.8pt;line-height:8.0pt"><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x2265;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 0.01 mg/ml</span></p>
<p style="top:538.5pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[106]</span></p>
<p style="top:558.8pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Isorel</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">&#xae;</span></sup></p>
<p style="top:558.8pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Cytotoxicity</span></p>
<p style="top:558.8pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">30 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/</span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">l</span></p>
<p style="top:558.7pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[107]</span></p>
<p style="top:579.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Isorel A, M, P,</span></p>
<p style="top:587.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ML I</span></p>
<p style="top:579.0pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Cytotoxicity</span></p>
<p style="top:579.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">&gt; 1 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">l/ml</span></p>
<p style="top:587.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">&gt; 1 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:579.0pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[108]</span></p>
<p style="top:607.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador M</span></p>
<p style="top:615.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Helixor M</span></p>
<p style="top:623.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">VAE M</span></p>
<p style="top:607.0pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">LC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span></p>
<p style="top:607.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">16 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:615.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">35,4 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:623.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">3,9 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.0pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">g/ml</span></p>
<p style="top:607.0pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[109,110]</span></p>
<p style="top:643.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Iscador M, Qu</span></p>
<p style="top:651.0pt;left:159.9pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Abnobaviscum Fr</span></p>
<p style="top:643.0pt;left:274.6pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Growth inhibition</span></p>
<p style="top:643.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.1&#x2013;1 mg/ml</span></p>
<p style="top:651.0pt;left:393.8pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">0.01 mg/ml</span></p>
<p style="top:643.0pt;left:508.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[81]</span></p>
<p style="top:671.0pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">GI</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">: 50% growth inhibitory concentration</span></p>
<p style="top:679.0pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">LC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">: 50% lethal concentration</span></p>
<p style="top:687.0pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">IC</span><span style="font-family:DdhngrGillSans,serif;font-size:5.6pt">50</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">: 50% inhibitory concentration</span></p>
<p style="top:695.0pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">MCF-7/ADR: adriamycin(doxorubicin)-resistant MCF-7 cell line</span></p>
<p style="top:703.0pt;left:56.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">HER: human epidermal growth factor receptor</span></p>
<p style="top:77.7pt;left:54.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Table 7: </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">In-vitro </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Studies on Cytotoxicity of VAE in Human Breast or Gynecological Cancer Cells</span></b><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt"> (Continued)</span></i></p>


<p style="top:41.9pt;left:54.1pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:41.9pt;left:405.7pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:757.4pt;left:497.1pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 22 of 33</span></p>
<p style="top:770.1pt;left:430.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:86.0pt;left:54.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Table 8: Animal Studies of VAE on Breast or Gynaecological Cancer (transplanted human or murine tumours or primary </span></b></p>
<p style="top:95.4pt;left:54.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">autochthonous tumour)</span></b></p>
<p style="top:113.4pt;left:56.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Tumour, site</span></b></p>
<p style="top:113.4pt;left:140.8pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Animal</span></b></p>
<p style="top:113.4pt;left:212.4pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">VAE, application and </span></b></p>
<p style="top:122.7pt;left:212.4pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">dosage</span></b></p>
<p style="top:113.4pt;left:320.4pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Tumour </span></b></p>
<p style="top:122.7pt;left:320.4pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">growth</span></b></p>
<p style="top:132.0pt;left:320.4pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">T/C</span></b></p>
<p style="top:113.4pt;left:381.3pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Survival</span></b></p>
<p style="top:122.7pt;left:381.3pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">ILS</span></b></p>
<p style="top:113.4pt;left:423.3pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Other outcomes</span></b></p>
<p style="top:113.4pt;left:508.9pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Reference</span></b></p>
<p style="top:153.2pt;left:56.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Human breast</span></b></p>
<p style="top:153.2pt;left:140.7pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Mice</span></b></p>
<p style="top:174.4pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">MAXF 449, sc</span></p>
<p style="top:174.4pt;left:140.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Nude mice</span></p>
<p style="top:174.4pt;left:212.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Local Abnobaviscum Qu 8 or 4 </span></p>
<p style="top:183.7pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">or 2 mg/kg, it, qd * 3</span></p>
<p style="top:174.4pt;left:320.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">6 to 20%</span></p>
<p style="top:174.4pt;left:508.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[116]</span></p>
<p style="top:204.9pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Systemic Abnobaviscum Qu 8 </span></p>
<p style="top:214.2pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">mg/kg, it, qd * 3</span></p>
<p style="top:204.9pt;left:320.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">78%</span></p>
<p style="top:235.5pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">MAXF 449, sc</span></p>
<p style="top:235.5pt;left:140.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Nude mice</span></p>
<p style="top:235.5pt;left:212.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Abnobaviscum M 8 mg/kg, sc, </span></p>
<p style="top:244.7pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">qd * 3 * 2 w</span></p>
<p style="top:235.5pt;left:320.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">68%</span></p>
<p style="top:235.5pt;left:508.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[116]</span></p>
<p style="top:265.9pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">BT474, sc</span></p>
<p style="top:265.9pt;left:140.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mice (BALB/c)</span></p>
<p style="top:265.9pt;left:212.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Helixor M or A 5 mg, it, qd * 3 </span></p>
<p style="top:275.2pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">* 2 w</span></p>
<p style="top:265.9pt;left:320.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">29 to 52%</span></p>
<p style="top:265.9pt;left:508.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[96]</span></p>
<p style="top:296.4pt;left:56.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Murine breast</span></b></p>
<p style="top:317.7pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Carcinoma, sc, iv</span></p>
<p style="top:317.7pt;left:140.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mice (CBA/HZgr)</span></p>
<p style="top:317.7pt;left:212.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Isorel M, 3 mg, sc, qod * 21</span></p>
<p style="top:317.7pt;left:320.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">No difference</span></p>
<p style="top:317.7pt;left:423.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Lung-metastases: VAE </span></p>
<p style="top:327.0pt;left:423.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">vs. control: 13.4 vs. 37.5</span></p>
<p style="top:317.7pt;left:508.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[117]</span></p>
<p style="top:348.2pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Carcinoma, sc</span></p>
<p style="top:348.2pt;left:140.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mice (CBA/HZgr)</span></p>
<p style="top:348.2pt;left:212.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Isorel M, 1400 mg/kg, 2 w</span></p>
<p style="top:348.2pt;left:320.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">20%</span></p>
<p style="top:348.2pt;left:508.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[118]</span></p>
<p style="top:369.4pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Carcinoma, sc</span></p>
<p style="top:369.4pt;left:140.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mice (CBA/HZgr)</span></p>
<p style="top:369.4pt;left:212.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Isorel M, 140 mg/kg</span></p>
<p style="top:369.4pt;left:423.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Recurrence after </span></p>
<p style="top:378.7pt;left:423.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">resection, VAE vs. </span></p>
<p style="top:387.9pt;left:423.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">control: 47% vs. 78%</span></p>
<p style="top:369.4pt;left:508.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[118]</span></p>
<p style="top:409.2pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Carcinoma, iv</span></p>
<p style="top:409.2pt;left:140.7pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mice (CBA/HZgr)</span></p>
<p style="top:409.2pt;left:212.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Isorel M, 140 mg/kg, ip</span></p>
<p style="top:409.2pt;left:423.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">52 lung-metastases</span></p>
<p style="top:409.2pt;left:508.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[118]</span></p>
<p style="top:430.5pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Endoxan, 50 mg/kg</span></p>
<p style="top:430.5pt;left:423.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">23 lung-metastases</span></p>
<p style="top:451.7pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Isorel M, 140 mg/kg &amp; Endoxan </span></p>
<p style="top:460.9pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">50 mg/kg</span></p>
<p style="top:451.7pt;left:423.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">10 lung-metastases</span></p>
<p style="top:482.2pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Control</span></p>
<p style="top:482.2pt;left:423.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">76 lung-metastases</span></p>
<p style="top:503.4pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">C3H adenocarcinoma, </span></p>
<p style="top:512.7pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">16/C</span></p>
<p style="top:503.4pt;left:140.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mice (B6C3F1)</span></p>
<p style="top:503.4pt;left:212.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador M, 50 or 100 mg/kg, ip, </span></p>
<p style="top:512.7pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">qd, day 1&#x2013;14</span></p>
<p style="top:503.4pt;left:320.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">28%</span></p>
<p style="top:503.4pt;left:381.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">15 to 20%</span></p>
<p style="top:503.4pt;left:508.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[119]</span></p>
<p style="top:534.0pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">RC adenocarcinoma, sc Mice (DBA)</span></p>
<p style="top:534.0pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">VAE </span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">I</span></sup><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">, sc</span></p>
<p style="top:534.0pt;left:320.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">20 to 40%</span></p>
<p style="top:534.0pt;left:509.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[111]</span></p>
<p style="top:555.2pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ECa, ip</span></p>
<p style="top:555.2pt;left:140.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mice (NMRI)</span></p>
<p style="top:555.2pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">VAE (supracritical CO</span><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">2 </span></p>
<p style="top:564.4pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">extraction), 2 mL/kg, ip, qd, </span></p>
<p style="top:573.7pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">starting day -7, day 0, or day 7</span></p>
<p style="top:555.2pt;left:320.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">65 to 100%</span><sup><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">II</span></sup></p>
<p style="top:555.2pt;left:508.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[120]</span></p>
<p style="top:595.0pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ECa, ip</span></p>
<p style="top:595.0pt;left:140.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mice (BALB/c)</span></p>
<p style="top:595.0pt;left:212.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador, 15 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">g, ip, day -1</span></p>
<p style="top:595.0pt;left:381.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">108%</span></p>
<p style="top:595.0pt;left:509.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[121]</span></p>
<p style="top:616.2pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Sodium caseinate &amp; Iscador, 15 </span></p>
<p style="top:625.5pt;left:212.4pt;line-height:8.2pt"><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">g, ip, day -1</span></p>
<p style="top:616.2pt;left:381.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">no death</span></p>
<p style="top:646.7pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Sodium caseinate, day -1</span></p>
<p style="top:646.7pt;left:381.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0%</span></p>
<p style="top:667.9pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ECa, ip</span></p>
<p style="top:667.9pt;left:140.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mice (BALB/c)</span></p>
<p style="top:667.9pt;left:212.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador, 15 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">g, ip, day 6</span></p>
<p style="top:667.9pt;left:381.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">82%</span></p>
<p style="top:667.9pt;left:509.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[121]</span></p>
<p style="top:689.2pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Sodium caseinate, day 6</span></p>
<p style="top:689.2pt;left:381.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">7%</span></p>
<p style="top:710.5pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ECa, ip</span></p>
<p style="top:710.5pt;left:140.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mice (BALB/c)</span></p>
<p style="top:710.5pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador-activated </span></p>
<p style="top:719.7pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">macrophages, ip, day 6</span></p>
<p style="top:710.5pt;left:381.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">49%</span></p>
<p style="top:710.5pt;left:508.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[121]</span></p>


<p style="top:41.9pt;left:54.1pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:41.9pt;left:405.7pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:757.4pt;left:497.1pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 23 of 33</span></p>
<p style="top:770.1pt;left:430.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:102.2pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Non-activated macrophages, </span></p>
<p style="top:111.4pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ip, day 6</span></p>
<p style="top:102.2pt;left:381.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">4%</span></p>
<p style="top:132.7pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ECa, ip</span></p>
<p style="top:132.7pt;left:140.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mice (BALB/c)</span></p>
<p style="top:132.7pt;left:212.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador activated macrophages, </span></p>
<p style="top:141.9pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ip, day 6, 10, 14</span></p>
<p style="top:132.7pt;left:381.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">98%</span></p>
<p style="top:132.7pt;left:508.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[121]</span></p>
<p style="top:163.2pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Non-activated macrophages, </span></p>
<p style="top:172.5pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ip, day 6, 10, 14</span></p>
<p style="top:163.2pt;left:381.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">9%</span></p>
<p style="top:193.7pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ECa, sc</span></p>
<p style="top:193.7pt;left:140.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mice (BALB/c)</span></p>
<p style="top:193.7pt;left:212.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador, 15 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">g, it, day 7</span></p>
<p style="top:193.7pt;left:423.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Severe necrosis, </span></p>
<p style="top:202.9pt;left:423.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">infiltration of </span></p>
<p style="top:212.2pt;left:423.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">lymphocytes and </span></p>
<p style="top:221.4pt;left:423.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">macrophages</span></p>
<p style="top:193.7pt;left:508.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[122]</span></p>
<p style="top:242.7pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ECa, sc</span></p>
<p style="top:242.7pt;left:140.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mice (Swiss)</span></p>
<p style="top:242.7pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador M, 1.66 mg, im, qod * 5 </span></p>
<p style="top:252.0pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">or 10</span></p>
<p style="top:242.7pt;left:320.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">3 to 10%</span></p>
<p style="top:242.7pt;left:508.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[123]</span></p>
<p style="top:273.2pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ECa, ip</span></p>
<p style="top:273.2pt;left:140.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mice (Swiss)</span></p>
<p style="top:273.2pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador M, 1.66 mg, ip, qod * </span></p>
<p style="top:282.4pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">10</span></p>
<p style="top:273.2pt;left:381.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">76%</span></p>
<p style="top:273.2pt;left:508.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[123]</span></p>
<p style="top:303.7pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ECa, ip</span></p>
<p style="top:303.7pt;left:140.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mice (Swiss)</span></p>
<p style="top:303.7pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador M, 25 or 50 mg/kg, ip, </span></p>
<p style="top:312.9pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">qd * 14</span></p>
<p style="top:303.7pt;left:381.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">69 to 97%</span></p>
<p style="top:303.7pt;left:423.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">No tumour-free mice</span></p>
<p style="top:303.7pt;left:508.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[119]</span></p>
<p style="top:334.2pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ECa, ip</span></p>
<p style="top:334.2pt;left:140.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mice (Swiss)</span></p>
<p style="top:334.2pt;left:212.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador M, sc, cumulative dose </span></p>
<p style="top:343.5pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">4, 5, 150, or 200 mg</span></p>
<p style="top:334.2pt;left:381.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-4 to 0%</span></p>
<p style="top:334.2pt;left:508.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[124]</span></p>
<p style="top:364.7pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ECa, sc</span></p>
<p style="top:364.7pt;left:140.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mice</span></p>
<p style="top:364.7pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">VAE, it, 0.1&#x2013;0.2 ccm, qod * 6&#x2013;</span></p>
<p style="top:373.9pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">10</span></p>
<p style="top:364.7pt;left:423.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Complete remission &amp; </span></p>
<p style="top:373.9pt;left:423.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">no recurrence: 27%</span></p>
<p style="top:364.7pt;left:508.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[125,126]</span></p>
<p style="top:395.2pt;left:56.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Murine breast</span></b></p>
<p style="top:395.2pt;left:140.8pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Rats</span></b></p>
<p style="top:416.4pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Walker carcinosarcoma </span></p>
<p style="top:425.7pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">256; sc</span></p>
<p style="top:416.4pt;left:140.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Rats (Sprague </span></p>
<p style="top:425.7pt;left:140.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Dawley)</span></p>
<p style="top:416.4pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador M, sc, cumulative dose </span></p>
<p style="top:425.7pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">11, 16, 500, or 750 mg or </span></p>
<p style="top:435.0pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">combination of Iscador M, sc, </span></p>
<p style="top:444.2pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">cumulative dose 11 or 500 mg </span></p>
<p style="top:453.4pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">&amp; Cetraria praeparata, </span></p>
<p style="top:462.7pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">cumulative dose 3 or 164 mg</span></p>
<p style="top:416.4pt;left:320.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">93 to 115%</span></p>
<p style="top:416.4pt;left:381.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-16 to 8%</span></p>
<p style="top:416.4pt;left:508.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[124]</span></p>
<p style="top:483.9pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Dunning DMBA-5A; sc</span></p>
<p style="top:483.9pt;left:140.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Rats</span></p>
<p style="top:483.9pt;left:212.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador M, 2.5&#x2013;15 mg, ip, qd</span></p>
<p style="top:483.9pt;left:320.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">No difference</span></p>
<p style="top:483.9pt;left:423.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Less tumour viability</span></p>
<p style="top:483.9pt;left:509.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[127]</span></p>
<p style="top:505.2pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Walker carcinosarkoma </span></p>
<p style="top:514.5pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">256</span></p>
<p style="top:505.2pt;left:140.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Rats</span></p>
<p style="top:505.2pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador M, 0.005&#x2013;0.5 mg, im, </span></p>
<p style="top:514.5pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">qd</span></p>
<p style="top:505.2pt;left:320.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">No difference</span></p>
<p style="top:505.2pt;left:423.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Metastases: no </span></p>
<p style="top:514.5pt;left:423.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">difference</span></p>
<p style="top:505.2pt;left:508.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[128]</span></p>
<p style="top:535.7pt;left:56.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Autochthonous</span></b></p>
<p style="top:556.9pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Methylnitrosurea-</span></p>
<p style="top:566.2pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">induced</span></p>
<p style="top:556.9pt;left:140.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Rats (Sprague </span></p>
<p style="top:566.2pt;left:140.8pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Dawley)</span></p>
<p style="top:556.9pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Iscador M c. Arg., sc, 0,2 ml/</span></p>
<p style="top:566.2pt;left:212.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">day, 50 mg/week * 6 weeks</span></p>
<p style="top:556.9pt;left:320.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">75%</span></p>
<p style="top:556.9pt;left:381.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">-16%</span></p>
<p style="top:556.9pt;left:508.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[124]</span></p>
<p style="top:587.5pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">sc: subcutaneous; im: intramuscular; it: intratumoural; ip: intraperitoneal; iv: intravenous; w: week;</span></p>
<p style="top:596.7pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">qod: every other day; qd: every day; T/C: treated tumour/control tumour; ILS: increase in life span</span></p>
<p style="top:606.0pt;left:56.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">All experiments did have control groups, but these were only mentioned if necessary for results</span></p>
<p style="top:615.1pt;left:56.1pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">I </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Part of a screening programme for substances with anticancer activity (1,000 plant extracts from 107 plant species)</span></p>
<p style="top:624.4pt;left:56.1pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">II </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Relating to volume of ascites; effects greatest with therapy started on day -7</span></p>
<p style="top:77.7pt;left:54.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Table 8: Animal Studies of VAE on Breast or Gynaecological Cancer (transplanted human or murine tumours or primary </span></b></p>
<p style="top:87.2pt;left:54.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">autochthonous tumour)</span></b><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt"> (Continued)</span></i></p>


<p style="top:41.9pt;left:54.1pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:41.9pt;left:405.7pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:757.4pt;left:497.1pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 24 of 33</span></p>
<p style="top:770.1pt;left:430.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:86.0pt;left:54.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Table 9: Animal Studies of VAE Compounds in Breast or Gynaecological Cancer (transplanted human or murine tumours)</span></b></p>
<p style="top:103.9pt;left:58.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Tumour, site</span></b></p>
<p style="top:103.9pt;left:135.4pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Animal</span></b></p>
<p style="top:103.9pt;left:198.9pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">VAE</span></b></p>
<p style="top:103.9pt;left:280.2pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Tumour growth</span></b></p>
<p style="top:113.2pt;left:280.2pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">T/C (%)</span></b></p>
<p style="top:103.9pt;left:350.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Survival</span></b></p>
<p style="top:103.9pt;left:426.0pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Other outcomes</span></b></p>
<p style="top:103.9pt;left:510.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Reference</span></b></p>
<p style="top:135.4pt;left:58.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Human breast tumour</span></b></p>
<p style="top:157.7pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Breast</span></p>
<p style="top:157.7pt;left:135.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mice</span></p>
<p style="top:157.7pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">rML 0,3 ng/kg &#x2013; 3 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">g/</span></p>
<p style="top:166.9pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">kg, ip, qd * 5 * 2&#x2013;4 w</span></p>
<p style="top:157.7pt;left:280.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">No effect</span></p>
<p style="top:157.7pt;left:510.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[129]</span></p>
<p style="top:189.2pt;left:58.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Murine breast tumour in mice</span></b></p>
<p style="top:211.5pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">C3L5, </span></p>
<p style="top:220.7pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">adenocarcinoma; sc</span></p>
<p style="top:211.5pt;left:135.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mice (C3H7HeJ)</span></p>
<p style="top:211.5pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ML I, 1 ng/kg, sc, q3d, </span></p>
<p style="top:220.7pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">day 7&#x2013;19</span></p>
<p style="top:211.5pt;left:280.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">160</span></p>
<p style="top:211.5pt;left:426.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">27.6 lung-metastases</span></p>
<p style="top:211.5pt;left:510.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[130]</span></p>
<p style="top:243.0pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">IL-2, twice 6 &#xd7; 104 </span></p>
<p style="top:252.2pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">IU/mouse, ip q8h 2 * </span></p>
<p style="top:261.4pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">qd * 5</span></p>
<p style="top:243.0pt;left:280.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">43</span></p>
<p style="top:243.0pt;left:426.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2.3 lung-metastases</span></p>
<p style="top:283.7pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Combination of ML 1 </span></p>
<p style="top:292.9pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">&amp; IL-2</span></p>
<p style="top:283.7pt;left:280.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">37</span></p>
<p style="top:283.7pt;left:426.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2.3 lung-metastases</span></p>
<p style="top:315.2pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Control</span></p>
<p style="top:315.2pt;left:426.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">7.5 lung-metastases</span></p>
<p style="top:337.5pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ECa, ip</span></p>
<p style="top:337.5pt;left:135.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mice (ICR)</span></p>
<p style="top:337.5pt;left:199.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ML I, 80 ng, ip, day 1</span></p>
<p style="top:337.5pt;left:350.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">70% died after 50 </span></p>
<p style="top:346.7pt;left:350.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">days</span></p>
<p style="top:337.5pt;left:510.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[131]</span></p>
<p style="top:369.0pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">A-chain of ML I, 100 </span></p>
<p style="top:378.2pt;left:198.9pt;line-height:8.2pt"><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">g, ip, day 1</span></p>
<p style="top:369.0pt;left:350.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">80% died after 57 </span></p>
<p style="top:378.2pt;left:350.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">days</span></p>
<p style="top:400.5pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">B-chain of ML I, 10 </span></p>
<p style="top:409.7pt;left:198.9pt;line-height:8.2pt"><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">g, ip, day 1</span></p>
<p style="top:400.5pt;left:350.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">80% died after 58 </span></p>
<p style="top:409.7pt;left:350.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">days</span></p>
<p style="top:432.0pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Control</span></p>
<p style="top:432.0pt;left:350.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">100% died after 20 </span></p>
<p style="top:441.2pt;left:350.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">days</span></p>
<p style="top:463.5pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ECa, sc</span></p>
<p style="top:463.5pt;left:135.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mice (BALB/c)</span></p>
<p style="top:463.5pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">VAE 5 kDa peptides, </span></p>
<p style="top:472.7pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">2 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">g, it, day 7</span></p>
<p style="top:463.5pt;left:426.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Severe necrosis, </span></p>
<p style="top:472.7pt;left:426.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">infiltration of </span></p>
<p style="top:481.9pt;left:426.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">lymphocytes and </span></p>
<p style="top:491.2pt;left:426.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">macrophages</span></p>
<p style="top:463.5pt;left:510.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[122]</span></p>
<p style="top:513.4pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ECa, ip</span></p>
<p style="top:513.4pt;left:135.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mice (CD-1)</span></p>
<p style="top:513.4pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Vester&apos; Proteins, ip, </span></p>
<p style="top:522.7pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">0.1 or 1 or 10 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">/kg, </span></p>
<p style="top:531.9pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">qd * 10</span></p>
<p style="top:513.4pt;left:350.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ILS: 0, 33, and -33%I</span></p>
<p style="top:513.4pt;left:510.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[132]</span></p>
<p style="top:554.2pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">ECa</span></p>
<p style="top:554.2pt;left:135.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mice</span></p>
<p style="top:554.2pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Polysaccharide </span></p>
<p style="top:563.5pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(&#x201e;Viscums&#xe4;ure&#x201c;), ip, </span></p>
<p style="top:572.7pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">qd * 6</span></p>
<p style="top:554.2pt;left:280.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Slight effect</span></p>
<p style="top:554.2pt;left:510.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[133]</span></p>
<p style="top:595.0pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Adenocarcinoma </span></p>
<p style="top:604.2pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">EO 771</span></p>
<p style="top:595.0pt;left:135.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mice</span></p>
<p style="top:595.0pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Polysaccharide </span></p>
<p style="top:604.2pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(&#x201e;Viscums&#xe4;ure&#x201c;), ip, </span></p>
<p style="top:613.5pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">qd * 6</span></p>
<p style="top:595.0pt;left:280.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Moderate effect</span></p>
<p style="top:595.0pt;left:510.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[133]</span></p>
<p style="top:635.7pt;left:58.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Murine breast tumour in rats</span></b></p>
<p style="top:658.0pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Walker </span></p>
<p style="top:667.2pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Carcinosarcoma</span></p>
<p style="top:658.0pt;left:135.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Rats</span></p>
<p style="top:658.0pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Polysaccharide </span></p>
<p style="top:667.2pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(&#x201e;Viscums&#xe4;ure&#x201c;), ip, </span></p>
<p style="top:676.5pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">qd * 6</span></p>
<p style="top:658.0pt;left:280.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Moderate effect</span></p>
<p style="top:658.0pt;left:510.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[133]</span></p>


<p style="top:41.9pt;left:54.1pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:41.9pt;left:405.7pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:757.4pt;left:497.1pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 25 of 33</span></p>
<p style="top:770.1pt;left:430.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:332.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">local recurrences were reduced after application of VAE or</span></p>
<p style="top:344.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">of VAE-activated macrophages; one study found no bene-</span></p>
<p style="top:356.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">fit. All experiments using local VAE application found a</span></p>
<p style="top:367.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">benefit in relation to survival and tumour-growth inhibi-</span></p>
<p style="top:379.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">tion. In rats, no clear benefit of VAE could be seen. Results</span></p>
<p style="top:391.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">from applying isolated or recombinant VAE compounds</span></p>
<p style="top:403.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">were inconsistent: some moderate effects of proteins (e.g.</span></p>
<p style="top:414.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">lectins) or polysaccharides were observed in relation to</span></p>
<p style="top:426.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">survival and tumour growth, while others observed none</span></p>
<p style="top:438.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">or possibly also adverse outcomes.</span></p>
<p style="top:461.8pt;left:54.1pt;line-height:9.5pt"><b><i><span style="font-family:FslmpdGillSans,serif;font-size:9.5pt">Cervical cancer</span></i></b></p>
<p style="top:473.5pt;left:54.1pt;line-height:9.7pt"><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Clinical studies: Survival </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(Table 3) was investigated by one</span></p>
<p style="top:485.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">RCT and three non-RCTs: all four reported a beneficial</span></p>
<p style="top:497.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">outcome which, however, was statistically significant only</span></p>
<p style="top:508.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">in the non-RCTs. </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Tumour behaviour </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(Table 4) was investi-</span></p>
<p style="top:520.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">gated by one non-RCT, which could not find an effect on</span></p>
<p style="top:532.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">disease recurrence or metastases mainly because these</span></p>
<p style="top:544.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">events scarcely occurred. One single-arm study reported</span></p>
<p style="top:555.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">41% complete and 27% partial remissions in CIN after</span></p>
<p style="top:567.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">VAE application. </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">QoL </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(Table 5) was assessed in one RCT</span></p>
<p style="top:579.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and one non-RCT; both reported a statistically significant</span></p>
<p style="top:591.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">benefit.</span></p>
<p style="top:614.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Regarding </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">preclinical studies </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(Table 7), only HeLa cells were</span></p>
<p style="top:626.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">investigated; here VAE and protein fractions showed cyto-</span></p>
<p style="top:638.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">toxic effects.</span></p>
<p style="top:661.5pt;left:54.1pt;line-height:9.5pt"><b><i><span style="font-family:FslmpdGillSans,serif;font-size:9.5pt">Uterus cancer</span></i></b></p>
<p style="top:673.3pt;left:54.1pt;line-height:9.7pt"><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Clinical studies: Survival </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(Table 3) was investigated by two</span></p>
<p style="top:685.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">RCTs and two non-RCTs; three reported a statistically sig-</span></p>
<p style="top:696.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">nificant benefit while one found no difference. </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">QoL </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(Table</span></p>
<p style="top:708.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">5) was assessed by one RCT and one non-RCT; both found</span></p>
<p style="top:720.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">a statistically highly significant benefit.</span></p>
<p style="top:332.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Regarding </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">preclinical studies </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(Tables 7 and 9), VAE and iso-</span></p>
<p style="top:344.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">lated ML I showed cytotoxic effects in different human</span></p>
<p style="top:356.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">uterus cancer cells. Concerning animal experiments, a pat-</span></p>
<p style="top:367.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ent specification mentions &quot;moderate&quot; effects of mistletoe</span></p>
<p style="top:379.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">polysaccharides on tumour growth in uterusepithelioma.</span></p>
<p style="top:403.0pt;left:312.1pt;line-height:9.5pt"><b><i><span style="font-family:FslmpdGillSans,serif;font-size:9.5pt">Ovarian cancer</span></i></b></p>
<p style="top:414.7pt;left:312.1pt;line-height:9.7pt"><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Clinical studies:</span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt"> Two RCTs and two non-RCTs investigated</span></p>
<p style="top:426.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">the influence of VAE on </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">survival </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(Table 3) and reported a</span></p>
<p style="top:438.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">benefit, one of each with statistical significance. </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Tumour</span></i></p>
<p style="top:450.0pt;left:312.1pt;line-height:9.7pt"><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">behaviour </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(Table 4) was investigated by two RCTs, each</span></p>
<p style="top:461.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">combining VAE and chemotherapy (plus radiotherapy in</span></p>
<p style="top:473.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">one study): these reported comparable outcomes. The</span></p>
<p style="top:485.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">influence of VAE on </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">QoL </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">tolerability of chemotherapy</span></i></p>
<p style="top:497.0pt;left:312.1pt;line-height:9.7pt"><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">and radiation </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(Table 5) was investigated by three RCTs and</span></p>
<p style="top:508.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">one non-RCT; all of them reported a statistically signifi-</span></p>
<p style="top:520.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">cant positive effect. In one trial using an aggressive chem-</span></p>
<p style="top:532.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">otherapy protocol, higher dosages of Cisplatin and</span></p>
<p style="top:544.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Holoxan could be given in the VAE group as the side</span></p>
<p style="top:555.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">effects were less intense [63]. One single-arm study</span></p>
<p style="top:567.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">applied recombinant lectins in ovarian cancer but found</span></p>
<p style="top:579.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">no remission.</span></p>
<p style="top:602.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Regarding </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">preclinical studies </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(Tables 7 and 9), VAE showed</span></p>
<p style="top:614.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">cytotoxic effects in various ovarian cancer cells. In SCID</span></p>
<p style="top:626.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">mice, rMLs led to increased survival and to more tumour-</span></p>
<p style="top:638.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">free animals at the highest and lowest dosage, while no</span></p>
<p style="top:649.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">effect was observed at the medium dosage.</span></p>
<p style="top:673.3pt;left:312.1pt;line-height:9.5pt"><b><i><span style="font-family:FslmpdGillSans,serif;font-size:9.5pt">Genital cancer</span></i></b></p>
<p style="top:685.0pt;left:312.1pt;line-height:9.7pt"><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Clinical studies:</span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt"> One non-RCT (published in 1963)</span></p>
<p style="top:696.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">reported partly improved disease-specific </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">survival </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(Table</span></p>
<p style="top:708.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">3). Regarding </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">preclinical studies </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(Table 7), VAE showed</span></p>
<p style="top:720.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">cytotoxic effects in vulvar cancer cells.</span></p>
<p style="top:92.7pt;left:58.1pt;line-height:8.2pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.2pt">Other gynaecological tumour</span></b></p>
<p style="top:114.9pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Ovary, SoT&#xfc; 3, ip</span></p>
<p style="top:114.9pt;left:135.3pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Mice (SCID)</span></p>
<p style="top:114.9pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">rML 30 ng/kg, ip, qd * </span></p>
<p style="top:124.2pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">5 * 12</span></p>
<p style="top:114.9pt;left:350.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">35% mice alive at </span></p>
<p style="top:124.2pt;left:350.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">day 84</span></p>
<p style="top:114.9pt;left:426.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">40% tumour-free mice </span></p>
<p style="top:124.2pt;left:426.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">at day 84</span></p>
<p style="top:114.9pt;left:510.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[134]</span></p>
<p style="top:146.4pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">rML 150 ng/kg, ip, qd </span></p>
<p style="top:155.7pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">* 5 * 12</span></p>
<p style="top:146.4pt;left:350.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">10% mice alive at </span></p>
<p style="top:155.7pt;left:350.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">day 84</span></p>
<p style="top:146.4pt;left:426.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">10% tumour-free mice </span></p>
<p style="top:155.7pt;left:426.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">at day 84</span></p>
<p style="top:177.9pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">rML 500 ng/kg, ip, qd </span></p>
<p style="top:187.2pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">* 5 * 12</span></p>
<p style="top:177.9pt;left:350.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">75% mice alive at </span></p>
<p style="top:187.2pt;left:350.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">day 84</span></p>
<p style="top:177.9pt;left:426.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">65% tumour-free mice </span></p>
<p style="top:187.2pt;left:426.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">at day 84</span></p>
<p style="top:209.4pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Control</span></p>
<p style="top:209.4pt;left:350.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">15 mice alive at day </span></p>
<p style="top:218.7pt;left:350.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">84</span></p>
<p style="top:209.4pt;left:426.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">10% tumour-free mice </span></p>
<p style="top:218.7pt;left:426.0pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">at day 84</span></p>
<p style="top:240.9pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Uterusepithelioma </span></p>
<p style="top:250.2pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">T-8 Gu&#xe9;rin</span></p>
<p style="top:240.9pt;left:135.4pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Rats</span></p>
<p style="top:240.9pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Polysaccharide </span></p>
<p style="top:250.2pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">(&quot;Viscums&#xe4;ure&quot;), ip, </span></p>
<p style="top:259.5pt;left:198.9pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">qd * 6</span></p>
<p style="top:240.9pt;left:280.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Moderate effect</span></p>
<p style="top:240.9pt;left:510.2pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">[133]</span></p>
<p style="top:281.7pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">All experiments did have control groups, but these were only mentioned if necessary for results.</span></p>
<p style="top:291.0pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">sc: subcutaneous; it: intratumoural; ip: intraperitoneal; iv: intravenous; w: week;</span></p>
<p style="top:300.2pt;left:58.1pt;line-height:8.2pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">qod: every other day; qd: every day; T/C: treated tumour/control tumour; ILS: increase in life span.</span></p>
<p style="top:309.4pt;left:58.1pt;line-height:5.8pt"><span style="font-family:DdhngrGillSans,serif;font-size:5.8pt">I </span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">Application of 10 </span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:8.2pt">&#x3bc;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.2pt">g/kg of proteins had toxic effects</span></p>
<p style="top:77.7pt;left:54.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Table 9: Animal Studies of VAE Compounds in Breast or Gynaecological Cancer (transplanted human or murine tumours)</span></b><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt"> (Continued)</span></i></p>


<p style="top:41.9pt;left:54.1pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:41.9pt;left:405.7pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:757.4pt;left:497.1pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 26 of 33</span></p>
<p style="top:770.1pt;left:430.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:85.8pt;left:54.1pt;line-height:9.5pt"><b><i><span style="font-family:FslmpdGillSans,serif;font-size:9.5pt">Malignant effusion</span></i></b></p>
<p style="top:97.5pt;left:54.1pt;line-height:9.7pt"><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Clinical studies:</span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt"> One RCT and four single-arm studies</span></p>
<p style="top:109.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">investigated treatment of malignant pleural effusion and</span></p>
<p style="top:121.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ascites (originating from breast or ovarian cancer, among</span></p>
<p style="top:132.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">other cancer sites), and all reported substantial remission</span></p>
<p style="top:144.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">rates (Tables 4 and 6).</span></p>
<p style="top:168.0pt;left:54.1pt;line-height:9.5pt"><b><i><span style="font-family:FslmpdGillSans,serif;font-size:9.5pt">Safety</span></i></b></p>
<p style="top:179.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Tolerability was generally good. One case of urticaria and</span></p>
<p style="top:191.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">angioedema [56] and one case of &quot;generalized reaction&quot;</span></p>
<p style="top:203.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">[69] were described. Otherwise no major side effects or</span></p>
<p style="top:215.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">toxicity were reported. Frequent minor, dose-dependent</span></p>
<p style="top:226.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and spontaneously subsiding symptoms included reac-</span></p>
<p style="top:238.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">tions at the injection site (swelling, induration, erythema,</span></p>
<p style="top:250.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">pruritus, local pain) and mild flu-like symptoms or fever.</span></p>
<p style="top:262.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">In one study, local reactions intensified during concomi-</span></p>
<p style="top:273.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">tant chemotherapy [64]. A higher prevalence of depres-</span></p>
<p style="top:285.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">sion was documented in the unadjusted data of a</span></p>
<p style="top:297.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">retrolective non-RCT [69] in VAE-treated patients; these</span></p>
<p style="top:309.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">patients also had a higher prevalence of other treatments</span></p>
<p style="top:320.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">such as hormones. After intrapleural instillation, VAE</span></p>
<p style="top:332.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">induced significantly fewer side effects than doxycycline</span></p>
<p style="top:344.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">[60]. No indication for an interaction of VAE and chemo-</span></p>
<p style="top:356.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">therapy could be found (i.e. remission rate) and VAE had</span></p>
<p style="top:367.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">no influence on the plasma concentration of gemcitabine</span></p>
<p style="top:379.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">[44,73]. No toxicity was observed in animal studies,</span></p>
<p style="top:391.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">except after application of high doses of an isolated pro-</span></p>
<p style="top:403.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">tein complex with unknown constituents [132].</span></p>
<p style="top:426.3pt;left:54.1pt;line-height:10.7pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:10.7pt">Discussion</span></b></p>
<p style="top:438.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">A variety of clinical studies and experiments have investi-</span></p>
<p style="top:450.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">gated the potential therapeutic effects of VAE and its com-</span></p>
<p style="top:461.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">pounds in breast and gynecological cancer, and</span></p>
<p style="top:473.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">predominantly reported positive effects. Nevertheless they</span></p>
<p style="top:485.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">have to be interpreted with caution and within their con-</span></p>
<p style="top:497.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">text.</span></p>
<p style="top:520.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">The strongest and most consistent results from VAE in</span></p>
<p style="top:532.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">clinical studies concern </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">QoL </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and improved </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">tolerability of</span></i></p>
<p style="top:544.0pt;left:54.1pt;line-height:9.7pt"><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">conventional treatment</span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">. QoL questionnaires included</span></p>
<p style="top:555.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">mostly well established and validated QoL instruments</span></p>
<p style="top:567.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and one on psychosomatic self-regulation. The latter is a</span></p>
<p style="top:579.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">16 item QoL instrument that measures competence and</span></p>
<p style="top:591.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">autonomy, in terms of the ability to actively adapt to</span></p>
<p style="top:602.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">stressful life situations and to restore well-being. [136]</span></p>
<p style="top:614.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">This tool has so far been exclusively used in studies focus-</span></p>
<p style="top:626.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ing on complementary cancer treatments. Improvement</span></p>
<p style="top:638.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">was seen especially in relation to self-regulation, fatigue,</span></p>
<p style="top:649.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">sleep, nausea/vomiting, appetite, diarrhoea, energy, abil-</span></p>
<p style="top:661.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ity to work, enjoyment of life, depression, anxiety, pain,</span></p>
<p style="top:673.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and general physical, emotional, and functional well-</span></p>
<p style="top:685.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">being (for more details see Kienle GS, Kiene H: Influence</span></p>
<p style="top:696.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">of mistletoe treatment on quality of life in cancer patients.</span></p>
<p style="top:708.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">A systematic review of controlled clinical studies. Submit-</span></p>
<p style="top:720.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ted). Regarding the side effects of conventional oncology</span></p>
<p style="top:732.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">treatments, reduced hematopoetic damage (i.e. leukope-</span></p>
<p style="top:85.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">nia) and immuno-suppression was reported by some, but</span></p>
<p style="top:97.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">not by all studies. Similar, less chemotherapy-related</span></p>
<p style="top:109.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">events were observed in some but not in all studies. Valid-</span></p>
<p style="top:121.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ity of this evidence is quite good. 15 RCTs are available,</span></p>
<p style="top:132.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">four of them double-blinded (three of them showing a</span></p>
<p style="top:144.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">positive result) and one with an active control treatment.</span></p>
<p style="top:156.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">5 RCTs reported following ICH-GCP guidelines and three</span></p>
<p style="top:168.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">of them comprised more than 200 patients each. Ques-</span></p>
<p style="top:179.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">tions remain regarding observation or reporting bias,</span></p>
<p style="top:191.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">which is of major importance in relation to subjectively</span></p>
<p style="top:203.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">assessed outcomes such as QoL and subjective symptoms.</span></p>
<p style="top:215.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Treatment should therefore be blinded; but blinded sub-</span></p>
<p style="top:226.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">cutaneous VAE application can easily be correctly identi-</span></p>
<p style="top:238.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">fied by doctors and patients [55,137], due to its local</span></p>
<p style="top:250.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">reactions and mild flu-like symptoms. In the four blinded</span></p>
<p style="top:262.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">trials reviewed here, a considerable degree of unblinding</span></p>
<p style="top:273.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">was detected by asking patients and physicians in one</span></p>
<p style="top:285.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">study [55]; and can be presumed in two other of these tri-</span></p>
<p style="top:297.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">als where substantially more VAE-treated patients</span></p>
<p style="top:309.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">reported local reactions than control patients [54,57].</span></p>
<p style="top:320.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Other RCTs did not blind treatment application, as blind-</span></p>
<p style="top:332.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ing is unreliable. Therefore questions will remain in</span></p>
<p style="top:344.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">&quot;blinded&quot; as well as in open trials even though in general</span></p>
<p style="top:356.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">cancer or non-cancer trials could not detect relevant</span></p>
<p style="top:367.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">improvements of QoL or disease symptoms due to sugges-</span></p>
<p style="top:379.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">tive administration of inert substances [138-140]. Never-</span></p>
<p style="top:391.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">theless, </span></p>
<p style="top:391.2pt;left:353.4pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">the </span></p>
<p style="top:391.2pt;left:377.2pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">frequency, </span></p>
<p style="top:391.2pt;left:431.5pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">magnitude, </span></p>
<p style="top:391.2pt;left:489.9pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">duration </span></p>
<p style="top:391.2pt;left:537.0pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and</span></p>
<p style="top:403.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">conditions of QoL or symptomatic improvement in the</span></p>
<p style="top:414.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">course of VAE treatment should be clarified in more</span></p>
<p style="top:426.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">detail. Especially relevant might be the further elucidation</span></p>
<p style="top:438.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">of possible effects on cancer-related fatigue (see also</span></p>
<p style="top:450.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">[141]), which is one of the most disabling conditions in</span></p>
<p style="top:461.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">cancer patients, with only few therapeutic options for</span></p>
<p style="top:473.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">influencing it effectively [142-144]. Regarding simple pre-</span></p>
<p style="top:485.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">post assessments of QoL in single-arm studies, it is prob-</span></p>
<p style="top:497.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ably unnecessary to state that they are generally not appro-</span></p>
<p style="top:508.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">priate for judging influences on QoL, since it is affected by</span></p>
<p style="top:520.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">many factors.</span></p>
<p style="top:544.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Concerning </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">survival </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(Table 3), some of the RCTs show a</span></p>
<p style="top:555.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">statistically significant benefit while others show a statisti-</span></p>
<p style="top:567.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">cal trend or no difference. Most of the non-RCTs (which</span></p>
<p style="top:579.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">included larger patient numbers) show a major impact.</span></p>
<p style="top:591.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">The validity of the studies is limited because of their small</span></p>
<p style="top:602.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">sample size (median only 52 participants per RCT), and</span></p>
<p style="top:614.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">because 8 of the 9 RCTs were imbedded in the same</span></p>
<p style="top:626.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(large) epidemiological cohort study. This study was</span></p>
<p style="top:638.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">started in the 1970s, before modern standards of data</span></p>
<p style="top:649.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">quality control (ICH-GCP, GEP) were established, and it</span></p>
<p style="top:661.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">therefore does not fulfil modern standards in this respect.</span></p>
<p style="top:673.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">The 9</span><sup><span style="font-family:BqvvhnGiovanni,serif;font-size:6.8pt">th </span></sup><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">RCT had enrolled more patients but was con-</span></p>
<p style="top:685.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ducted even earlier, and suffers from a major attrition rate</span></p>
<p style="top:696.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">due to protocol violation [62]; the subsequent analysis</span></p>
<p style="top:708.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">followed the &quot;as treated&quot; instead of the &quot;intention-to-</span></p>
<p style="top:720.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">treat&quot; principle [145]. Hence bias cannot be excluded.</span></p>
<p style="top:732.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">None of the survival studies was blinded, but survival is</span></p>


<p style="top:41.9pt;left:54.1pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:41.9pt;left:405.7pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:757.4pt;left:497.1pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 27 of 33</span></p>
<p style="top:770.1pt;left:430.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:85.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">generally not easily affected by observer bias or suggestive</span></p>
<p style="top:97.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">effects [138-140]. Seen altogether, although results were</span></p>
<p style="top:109.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">consistent, questions regarding survival remain and valid-</span></p>
<p style="top:121.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ity of evidence is moderate at best. An independent, GCP-</span></p>
<p style="top:132.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">conform trial with sufficient power would be desirable to</span></p>
<p style="top:144.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">further evaluate potential survival benefit.</span></p>
<p style="top:168.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Regarding </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">tumour behaviour</span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">, evidence from RCTs is scanty;</span></p>
<p style="top:179.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">most benefits were shown in non-randomized studies. In</span></p>
<p style="top:191.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">single-arm studies of patients with no concomitant con-</span></p>
<p style="top:203.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ventional cancer treatment, high-dose or local application</span></p>
<p style="top:215.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">of whole VAE led to substantial remission of tumour or</span></p>
<p style="top:226.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">malignant effusion. This was also observed in animal</span></p>
<p style="top:238.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">studies: local application resulted in tumour-growth inhi-</span></p>
<p style="top:250.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">bition and increased survival. However, this application</span></p>
<p style="top:262.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and dosage is not standard and cannot be recommended</span></p>
<p style="top:273.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">widely due to potential risks of high dose or local applica-</span></p>
<p style="top:285.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">tion. With ordinary VAE application, schedule and dos-</span></p>
<p style="top:297.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">age, spectacular tumour remissions tend to be the</span></p>
<p style="top:309.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">exception [20,36]. No tumour remission was observed</span></p>
<p style="top:320.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">after application of rMLs. Remission in CIN cannot be dis-</span></p>
<p style="top:332.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">tinguished from spontaneous remission rates, which are</span></p>
<p style="top:344.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">frequent in this indication.</span></p>
<p style="top:367.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Apart from the discussed issues, the following validity</span></p>
<p style="top:379.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">aspects have to be considered: An attrition rate above 10%</span></p>
<p style="top:391.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">was present in 10 RCTs. In 5 of these RCTs [49-51,53],</span></p>
<p style="top:403.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">patients were excluded before baseline assessment. Here</span></p>
<p style="top:414.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">the patients were provisionally enrolled into the matching</span></p>
<p style="top:426.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and pairwise randomization procedure; subsequently</span></p>
<p style="top:438.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">they were asked for informed consent, and were excluded</span></p>
<p style="top:450.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">from the study if they declined, together with their</span></p>
<p style="top:461.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">matched twin. Even though the risk of bias with this pro-</span></p>
<p style="top:473.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">cedure is small, as the complete randomization unit</span></p>
<p style="top:485.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(patient pair) is excluded, the preferred conservative qual-</span></p>
<p style="top:497.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ity assessment in this review assessed these studies as not</span></p>
<p style="top:508.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">having excluded a drop-out bias. Of the remaining 5 trials,</span></p>
<p style="top:520.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">one had protocol violations in about 20% of patients as</span></p>
<p style="top:532.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">discussed above [62], and one trial used an aggressive</span></p>
<p style="top:544.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">chemotherapy that inevitably had to be halted in several</span></p>
<p style="top:555.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">patients [63]. Three trials did not report details.</span></p>
<p style="top:579.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">To reduce publication bias we also included unpublished</span></p>
<p style="top:591.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">studies and conducted a thorough literature search with</span></p>
<p style="top:602.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">extensive expert consultations. One unpublished RCT</span></p>
<p style="top:614.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(Lektinol in breast cancer by Schwiersch et al.) could not</span></p>
<p style="top:626.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">be included as it was not released by the manufacturer.</span></p>
<p style="top:638.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Beyond this, we cannot rule out the existence of unpub-</span></p>
<p style="top:649.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">lished and unknown RCTs, but we presume that no well-</span></p>
<p style="top:661.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">conducted, large-size and valid trials escaped our atten-</span></p>
<p style="top:673.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">tion. &#x2013; Regarding preclinical studies achieving complete-</span></p>
<p style="top:685.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ness is nearly impossible. These experiments are usually</span></p>
<p style="top:696.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">explorative, for instance when plant extracts are chemi-</span></p>
<p style="top:708.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">cally analysed for active compounds or for cytotoxic</span></p>
<p style="top:720.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">effects; in general only relevant results are published, but</span></p>
<p style="top:732.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">not results of non-relevant or non-working models or</span></p>
<p style="top:85.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">unstable chemicals. (Even in the reviewed experiments,</span></p>
<p style="top:97.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">often not all but only the noteworthy results were pre-</span></p>
<p style="top:109.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">sented in detail.)</span></p>
<p style="top:132.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Regarding funding, 27 of 28 controlled studies published</span></p>
<p style="top:144.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">since 2000 reported their funding source: 11 studies</span></p>
<p style="top:156.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">received funding from the pharmaceutical industry alone,</span></p>
<p style="top:168.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">16 studies (all by Grossarth et al.) had both industry and</span></p>
<p style="top:179.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">public funding. There was no difference of results depend-</span></p>
<p style="top:191.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ing on funding source.</span></p>
<p style="top:215.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Regarding non-RCTs, bias by self-selecting the treatment</span></p>
<p style="top:226.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">is usually present in raw data. In particular, patients who</span></p>
<p style="top:238.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">choose complementary treatments differ substantially</span></p>
<p style="top:250.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">from patients not choosing them [70,146]. It is therefore</span></p>
<p style="top:262.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">indispensable to conduct careful adjustment of baseline</span></p>
<p style="top:273.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">imbalances or matching [147-149]. This has been done to</span></p>
<p style="top:285.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">a varying degree in most studies except in one without any</span></p>
<p style="top:297.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">adjustment [64], and in another which only adjusted for</span></p>
<p style="top:309.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">the main outcome parameter but not for the other</span></p>
<p style="top:320.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">reported results [69]. Without any adjustment, no conclu-</span></p>
<p style="top:332.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">sions can be drawn regarding the applied treatment.</span></p>
<p style="top:344.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">When conducted and analysed carefully, non-RCTs can</span></p>
<p style="top:356.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">provide valuable information regarding external validity</span></p>
<p style="top:367.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and effectiveness, as they can investigate treatment effec-</span></p>
<p style="top:379.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">tiveness under routine conditions without distortion by</span></p>
<p style="top:391.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">the artificial and selective conditions of an RCT&apos;s experi-</span></p>
<p style="top:403.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">mental situation [150].</span></p>
<p style="top:426.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">In </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">preclinical studies</span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">, VAE show substantial cytotoxic effects</span></p>
<p style="top:438.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">in cells originating from breast and gynaecological cancer,</span></p>
<p style="top:450.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and display tumour-growth inhibition in animal studies.</span></p>
<p style="top:461.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Cytotoxicity, especially of the MLs (which bind on human</span></p>
<p style="top:473.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">breast cancer cells [151]), may be the cause of tumour</span></p>
<p style="top:485.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">reduction after local, intratumoural application of VAE. If</span></p>
<p style="top:497.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">systemically applied, the cytotoxicity of the MLs is of less</span></p>
<p style="top:508.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">relevance, as it is inhibited by serum glycoproteins [152]</span></p>
<p style="top:520.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and by anti-ML antibodies [153] which are produced after</span></p>
<p style="top:532.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">a few weeks of VAE application. Therapeutic effects of the</span></p>
<p style="top:544.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">MLs were inconsistent and not very impressive in the</span></p>
<p style="top:555.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">reviewed experiments. However, in other tumour types,</span></p>
<p style="top:567.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">MLs have also shown substantial growth-inhibiting effects</span></p>
<p style="top:579.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(e.g. [154-157]). Interestingly, in two experiments, the</span></p>
<p style="top:591.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">application of VAE-activated macrophages in mice not</span></p>
<p style="top:602.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">directly treated with VAE also showed tumour-growth</span></p>
<p style="top:614.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">inhibiting effects, while the application of non-activated</span></p>
<p style="top:626.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">macrophages had no effects [121]. Similarly in</span></p>
<p style="top:638.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">melanoma, the application of VAE-activated splenocytes</span></p>
<p style="top:649.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">inhibited metastasis [158,159].</span></p>
<p style="top:673.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">In general, the predictive reliability of the preclinical stud-</span></p>
<p style="top:685.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ies for clinical application is fairly limited in most</span></p>
<p style="top:696.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">instances. Clinical cancer disease is insufficiently mim-</span></p>
<p style="top:708.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">icked by animal models, with major differences regarding</span></p>
<p style="top:720.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">age, general condition, co-morbidity, invasiveness, metas-</span></p>
<p style="top:732.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">tases, antigenicity, immune system etc. The results of pre-</span></p>


<p style="top:41.9pt;left:54.1pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:41.9pt;left:405.7pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:757.4pt;left:497.1pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 28 of 33</span></p>
<p style="top:770.1pt;left:430.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:85.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">clinical screening, especially for treatment of solid</span></p>
<p style="top:97.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">tumours, have therefore been largely disappointing. The</span></p>
<p style="top:109.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">models currently regarded as best for cytotoxic substances</span></p>
<p style="top:121.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">use patient-derived tumours that grow subcutaneously or</span></p>
<p style="top:132.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">orthotopically in nude mice, as in several cases reviewed</span></p>
<p style="top:144.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">here. Immuno-active substances may however still be</span></p>
<p style="top:156.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">insufficiently assessed in immune-deficient animals, as</span></p>
<p style="top:168.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">the main components of the immune system are missing</span></p>
<p style="top:179.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">(nude mice, for instance, cannot generate mature T-lym-</span></p>
<p style="top:191.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">phocytes). Nevertheless, these preclinical experiments can</span></p>
<p style="top:203.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">provide important additional information for detecting</span></p>
<p style="top:215.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">the possible anti-cancer effects of medicinal plants, their</span></p>
<p style="top:226.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">active compounds, their mode of action and potential</span></p>
<p style="top:238.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">risks [20,160-162].</span></p>
<p style="top:262.0pt;left:54.1pt;line-height:9.5pt"><b><i><span style="font-family:FslmpdGillSans,serif;font-size:9.5pt">Safety aspects</span></i></b></p>
<p style="top:273.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Mistletoe therapy was well tolerated in the reviewed stud-</span></p>
<p style="top:285.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ies. Mild flu-like symptoms and local reactions at the</span></p>
<p style="top:297.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">injections sites are frequent, dose-dependent and self-lim-</span></p>
<p style="top:309.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ited. Allergic reactions can occur, and a few case reports of</span></p>
<p style="top:320.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">anaphylactic reactions exist [163-166]. A phase I study,</span></p>
<p style="top:332.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">conducted at the NCCAM/NCI, investigated safety, toxic-</span></p>
<p style="top:344.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ity and drug interactions between VAE and gemcitabine</span></p>
<p style="top:356.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">[73] and reported good tolerability, with neither dose-</span></p>
<p style="top:367.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">limiting toxicity of the VAE nor any effects on the plasma</span></p>
<p style="top:379.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">concentration of gemcitabine [44]. Combination of VAE</span></p>
<p style="top:391.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">with chemotherapy or radiotherapy did not negatively</span></p>
<p style="top:403.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">influence remission rate in clinical and in animal studies</span></p>
<p style="top:414.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">[56,63,118]. A higher prevalence of depression in VAE-</span></p>
<p style="top:426.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">treated patients in one study was observed in raw data of</span></p>
<p style="top:438.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">a self-selected population, without adjustment of baseline</span></p>
<p style="top:450.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">imbalances. This difference can be ascribed to variations</span></p>
<p style="top:461.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">in the patient population; for instance, they differed</span></p>
<p style="top:473.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">markedly in the prevalence of hormone treatment. No</span></p>
<p style="top:485.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">toxicity was observed in animal experiments.</span></p>
<p style="top:508.6pt;left:54.1pt;line-height:10.7pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:10.7pt">Conclusion</span></b></p>
<p style="top:520.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Preclinical and clinical studies investigating the influence</span></p>
<p style="top:532.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">of VAE and its isolated compounds on breast or gynaeco-</span></p>
<p style="top:544.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">logical cancer suggest a benefit, with the strongest evi-</span></p>
<p style="top:555.7pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">dence in relation to QoL and tolerability of conventional</span></p>
<p style="top:567.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">anti-cancer treatments. Regarding survival, evidence is less</span></p>
<p style="top:579.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">conclusive; most of the clinical studies had a very small</span></p>
<p style="top:591.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">sample size (RCTs) and were embedded in the same large</span></p>
<p style="top:602.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">cohort study; therefore an independent trial would be</span></p>
<p style="top:614.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">needed. Tumour-growth inhibition has been insuffi-</span></p>
<p style="top:626.2pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ciently assessed in prospective clinical trials. Tumour</span></p>
<p style="top:638.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">regression seems not to have been connected with regular</span></p>
<p style="top:649.8pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">low-dose subcutaneous VAE treatment, but with high</span></p>
<p style="top:661.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">dose and local application. The latter has not yet been</span></p>
<p style="top:673.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">thoroughly assessed and is not generally recommended.</span></p>
<p style="top:696.6pt;left:54.1pt;line-height:10.7pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:10.7pt">Abbreviations</span></b></p>
<p style="top:708.5pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">AMED: Allied and Complementary Medicine; CI: confi-</span></p>
<p style="top:720.3pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">dence interval; CIN: cervical intraepithelial neoplasia;</span></p>
<p style="top:732.0pt;left:54.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">DNA: deoxyribonucleic acid; ECa: Ehrlich carcinoma;</span></p>
<p style="top:85.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">EORTC QLQ-C30: European Organization for Research</span></p>
<p style="top:97.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and Treatment of Cancer Quality of Life Questionnaire-</span></p>
<p style="top:109.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Cancer; EORTC QLQ-BR23: European Organization for</span></p>
<p style="top:121.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Research and Treatment of Cancer Quality of Life Breast</span></p>
<p style="top:132.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Cancer Questionnaire; FACT-G: Functional Assessment of</span></p>
<p style="top:144.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Cancer Therapy-General; FLIC: Functional Living Index &#x2013;</span></p>
<p style="top:156.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Cancer; GCP: Good Clinical Practice; GEP: Good Epide-</span></p>
<p style="top:168.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">miological Practice; GLQ-8: Global Life Quality; GM-CSF:</span></p>
<p style="top:179.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">granulocyte macrophage colony-stimulating factor; HeLa</span></p>
<p style="top:191.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">cells: immortal cell line from Henrietta Lacks; HR: hazard</span></p>
<p style="top:203.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ratio; ICH: International Conference on Harmonisation;</span></p>
<p style="top:215.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">IFN-</span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:9.7pt">&#x3b3;</span><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">: interferon-gamma; IL: interleukin; kDa: kilodalton;</span></p>
<p style="top:226.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">KPS: Karnofsky performance status scale; MDR+: multid-</span></p>
<p style="top:238.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">rug resistant; ML: mistletoe lectin; NCCAM: National</span></p>
<p style="top:250.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Center for Complementary and Alternative Medicine;</span></p>
<p style="top:262.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">NCI: National Cancer Institute; NHS: National Health</span></p>
<p style="top:273.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Service; NK: neutral killer (cell); NLM: National Library of</span></p>
<p style="top:285.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Medicine; non-RCT: non-randomized controlled trial;</span></p>
<p style="top:297.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">QoL: quality of life; RCT: randomized controlled trial;</span></p>
<p style="top:309.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">rML: recombinant mistletoe lectin; SCE: sister chromatid</span></p>
<p style="top:320.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">exchange; SCID mice: Severe Combined Immunodefi-</span></p>
<p style="top:332.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">ciency mice; T-cells: lymphocytes matured in thymus;</span></p>
<p style="top:344.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">TCM: Traditional Chinese Medicine Index; TNF-</span><span style="font-family:PcvfsrSymbol,sans-serif;font-size:9.7pt">&#x3b1;</span><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">: tumor</span></p>
<p style="top:356.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">necrosis factor-alpha; TNM: tumor, node, metastasis; VAE:</span></p>
<p style="top:367.8pt;left:312.1pt;line-height:9.7pt"><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Viscum album </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">extracts; VisalbCBA: </span><i><span style="font-family:KpfdvmGiovanni,serif;font-size:9.7pt">Viscum album </span></i><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">chitin-</span></p>
<p style="top:379.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">binding agglutinin.</span></p>
<p style="top:402.8pt;left:312.1pt;line-height:10.7pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:10.7pt">Competing interests</span></b></p>
<p style="top:414.7pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">IFAEMM has received restricted research grants from</span></p>
<p style="top:426.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">Weleda, Abnoba and Helixor for other projects not con-</span></p>
<p style="top:438.3pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">nected to this review.</span></p>
<p style="top:461.6pt;left:312.1pt;line-height:10.7pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:10.7pt">Authors&apos; contributions</span></b></p>
<p style="top:473.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">The study protocol was written by GK and HK. Studies</span></p>
<p style="top:485.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">were read by GK, HK, AG. Study quality was assessed by</span></p>
<p style="top:497.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">GK and HK. Data were extracted by GK and checked by AG</span></p>
<p style="top:508.8pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">and HK. MS contributed substantially to data acquisition,</span></p>
<p style="top:520.5pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">analysis and interpretation of preclinical studies. GK</span></p>
<p style="top:532.2pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">wrote the paper which was critically revised and finally</span></p>
<p style="top:544.0pt;left:312.1pt;line-height:9.7pt"><span style="font-family:BqvvhnGiovanni,serif;font-size:9.7pt">approved by HK, MS and AG.</span></p>
<p style="top:567.3pt;left:312.1pt;line-height:10.7pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:10.7pt">Acknowledgements</span></b></p>
<p style="top:579.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">This review was funded by the Gesellschaft f&#xfc;r Biologische Krebsabwehr </span></p>
<p style="top:590.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">and the Software AG Stiftung. We thank Dr. Renatus Ziegler for providing </span></p>
<p style="top:600.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">additional data on the studies by Grossarth-Maticek &amp; Ziegler.</span></p>
<p style="top:632.7pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1.</span><sup><b><span style="font-family:DrpfqgGillSans,serif;font-size:10.7pt">References</span></b></sup></p>
<p style="top:632.7pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Esti-</span></b></p>
<p style="top:641.3pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">mates of the cancer incidence and mortality in Europe in</span></b></p>
<p style="top:649.7pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">2006.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Ann Oncol</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2007, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">18:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">581-592.</span></p>
<p style="top:658.2pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">2.</span></p>
<p style="top:658.2pt;left:330.1pt;line-height:8.0pt"><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Stat Bite</span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">: Number of Cancer Survivors by Site, 2003.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">J Natl</span></i></p>
<p style="top:666.8pt;left:330.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Cancer Inst</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2006, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">98(21):</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1514.</span></p>
<p style="top:675.2pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">3.</span></p>
<p style="top:675.2pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Fasching PA, Thiel F, Nicolaisen-Murmann K, Rauh C, Engel J, Lux MP,</span></p>
<p style="top:683.7pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Beckmann MW, Bani MR: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Association of complementary meth-</span></b></p>
<p style="top:692.3pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">ods with quality of life and life satisfaction in patients with</span></b></p>
<p style="top:700.7pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">gynecologic and breast malignancies.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Support Care Cancer</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2007,</span></p>
<p style="top:709.2pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">55:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1277-1284.</span></p>
<p style="top:717.8pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">4.</span></p>
<p style="top:717.8pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Helyer LK, Chin S, Chuim BK, Fitzgerald B, Verma S, Rakovitch E,</span></p>
<p style="top:726.2pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Dranitsaris G, Clemons M: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">The use of complementary and alter-</span></b></p>


<p style="top:41.9pt;left:54.1pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:41.9pt;left:405.7pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:757.4pt;left:497.1pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 29 of 33</span></p>
<p style="top:770.1pt;left:430.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:86.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">native medicines among patients with locally advanced</span></b></p>
<p style="top:94.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">breast cancer &#x2013; a descriptive study.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">BMC Cancer</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2006, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">6:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">39.</span></p>
<p style="top:102.9pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">5.</span></p>
<p style="top:102.9pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">DiGianni LM, Garber JE, WIner EP: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Complementary and alterna-</span></b></p>
<p style="top:111.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">tive medicine use among women with breast cancer.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">J Clin</span></i></p>
<p style="top:120.0pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Oncol</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2002, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">20:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">34s-38s.</span></p>
<p style="top:128.4pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">6.</span></p>
<p style="top:128.4pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Boon HS, Olatunde F, Zick SM: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Trends in complementary/alter-</span></b></p>
<p style="top:137.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">native medicine use by breast cancer survivors: comparing</span></b></p>
<p style="top:145.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">survey data from 1998 and 2005.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">BMC Woman&apos;s Health</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2007, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">7:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">4.</span></p>
<p style="top:153.9pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">7.</span></p>
<p style="top:153.9pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Molassiotis A, Scott JA, Kearney N, Pud D, Magri M, Selvekerova S,</span></p>
<p style="top:162.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Bruyns I, Fernandez-Ortega P, Panteli V, Margulies A, Gudmundsdot-</span></p>
<p style="top:171.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">tir G, Milovics L, Ozden G, Platin N, Patiraki E: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Complementary</span></b></p>
<p style="top:179.4pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">and alternative medicine use in breast cancer patients in</span></b></p>
<p style="top:188.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Europe.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Support Care Cancer</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2006, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">14:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">260-267.</span></p>
<p style="top:196.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">8.</span></p>
<p style="top:196.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Molassiotis A, Browall M, Milovics L, Panteli V, Patiraki E, Fernandez-</span></p>
<p style="top:204.9pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Ortega P: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Complementary and alternative medicine use in</span></b></p>
<p style="top:213.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">patients with gynecological cancers in Europe.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">International</span></i></p>
<p style="top:222.0pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Journal of Gynecological Cancer</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2006, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">16:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">219-224.</span></p>
<p style="top:230.4pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">9.</span></p>
<p style="top:230.4pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Cragg GM, Newman DJ: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Plants as a source of anti-cancer</span></b></p>
<p style="top:239.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">agents.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Ethnopharmacology. Encyclopedia of Life Support Systems</span></i></p>
<p style="top:247.5pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">(EOLSS), developed under the Auspices of the UNESCO</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2006 [http://</span></p>
<p style="top:256.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">www.eolss.net]. Oxford, UK, Eolss Publishers</span></p>
<p style="top:264.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">10.</span></p>
<p style="top:264.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Molassiotis A, Fernandez-Ortega P, Pud D, Ozden G, Scott JA, Panteli</span></p>
<p style="top:273.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">V, Margulies A, Browall M, Magri M, Selvekerova S, Madsen E, Milovics</span></p>
<p style="top:281.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">L, Bruyns I, Gudmundsdottir G, Hummerston S, Ahmad AM, Platin N,</span></p>
<p style="top:290.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Kearney N, Patiraki E: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Use of complementary and alternative</span></b></p>
<p style="top:298.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">medicine in cancer patients: a European survey.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Ann Oncol</span></i></p>
<p style="top:307.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">2005, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">16:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">655-663.</span></p>
<p style="top:315.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">11.</span></p>
<p style="top:315.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Endo Y, Tsurugi K, Franz H: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">The site of action of the A-chain of</span></b></p>
<p style="top:324.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">mistletoe lectin I on eukaryotic ribosomes.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">FEBS Letters</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1988,</span></p>
<p style="top:332.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">231:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">378-380.</span></p>
<p style="top:341.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">12.</span></p>
<p style="top:341.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Stirpe F, Sandvig K, Olsnes S, Pihl A: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Action of viscumin, a toxic</span></b></p>
<p style="top:349.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">lectin from mistletoe, on cells in culture.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">The Journal of Biological</span></i></p>
<p style="top:358.0pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Chemistry</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1982, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">257:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">13271-13277.</span></p>
<p style="top:366.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">13.</span></p>
<p style="top:366.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Stirpe F, Barbieri L, Battelli MG, Soria M, Lappi DA: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Ribosome-inac-</span></b></p>
<p style="top:375.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">tivating proteins from plants: present status and future pros-</span></b></p>
<p style="top:383.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">pects.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Biotechnology (N Y). </span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1992, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">10(4):</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">405-412.</span></p>
<p style="top:392.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">14.</span></p>
<p style="top:392.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Peumans WJ, Verhaert P, Pf&#xfc;ller U, Van Damme EJM: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Isolation and</span></b></p>
<p style="top:400.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">partial characterization of a small chitin-binding lectin from</span></b></p>
<p style="top:409.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">mistletoe (</span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album</span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">).</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">FEBS Letters</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1996, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">396:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">261-265.</span></p>
<p style="top:417.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">15.</span></p>
<p style="top:417.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Klett CY, Anderer FA: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Activation of natural killer cell cytotox-</span></b></p>
<p style="top:426.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">icity of human blood monocytes by a low molecular weight</span></b></p>
<p style="top:434.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">component from </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">extract.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Arzneimittelforschung.</span></i></p>
<p style="top:443.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1989, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">39(12):</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1580-1585.</span></p>
<p style="top:451.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">16.</span></p>
<p style="top:451.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Mueller EA, Anderer FA: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">A </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">oligosaccharide acti-</span></b></p>
<p style="top:460.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">vating human natural cytotoxicity is an interferon gamma</span></b></p>
<p style="top:468.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">inducer.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Cancer Immunol Immunother</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1990, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">32:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">221-227.</span></p>
<p style="top:477.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">17.</span></p>
<p style="top:477.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Orhan DD, K&#xfc;peli E, Yesilada E, Ergun F: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Anti-inflammatory and</span></b></p>
<p style="top:485.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">antinociceptive activity of flavonoids isolated from VISCUM</span></b></p>
<p style="top:494.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">ALBUM ssp. ALBUM.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Z Naturforsch C.</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2006, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">61(1-2):</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">26-30.</span></p>
<p style="top:502.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">18.</span></p>
<p style="top:502.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Winkler K, Leneweit G, Schubert R: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Characterization of mem-</span></b></p>
<p style="top:511.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">brane vesicles in plant extracts.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Colloids and surfaces B, Biointer-</span></i></p>
<p style="top:519.5pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">faces</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2005, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">45:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">57-65.</span></p>
<p style="top:528.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">19.</span></p>
<p style="top:528.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Jager S, Winkler K, Pfuller U, Scheffler A: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Solubility studies of olea-</span></b></p>
<p style="top:536.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">nolic acid and betulinic acid in aqueous solutions and plant</span></b></p>
<p style="top:545.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">extracts of Viscum album L.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Planta Med</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2007, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">73:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">157-162.</span></p>
<p style="top:553.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">20.</span></p>
<p style="top:553.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Kienle GS, Kiene H: </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Die Mistel in der Onkologie &#x2013; Fakten und konzep-</span></i></p>
<p style="top:562.0pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">tionelle Grundlagen</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> Stuttgart, New York: Schattauer Verlag; 2003. </span></p>
<p style="top:570.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">21.</span></p>
<p style="top:570.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">B&#xfc;ssing A, (ed): </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Mistletoe. The Genus Viscum</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> Amsterdam: Hardwood</span></p>
<p style="top:579.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Academic Publishers; 2000. </span></p>
<p style="top:587.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">22.</span></p>
<p style="top:587.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Eggenschwiler J, von BL, Stritt B, Pruntsch D, Ramos M, Urech K, Rist</span></p>
<p style="top:596.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">L, Simoes-Wust AP, Viviani A: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Mistletoe lectin is not the only</span></b></p>
<p style="top:604.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">cytotoxic component in fermented preparations of Viscum</span></b></p>
<p style="top:613.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">album from white fir (Abies pectinata).</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">BMC Complement Altern</span></i></p>
<p style="top:621.5pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Med</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2007, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">7:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">14.</span></p>
<p style="top:630.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">23.</span></p>
<p style="top:630.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">B&#xfc;ssing A, Schietzel M: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Apoptosis-inducing properties of </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum</span></i></b></p>
<p style="top:638.5pt;left:72.1pt;line-height:8.0pt"><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">album </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">L. extracts from different host trees, correlate with</span></b></p>
<p style="top:647.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">their content of toxic mistletoe lectins.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Anticancer Res</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1999,</span></p>
<p style="top:655.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">19:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">23-28.</span></p>
<p style="top:664.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">24.</span></p>
<p style="top:664.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Els&#xe4;sser-Beile U, Lusebrink S, Grussenmeyer U, Wetterauer U,</span></p>
<p style="top:672.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Schultze-Seemann W: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Comparison of the effects of various clin-</span></b></p>
<p style="top:681.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">ically applied mistletoe preparations on peripheral blood</span></b></p>
<p style="top:689.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">leukocytes.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Arzneimittelforschung. </span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1998, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">48(12):</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1185-1189.</span></p>
<p style="top:698.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">25.</span></p>
<p style="top:698.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Valentiner U, Pf&#xfc;ller U, Baum C, Schumacher U: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">The cytotoxic</span></b></p>
<p style="top:706.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">effect of mistletoe lectins I, II and III on sensitive and multi-</span></b></p>
<p style="top:715.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">drug resistant human colon cancer cell lines in vitro.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Toxicol-</span></i></p>
<p style="top:723.5pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">ogy</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2002, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">171:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">187-199.</span></p>
<p style="top:86.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">26.</span></p>
<p style="top:86.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Siegle I, Fritz P, McClellan M, Gutzeit S, Murdter TE: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Combined</span></b></p>
<p style="top:94.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">cytotoxic action of </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">agglutinin-1 and anticancer</span></b></p>
<p style="top:102.9pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">agents against human A549 lung cancer cells.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Anticancer Res</span></i></p>
<p style="top:111.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">2001, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">21:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">2687-2691.</span></p>
<p style="top:120.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">27.</span></p>
<p style="top:120.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Bantel H, Engels IH, Voelter W, Schulze-Osthoff K, Wesselborg S:</span></p>
<p style="top:128.4pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Mistletoe lectin activates caspase-8/FLICE independently of</span></b></p>
<p style="top:137.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">death receptor signaling and enhances anticancer drug-</span></b></p>
<p style="top:145.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">induced apoptosis.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Cancer Research</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1999, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">59:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">2083-2090.</span></p>
<p style="top:153.9pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">28.</span></p>
<p style="top:153.9pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Mueller EA, Anderer FA: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Synergistic action of a plant rham-</span></b></p>
<p style="top:162.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">nogalacturonan enhancing antitumor cytotoxicity of human</span></b></p>
<p style="top:171.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">natural killer and lymphokine-activated killer cells: Chemical</span></b></p>
<p style="top:179.4pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">specificity of target cell recognition.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Cancer Research</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1990,</span></p>
<p style="top:188.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">50:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">3646-3651.</span></p>
<p style="top:196.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">29.</span></p>
<p style="top:196.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Zhu HG, Zollner TM, Klein-Franke A, Anderer FA: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Enhancement</span></b></p>
<p style="top:204.9pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">of </span></b></p>
<p style="top:204.9pt;left:347.7pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">MHC-unrestricted </span></b></p>
<p style="top:204.9pt;left:426.7pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">cytotoxic </span></b></p>
<p style="top:204.9pt;left:471.8pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">activity </span></b></p>
<p style="top:204.9pt;left:509.6pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">of </span></b></p>
<p style="top:204.9pt;left:527.2pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">human</span></b></p>
<p style="top:213.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">CD56+CD3- natural killer (NK) cells and CD+T cells by</span></b></p>
<p style="top:222.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">rhamnogalacturonan: target cell specificity and activity</span></b></p>
<p style="top:230.4pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">against NK-insensitive targets.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">J Cancer Res Clin Oncol</span></i></p>
<p style="top:239.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1994:383-388.</span></p>
<p style="top:247.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">30.</span></p>
<p style="top:247.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Park W-B, Lyu SY, Kim JH, Choi SH, Chung HK, Ahn SH, Hong SY,</span></p>
<p style="top:256.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Yoon TJ, Choi MJ: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Inhibition of tumor growth and metastasis</span></b></p>
<p style="top:264.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">by Korean mistletoe lectin is associated with apoptosis and</span></b></p>
<p style="top:273.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">antiangiogenesis.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Cancer Biother Radiopharm</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2001, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">16:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">439-447.</span></p>
<p style="top:281.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">31.</span></p>
<p style="top:281.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Van Huyen JP, Bayry J, Delignat S, Gaston AT, Michel O, Bruneval P,</span></p>
<p style="top:290.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Kazatchkine MD, Nicoletti A, Kaveri SV: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Induction of apoptosis of</span></b></p>
<p style="top:298.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">endothelial cells by Viscum album: a role for anti-tumoral</span></b></p>
<p style="top:307.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">properties of mistletoe lectins.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Mol Med</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2002, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">8:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">600-606.</span></p>
<p style="top:315.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">32.</span></p>
<p style="top:315.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Sch&#xf6;ffski P, Riggert S, Fumoleau P, Campone M, Bolte O, Marreaud S,</span></p>
<p style="top:324.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Lacombe D, Baron B, Herold M, Zwierzina H, Wilhelm-Ogunbiyi K,</span></p>
<p style="top:332.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Lentzen H, Twelves C, European Organization for Research and</span></p>
<p style="top:341.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Treatment of Cancer New Drug Development Group: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Phase I trial</span></b></p>
<p style="top:349.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">on intravenous aviscumine (rViscumin) in patients with solid</span></b></p>
<p style="top:358.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">tumors: a study of the European Organization for Research</span></b></p>
<p style="top:366.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">and Treatment of Cancer New Drug Development Group.</span></b></p>
<p style="top:375.0pt;left:330.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Ann Oncol</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2004, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">15:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1816-1824.</span></p>
<p style="top:383.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">33.</span></p>
<p style="top:383.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Sch&#xf6;ffski P, Breidenbach I, Krauter J, Bolte O, Stadler M, Ganser A,</span></p>
<p style="top:392.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Wilhelm-Ogunbiyi K, Lentzen H: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Weekly 24 h infusion of aviscu-</span></b></p>
<p style="top:400.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">mine (rViscumin): a phase I study in patients with solid</span></b></p>
<p style="top:409.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">tumours.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Eur J Cancer</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2005, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">41:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1431-1438.</span></p>
<p style="top:417.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">34.</span></p>
<p style="top:417.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Kienle GS, Berrino F, B&#xfc;ssing A, Portalupi E, Rosenzweig S, Kiene H:</span></p>
<p style="top:426.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Mistletoe in cancer &#x2013; a systematic review on controlled clin-</span></b></p>
<p style="top:434.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">ical trials.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Eur J Med Res</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2003, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">8:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">109-119.</span></p>
<p style="top:443.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">35.</span></p>
<p style="top:443.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Stauder H, Kreuser E-D: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Mistletoe extracts standardised in</span></b></p>
<p style="top:451.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">terms of mistletoe lectins (ML I) in oncology: current state</span></b></p>
<p style="top:460.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">of clinical research.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Onkologie</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2002, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">25:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">374-380.</span></p>
<p style="top:468.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">36.</span></p>
<p style="top:468.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Kienle GS, Kiene H: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Complementary Cancer Therapy: A Sys-</span></b></p>
<p style="top:477.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">tematic Review of Prospective Clinical Trials on Anthropo-</span></b></p>
<p style="top:485.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">sophic Mistletoe Extracts.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Eur J Med Res</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2007, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">12:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">103-119.</span></p>
<p style="top:494.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">37.</span></p>
<p style="top:494.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Ernst E, Schmidt K, Steuer-Vogt MK: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Mistletoe for cancer? A sys-</span></b></p>
<p style="top:502.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">tematic review of randomized clincial trials.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Int J Cancer</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2003,</span></p>
<p style="top:511.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">107:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">262-267.</span></p>
<p style="top:519.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">38.</span></p>
<p style="top:519.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Horneber MA, Bueschel G, Huber R, Linde K, Rostock M: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Mistletoe</span></b></p>
<p style="top:528.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">therapy in oncology.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Cochrane Database Syst Rev</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2008:CD003297.</span></p>
<p style="top:536.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">39.</span></p>
<p style="top:536.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Lange-Lindberg AM, Velasco Garrido M, Busse R: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Misteltherapie</span></b></p>
<p style="top:545.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">als begleitende Behandlung zur Reduktion der Toxizit&#xe4;t der</span></b></p>
<p style="top:553.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Chemotherapie maligner Erkrankungen. </span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">GMS Health Technol</span></i></p>
<p style="top:562.0pt;left:330.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Assess 2006; 2:Doc18 (20060919)</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2006.</span></p>
<p style="top:570.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">40.</span></p>
<p style="top:570.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Khan KS, ter Riet G, Glanville J, Sowden AJ, Kleijnen J: </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Undertaking Sys-</span></i></p>
<p style="top:579.0pt;left:330.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">tematic Reviews of Research on Effectiveness. CRD&apos;S Guidance for those</span></i></p>
<p style="top:587.5pt;left:330.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Carrying Out or Commissioning Reviews. CRD Report Number 4</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2nd edi-</span></p>
<p style="top:596.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">tion. University of York: NHS Centre for Reviews and Dissemination;</span></p>
<p style="top:604.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">2001. </span></p>
<p style="top:613.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">41.</span></p>
<p style="top:613.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Kleijnen J, Knipschild P: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Mistletoe treatment for cancer &#x2013; review</span></b></p>
<p style="top:621.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">of controlled trials in humans.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Phytomedicine</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1994, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">1:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">255-260.</span></p>
<p style="top:630.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">42.</span></p>
<p style="top:630.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Jach R, Basta A: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Iscador QuS and human recombinant inter-</span></b></p>
<p style="top:638.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">feron alpha (Intron A) in cervical intraepithelial neoplasia</span></b></p>
<p style="top:647.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">(CIN).</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Przeglad Lekarski</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1999, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">56:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">86-88.</span></p>
<p style="top:655.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">43.</span></p>
<p style="top:655.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Jach R, Basta A, Szczudrawa A: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Role of immunomodulatory</span></b></p>
<p style="top:664.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">treatment with Iscador QuS and Intron A of women with</span></b></p>
<p style="top:672.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">CIN1 with concurrent HPV infection.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Ginekol Pol</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2003,</span></p>
<p style="top:681.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">74:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">729-735.</span></p>
<p style="top:689.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">44.</span></p>
<p style="top:689.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Mansky PJ, Wallerstedt DB, Monahan BP, Lee C, Sannes T, Stagl J,</span></p>
<p style="top:698.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Blackman MA, Swain SL, Grem J: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Phase I study of mistletoe</span></b></p>
<p style="top:706.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">extract/gemcitabine combination treatment in patients with</span></b></p>
<p style="top:715.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">advanced solid tumors.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Onkologie</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2008, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">31:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">200.</span></p>


<p style="top:41.9pt;left:54.1pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:41.9pt;left:405.7pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:757.4pt;left:497.1pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 30 of 33</span></p>
<p style="top:770.1pt;left:430.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:86.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">45.</span></p>
<p style="top:86.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Schink M, Tr&#xf6;ger W, Goyert A, Scheuerecker H, Selbmann K, Glaser</span></p>
<p style="top:94.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">F: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Zusammenhang der NK-Zellaktivit&#xe4;t gegen autologe</span></b></p>
<p style="top:102.9pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Tumor- und K562-Zellen mit dem klinischen Verlauf unter</span></b></p>
<p style="top:111.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Misteltherapie.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Forsch Komplement&#xe4;rmed</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2006, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">13:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">147-155.</span></p>
<p style="top:120.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">46.</span></p>
<p style="top:120.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Bar-Sela G, Goldberg H, Beck D, Amit A, Kuten A: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Reducing malig-</span></b></p>
<p style="top:128.4pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">nant ascites accumulation by repeated intraperitoneal</span></b></p>
<p style="top:137.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">administrations of a </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">extract.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Anticancer Res</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2006,</span></p>
<p style="top:145.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">26:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">709-714.</span></p>
<p style="top:153.9pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">47.</span></p>
<p style="top:153.9pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Tr&#xf6;ger W, Matija&#x161;evic M, </span><span style="font-family:BqvvhnGiovanni,serif;font-size:8.0pt">&#x17d;</span><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">drale Z, Tisma N, Jezdic S: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Additional</span></b></p>
<p style="top:162.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">therapy with mistletoe extracts in breast cancer patients</span></b></p>
<p style="top:171.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">receiving chemotherapy: a prospective randomized open</span></b></p>
<p style="top:179.4pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">label pilot study.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  In </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Die Mistel in der Tumortherapie 2. &#x2013; Aktueller</span></i></p>
<p style="top:188.0pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Stand der Forschung und klinische Anwendung</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> Edited by: Scheer R, Alban</span></p>
<p style="top:196.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">S, Becker H, Holzgrabe U, Kemper FH, Kreis W, Matthes H, Schilcher</span></p>
<p style="top:204.9pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">H. Essen, KVC-Verlag; 2009:509-521. </span></p>
<p style="top:213.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">48.</span></p>
<p style="top:213.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">B&#xfc;ssing A, Br&#xfc;ckner U, Enser-Weis U, Schnelle M, Schumann A, Schi-</span></p>
<p style="top:222.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">etzel M, Hatzmann W, Hackmann J: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Modulation of chemother-</span></b></p>
<p style="top:230.4pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">apy-associated </span></b></p>
<p style="top:230.4pt;left:140.0pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">immunosuppression </span></b></p>
<p style="top:230.4pt;left:228.9pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">by </span></b></p>
<p style="top:230.4pt;left:251.2pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">intravenous</span></b></p>
<p style="top:239.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">application of </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">L. extract (Iscador): a ran-</span></b></p>
<p style="top:247.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">domised physe II study.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">European Journal for Integrative Medicine</span></i></p>
<p style="top:256.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">2008, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">1:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">S44-S54.</span></p>
<p style="top:264.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">49.</span></p>
<p style="top:264.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Grossarth-Maticek R, Ziegler R: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Randomized and non-rand-</span></b></p>
<p style="top:273.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">omized prospective controlled cohort studies in matched</span></b></p>
<p style="top:281.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">pair design for the long-term therapy of corpus uteri cancer</span></b></p>
<p style="top:290.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">patients with a mistletoe preparation (Iscador).</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Eur J Med Res</span></i></p>
<p style="top:298.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">2008, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">13:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">107-120.</span></p>
<p style="top:307.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">50.</span></p>
<p style="top:307.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Grossarth-Maticek R, Ziegler R: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Prospective controlled cohort</span></b></p>
<p style="top:315.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">studies on long-term therapy of ovarian cancer patients with</span></b></p>
<p style="top:324.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">mistletoe (</span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">L.) extracts Iscador.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Arzneimittelforsc-</span></i></p>
<p style="top:332.5pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">hung</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2007, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">57(10):</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">665-678.</span></p>
<p style="top:341.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">51.</span></p>
<p style="top:341.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Grossarth-Maticek R, Ziegler R: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Prospective controlled cohort</span></b></p>
<p style="top:349.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">studies on long-term therapy of cervical cancer patients with</span></b></p>
<p style="top:358.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">a mistletoe preparation (Iscador</span></b><sup><b><span style="font-family:DrpfqgGillSans,serif;font-size:5.6pt">&#xae;</span></b></sup><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">).</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Forsch Komplement&#xe4;rmed</span></i></p>
<p style="top:366.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">2007, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">14:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">140-147.</span></p>
<p style="top:375.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">52.</span></p>
<p style="top:375.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Grossarth-Maticek R, Ziegler R: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Prospective controlled cohort</span></b></p>
<p style="top:383.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">studies on long-term therapy of breast cancer patients with</span></b></p>
<p style="top:392.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">a mistletoe preparation (Iscador) &#x2013; Supplementary materi-</span></b></p>
<p style="top:400.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">als.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  2006.</span></p>
<p style="top:409.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">53.</span></p>
<p style="top:409.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Grossarth-Maticek R, Ziegler R: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Prospective controlled cohort</span></b></p>
<p style="top:417.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">studies on long-term therapy of breast cancer patients with</span></b></p>
<p style="top:426.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">a mistletoe preparation (Iscador).</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Forsch Komplement&#xe4;rmed</span></i></p>
<p style="top:434.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">2006, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">13:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">285-292.</span></p>
<p style="top:443.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">54.</span></p>
<p style="top:443.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Semiglasov VF, Stepula VV, Dudov A, Schnitker J, Mengs U: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Quality</span></b></p>
<p style="top:451.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">of life is improved in breast cancer patients by Standardised</span></b></p>
<p style="top:460.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Mistletoe Extract PS76A2 during chemotherapy and follow-</span></b></p>
<p style="top:468.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">up: a randomised, placebo-controlled, double-blind, multi-</span></b></p>
<p style="top:477.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">centre clinical trial.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Anticancer Res</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2006, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">26:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1519-1530.</span></p>
<p style="top:485.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">55.</span></p>
<p style="top:485.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Auerbach L, Dostal V, V&#xe1;clavik-Fleck I, Kubista E, Rosenberger A,</span></p>
<p style="top:494.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Rieger S, Tr&#xf6;ger W, Schierholz JM: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Signifikant h&#xf6;herer Anteil</span></b></p>
<p style="top:502.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">aktivierter NK-Zellen durch additive Misteltherapie bei</span></b></p>
<p style="top:511.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">chemotherapierten </span></b></p>
<p style="top:511.0pt;left:154.8pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Mamma-Ca-Patientinnen </span></b></p>
<p style="top:511.0pt;left:259.2pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">in </span></b></p>
<p style="top:511.0pt;left:275.9pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">einer</span></b></p>
<p style="top:519.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">prospektiven randomisierten doppelblinden Studie.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  In </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Fort-</span></i></p>
<p style="top:528.0pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">schritte in der Misteltherapie. Aktueller Stand der Forschung und klinischen</span></i></p>
<p style="top:536.5pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Anwendung</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> Edited by: Scheer R, Bauer R, Becker H, Fintelmann V,</span></p>
<p style="top:545.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Kemper FH, Schilcher H. Essen, KVC Verlag; 2005:543-554. </span></p>
<p style="top:553.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">56.</span></p>
<p style="top:553.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Piao BK, Wang YX, Xie GR, Mansmann U, Matthes H, Beuth J, Lin HS:</span></p>
<p style="top:562.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Impact of complementary mistletoe extract treatment on</span></b></p>
<p style="top:570.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">quality of life in breast, ovarian and non-small cell lung can-</span></b></p>
<p style="top:579.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">cer patients. A prospective randomized controlled clinical</span></b></p>
<p style="top:587.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">trial.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Anticancer Res</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2004, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">24:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">303-309.</span></p>
<p style="top:596.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">57.</span></p>
<p style="top:596.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Semiglasov VF, Stepula VV, Dudov A, Lehmacher W, Mengs U: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">The</span></b></p>
<p style="top:604.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">standardised mistletoe extract PS76A2 improves QoL in</span></b></p>
<p style="top:613.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">patients with breast cancer receiving adjuvant CMF chemo-</span></b></p>
<p style="top:621.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">therapy: a randomised, placebo-controlled, double-blind,</span></b></p>
<p style="top:630.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">multicentre clinical trial.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Anticancer Res</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2004, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">24:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1293-1302.</span></p>
<p style="top:638.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">58.</span></p>
<p style="top:638.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Borrelli E: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Evaluation of the quality of life in breast cancer</span></b></p>
<p style="top:647.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">patients undergoing lectin standardized mistletoe therapy.</span></b></p>
<p style="top:655.5pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Minerva Medica</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2001, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">92:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">105-107.</span></p>
<p style="top:664.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">59.</span></p>
<p style="top:664.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Grossarth-Maticek R, Kiene H, Baumgartner S, Ziegler R: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Use of</span></b></p>
<p style="top:672.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Iscador, an extract of European mistletoe (</span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album</span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">), in</span></b></p>
<p style="top:681.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">cancer treatment: prospective nonrandomized and rand-</span></b></p>
<p style="top:689.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">omized matched-pair studies nested within a cohort study.</span></b></p>
<p style="top:698.0pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Altern Ther Health Med</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2001, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">7:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">57-78.</span></p>
<p style="top:706.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">60.</span></p>
<p style="top:706.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Kim M-H, Park Y-K, Lee S-H, Kim S-C, Lee S-Y, Kim C-H, Kim Y-K,</span></p>
<p style="top:715.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Kim K-H, Moon H-S, Song J-S, Park S-H: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Comparative study on</span></b></p>
<p style="top:723.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">the effects of a </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">(L.) extract (mistletoe) and dox-</span></b></p>
<p style="top:86.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">ycycline for pleurodesis in patients with malignant pleural</span></b></p>
<p style="top:94.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">effusion. 51th Meeting of The Korean Association of Internal</span></b></p>
<p style="top:102.9pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Medicine. Translation by Helixor Heilmittel GmbH.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Korean</span></i></p>
<p style="top:111.5pt;left:330.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Journal of Medicine</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1999, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">57:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">S121.</span></p>
<p style="top:120.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">61.</span></p>
<p style="top:120.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Heiny B-M: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Additive Therapie mit standardisiertem Mistelex-</span></b></p>
<p style="top:128.4pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">trakt reduziert die Leukopenie und verbessert die Leben-</span></b></p>
<p style="top:137.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">squalit&#xe4;t </span></b></p>
<p style="top:137.0pt;left:374.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">von </span></b></p>
<p style="top:137.0pt;left:399.8pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Patientinnen </span></b></p>
<p style="top:137.0pt;left:459.7pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">mit </span></b></p>
<p style="top:137.0pt;left:484.8pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">fortgeschrittenem</span></b></p>
<p style="top:145.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Mammakarzinom unter palliativer Chemotherapie (VEC-</span></b></p>
<p style="top:153.9pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Schema).</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Krebsmedizin</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1991, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">12:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1-14.</span></p>
<p style="top:162.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">62.</span></p>
<p style="top:162.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Gutsch J, Berger H, Scholz G, Denck H: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Prospektive Studie beim</span></b></p>
<p style="top:171.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">radikal operierten Mammakarzinom mit Polychemothera-</span></b></p>
<p style="top:179.4pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">pie, Helixor und unbehandelter Kontrolle.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Dtsch Zschr Onkol</span></i></p>
<p style="top:188.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1988:94-100.</span></p>
<p style="top:196.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">63.</span></p>
<p style="top:196.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Lange O, Scholz G, Gutsch J: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Modulation der subjektiven und</span></b></p>
<p style="top:204.9pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">objektiven Toxizit&#xe4;t einer aggressiven Chemotherapie mit</span></b></p>
<p style="top:213.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Helixor. Unpublished Report.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  1985.</span></p>
<p style="top:222.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">64.</span></p>
<p style="top:222.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Loewe-Mesch A, Kuehn JH, Borho K, Abel U, Bauer C, Gerhard I,</span></p>
<p style="top:230.4pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Schneeweiss A, Sohn C, Strowitzki T, Hagens C: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Adjuvante simul-</span></b></p>
<p style="top:239.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">tane Mistel-/Chemotherapie bei Mammakarzinom &#x2013; Einfluss</span></b></p>
<p style="top:247.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">auf Immunparameter, Lebensqualit&#xe4;t und Vertr&#xe4;glichkeit.</span></b></p>
<p style="top:256.0pt;left:330.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Forsch Komplement&#xe4;rmed</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2008, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">15:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">22-30.</span></p>
<p style="top:264.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">65.</span></p>
<p style="top:264.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">B&#xfc;ssing A, Bischof M, Hatzmann W, Bartsch F, Soto-Vera D, Fronk E-</span></p>
<p style="top:273.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">M, Gmeindl M, Stein GM: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Prevention of surgery-induced depres-</span></b></p>
<p style="top:281.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">sion of granulocyte function by intravenous application of a</span></b></p>
<p style="top:290.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">fermented extract from Viscum album L. in breast cancer</span></b></p>
<p style="top:298.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">patients.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Anticancer Res</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2005, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">25:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">4753-4758.</span></p>
<p style="top:307.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">66.</span></p>
<p style="top:307.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Salzer G: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">30 Jahre Erfahrung mit der Misteltherapie an</span></b></p>
<p style="top:315.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">&#xf6;ffentlichen Krankenanstalten.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  In </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Misteltherapie. Eine Antwort auf</span></i></p>
<p style="top:324.0pt;left:330.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">die Herausforderung Krebs</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> Edited by: Leroi R. Stuttgart, Verlag Freies</span></p>
<p style="top:332.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Geistesleben; 1987:173-215. </span></p>
<p style="top:341.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">67.</span></p>
<p style="top:341.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Fellmer Ch, Fellmer KE: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Nachbehandlung bestrahlter Genit-</span></b></p>
<p style="top:349.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">alkarzinome mit dem Viscum-album-Pr&#xe4;parat &quot;Iscador&quot;.</span></b></p>
<p style="top:358.0pt;left:330.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Krebsarzt</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1966, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">21:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">174-185.</span></p>
<p style="top:366.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">68.</span></p>
<p style="top:366.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Majewski A, Bentele W: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">&#xdc;ber Zusatzbehandlung beim weibli-</span></b></p>
<p style="top:375.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">chen Genitalkarzinom.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Zentralbl Gyn&#xe4;kol</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1963, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">85:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">696-700.</span></p>
<p style="top:383.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">69.</span></p>
<p style="top:383.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Beuth J, Schneider B, Schierholz JM: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Impact of complementary</span></b></p>
<p style="top:392.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">treatment of breast cancer patients with standardized mis-</span></b></p>
<p style="top:400.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">tletoe extract during aftercare: a controlled multicenter</span></b></p>
<p style="top:409.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">comparative epidemiological cohort study.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Anticancer Res</span></i></p>
<p style="top:417.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">2008, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">28:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">523-528.</span></p>
<p style="top:426.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">70.</span></p>
<p style="top:426.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Bock PR, Friedel WE, Hanisch J, Karasmann M, Schneider B: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Wirk-</span></b></p>
<p style="top:434.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">samkeit und Sicherheit der komplement&#xe4;ren Langzeitbe-</span></b></p>
<p style="top:443.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">handlung </span></b></p>
<p style="top:443.0pt;left:374.4pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">mit </span></b></p>
<p style="top:443.0pt;left:397.7pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">einem </span></b></p>
<p style="top:443.0pt;left:431.2pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">standardisierten </span></b></p>
<p style="top:443.0pt;left:502.2pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Extrakt </span></b></p>
<p style="top:443.0pt;left:540.7pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">aus</span></b></p>
<p style="top:451.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Europ&#xe4;ischer Mistel (</span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album L.</span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">) zus&#xe4;tzlich zur konven-</span></b></p>
<p style="top:460.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">tionellen adjuvanten onkologischen Therapie bei prim&#xe4;rem,</span></b></p>
<p style="top:468.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">nicht metastasiertem Mammakarzinom. Ergebnisse einer</span></b></p>
<p style="top:477.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">multizentrischen, </span></b></p>
<p style="top:477.0pt;left:412.4pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">komparativen, </span></b></p>
<p style="top:477.0pt;left:483.5pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">epidemiologischen</span></b></p>
<p style="top:485.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Kohortenstudie in Deutschland und der Schweiz.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Arzneim &#x2013;</span></i></p>
<p style="top:494.0pt;left:330.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Forsch/Drug Res</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2004, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">54:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">456-466.</span></p>
<p style="top:502.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">71.</span></p>
<p style="top:502.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Schumacher K, Schneider B, Reich G, Stiefel T, Stoll G, Bock PR,</span></p>
<p style="top:511.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Hanisch J, Beuth J: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Influence of postoperative complementary</span></b></p>
<p style="top:519.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">treatment with lectin-standardized mistletoe extract on</span></b></p>
<p style="top:528.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">breast cancer patients. A controlled epidemiological multi-</span></b></p>
<p style="top:536.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">centric retrolective cohort study.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Anticancer Res</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2003,</span></p>
<p style="top:545.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">23:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">5081-5088.</span></p>
<p style="top:553.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">72.</span></p>
<p style="top:553.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Schumacher K, Schneider B, Reich G, Stiefel T, Stoll G, Bock PR,</span></p>
<p style="top:562.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Hanisch J, Beuth J: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Postoperative komplement&#xe4;re Therapie des</span></b></p>
<p style="top:570.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">prim&#xe4;ren Mammakarzinoms mit lektinnormiertem Mis-</span></b></p>
<p style="top:579.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">telextrakt &#x2013; eine epidemiologische, multizentrische retrole-</span></b></p>
<p style="top:587.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">ktive Kohortenstudie.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Dtsch Zschr Onkol</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2002, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">34:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">106-114.</span></p>
<p style="top:596.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">73.</span></p>
<p style="top:596.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Mansky PJ, Grem J, Wallerstedt DB, Monahan BP, Blackman MR: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Mis-</span></b></p>
<p style="top:604.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">tletoe and Gemcitabine in patients with advanced cancer: A</span></b></p>
<p style="top:613.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">model for the phase I study of botanicals and botanical-drug</span></b></p>
<p style="top:621.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">interactions in cancer therapy.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Integr Cancer Ther</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2003,</span></p>
<p style="top:630.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">2:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">345-352.</span></p>
<p style="top:638.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">74.</span></p>
<p style="top:638.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Mahfouz MM, Ghaleb HA, Hamza MR, Fares L, Moussa L, Moustafua</span></p>
<p style="top:647.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">A, El-Za Wawy A, Kourashy L, Mobarak L, Saed S, Fouad F, Tony O,</span></p>
<p style="top:655.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Tohamy A: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Multicenter open labeled clinical study in</span></b></p>
<p style="top:664.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">advanced breast cancer patients. A preliminary report.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Jour-</span></i></p>
<p style="top:672.5pt;left:330.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">nal of the Egyptian Nat Cancer Inst</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1999, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">11:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">221-227.</span></p>
<p style="top:681.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">75.</span></p>
<p style="top:681.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Mahfouz MM, Ghaleb HA, Zawawy A, Scheffler A: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Significant</span></b></p>
<p style="top:689.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">tumor reduction, improvement of pain and quality of life and</span></b></p>
<p style="top:698.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">normalization of sleeping patterns of cancer patients treated</span></b></p>
<p style="top:706.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">with a high dose of mistletoe.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Ann Oncol</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1998, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">9:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">129.</span></p>


<p style="top:41.9pt;left:54.1pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:41.9pt;left:405.7pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:757.4pt;left:497.1pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 31 of 33</span></p>
<p style="top:770.1pt;left:430.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:86.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">76.</span></p>
<p style="top:86.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Finelli A, Limberg R: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Mistel-Lektin bei Patienten mit Tumorer-</span></b></p>
<p style="top:94.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">krankungen.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Medizin im Bild Diagnostik und Therapie im Bild</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1998,</span></p>
<p style="top:102.9pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">1:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1-8.</span></p>
<p style="top:111.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">77.</span></p>
<p style="top:111.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Portalupi E: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Neoadjuvant treatment in HPV-related CIN with</span></b></p>
<p style="top:120.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Mistletoe preparation (Iscador). </span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Dissertation Universit&#xe4;t Pavia</span></i></p>
<p style="top:128.4pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">1991/1992</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1995.</span></p>
<p style="top:137.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">78.</span></p>
<p style="top:137.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Werner H, Mahfouz MM, Fares L, Fouad F, Ghaleb HA, Hamza MR,</span></p>
<p style="top:145.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Kourashy L, Mobarak AL, Moustafa A, Saed S, Zaky O, Zawawy A,</span></p>
<p style="top:153.9pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Fischer S, Scheer R, Scheffler A: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Zur Therapie des malignen Pleu-</span></b></p>
<p style="top:162.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">raergusses mit einem Mistelpr&#xe4;parat.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Der Merkurstab</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1999,</span></p>
<p style="top:171.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">52:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">298-301.</span></p>
<p style="top:179.4pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">79.</span></p>
<p style="top:179.4pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Stumpf C, Schietzel M: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Intrapleurale Instillation eines Extraktes</span></b></p>
<p style="top:188.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">aus </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">[L.] zur Behandlung maligner Pleuraer-</span></b></p>
<p style="top:196.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">g&#xfc;sse.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Tumordiagnose u Therapie</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1994:57-62.</span></p>
<p style="top:204.9pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">80.</span></p>
<p style="top:204.9pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Friedrichson UKH: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Intraperitoneal instillation of </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album</span></i></b></p>
<p style="top:213.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">(L.) extrat (mistletoe) for therapy and malignant ascites.</span></b></p>
<p style="top:222.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Unpublished. Department of Radiology/Oncology, Commu-</span></b></p>
<p style="top:230.4pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">nity Hospital of Herdecke, University Witten/Herdecke.</span></b></p>
<p style="top:239.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1995.</span></p>
<p style="top:247.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">81.</span></p>
<p style="top:247.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Kn&#xf6;pfl-Sidler F, Viviani A, Rist L, Hensel A: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Human cancer cells</span></b></p>
<p style="top:256.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">exhibit in vitro individual receptiveness towards different</span></b></p>
<p style="top:264.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">mistletoe extracts.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Pharmazie</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2005, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">60:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">448-454.</span></p>
<p style="top:273.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">82.</span></p>
<p style="top:273.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Zuzak T, Rist L, Viviani A, Eggenschwiler J, Mol C, Riegert U, Meyer</span></p>
<p style="top:281.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">U: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Das Mistelpr&#xe4;parat Iscucin</span></b><sup><b><span style="font-family:DrpfqgGillSans,serif;font-size:5.6pt">&#xae; </span></b></sup><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">&#x2013; Herstellung, Analytik,</span></b></p>
<p style="top:290.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Wirkung in vitro.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Der Merkurstab</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2004, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">57:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">467-473.</span></p>
<p style="top:298.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">83.</span></p>
<p style="top:298.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">B&#xfc;ssing A, Schietzel D, Schietzel M, Schink M, Stein GM: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Keine Stim-</span></b></p>
<p style="top:307.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">ulation in vitro kultivierter Tumorzellen durch Mistellektin.</span></b></p>
<p style="top:315.5pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Dtsch Zschr Onkol</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2004, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">36:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">66-70.</span></p>
<p style="top:324.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">84.</span></p>
<p style="top:324.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Burger AM, Mengs U, Kelter G, Sch&#xfc;ler JB, Fiebig HH: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">No evidence</span></b></p>
<p style="top:332.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">of stimulation of human tumor cell proliferation by a stand-</span></b></p>
<p style="top:341.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">ardized aqueous mistletoe extrakt </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">in vitro</span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Anticancer Res</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2003,</span></p>
<p style="top:349.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">23:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">3801-3806.</span></p>
<p style="top:358.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">85.</span></p>
<p style="top:358.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Ramaekers FC, Harmsma M, Tusenius KJ, Schutte B, Werner M,</span></p>
<p style="top:366.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Ramos M: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Mistletoe extracts (Viscum album L.) Iscador</span></b><sup><b><span style="font-family:DrpfqgGillSans,serif;font-size:5.6pt">&#xae;</span></b></sup></p>
<p style="top:375.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">interact with the cell cycle machinery and target survival</span></b></p>
<p style="top:383.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">mechanisms in cancer cells.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Medicina</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2007, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">67:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">79-84.</span></p>
<p style="top:392.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">86.</span></p>
<p style="top:392.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Harmsma M, Gromme M, Ummelen M, Dignef W, Tusenius KJ, Ram-</span></p>
<p style="top:400.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">aekers FC: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Differential effects of Viscum album extract</span></b></p>
<p style="top:409.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">IscadorQu on cell cycle progression and apoptosis in cancer</span></b></p>
<p style="top:417.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">cells.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Int J Oncol</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2004, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">25:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1521-1529.</span></p>
<p style="top:426.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">87.</span></p>
<p style="top:426.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Harmsma M, Ummelen M, Dignef W, Tusenius KJ, Ramaekers FC:</span></p>
<p style="top:434.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Effects of mistletoe (Viscum album L.) extracts Iscador on</span></b></p>
<p style="top:443.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">cell cycle and survival of tumor cells.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Arzneimittelforschung</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2006,</span></p>
<p style="top:451.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">56:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">474-482.</span></p>
<p style="top:460.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">88.</span></p>
<p style="top:460.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Kelter G, Fiebig HH: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Absence of tumor growth stimulation in a</span></b></p>
<p style="top:468.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">panel of 26 human tumor cell lines by mistletoe (Viscum</span></b></p>
<p style="top:477.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">album L.) extracts Iscador in vitro.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Arzneimittelforschung. </span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2006,</span></p>
<p style="top:485.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">56(6A):</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">435-440.</span></p>
<p style="top:494.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">89.</span></p>
<p style="top:494.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Maier G, Fiebig HH: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Absence of tumor growth stimulation in a</span></b></p>
<p style="top:502.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">panel of 16 human tumor cell lines by mistletoe extracts </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">in</span></i></b></p>
<p style="top:511.0pt;left:72.1pt;line-height:8.0pt"><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">vitro</span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Anti-Cancer Drugs</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2002, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">13:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">373-379.</span></p>
<p style="top:519.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">90.</span></p>
<p style="top:519.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Kahle B, Debreczeni J&#xc9;, Sheldrick GM, Zeeck A: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Vergleichende</span></b></p>
<p style="top:528.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Zytotoxizit&#xe4;tsstudien von Viscotoxin-Isoformen und R&#xf6;nt-</span></b></p>
<p style="top:536.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">genstruktur von Viscotoxin A3 aus Mistelextrakten.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  In </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Fort-</span></i></p>
<p style="top:545.0pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">schritte in der Misteltherapie. Aktueller Stand der Forschung und klinischen</span></i></p>
<p style="top:553.5pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Anwendung</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> Edited by: Scheer R, Bauer R, Becker H, Fintelmann V,</span></p>
<p style="top:562.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Kemper FH, Schilcher H. Essen, KVC Verlag; 2005:83-98. </span></p>
<p style="top:570.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">91.</span></p>
<p style="top:570.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Mukthar D, Pf&#xfc;ller U, Tonevitsky AG, Witthohn K, Schumacher U:</span></p>
<p style="top:579.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Cell biological investigations on the use of mistletoe lectins</span></b></p>
<p style="top:587.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">in cancer therapy.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  In </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">COST 98. Effects of antinutrients on the nutri-</span></i></p>
<p style="top:596.0pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">tional value of legume diets</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> Edited by: Bardocz S, Pf&#xfc;ller U, Pusztai A.</span></p>
<p style="top:604.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Luxembourg, Office for Official Publications of the European Com-</span></p>
<p style="top:613.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">munities; 1998:187-193. </span></p>
<p style="top:621.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">92.</span></p>
<p style="top:621.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Pae H-O, Seo W-G, Oh G-S, Shin M-K, Lee H-S, Lee HS, Kim SB,</span></p>
<p style="top:630.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Chung H-T: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Potentiation of tumor necrosis factor- -induced</span></b></p>
<p style="top:638.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">apoptosis by mistletoe lectin.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Immunopharmacology and Immuno-</span></i></p>
<p style="top:647.0pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">toxicology</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2000, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">22:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">697-709.</span></p>
<p style="top:655.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">93.</span></p>
<p style="top:655.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Burger AM, Mengs U, Sch&#xfc;ler JB, Fiebig HH: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Antiproliferative</span></b></p>
<p style="top:664.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">activity of an aqueous mistletoe extract in human tumor cell</span></b></p>
<p style="top:672.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">lines and xenografts in vitro.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Arzneimittelforschung</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2001,</span></p>
<p style="top:681.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">51(9):</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">748-757.</span></p>
<p style="top:689.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">94.</span></p>
<p style="top:689.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Kelter G, Schierholz JM, Fischer IU, Fiebig H-H: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Cytotoxic activity</span></b></p>
<p style="top:698.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">and absence of tumor growth stimulation of standardized</span></b></p>
<p style="top:706.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">mistleteo extracts in human tumor models </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">in vitro</span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Anticancer</span></i></p>
<p style="top:715.0pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Res</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2007, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">27:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">223-233.</span></p>
<p style="top:86.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">95.</span></p>
<p style="top:86.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Hugo F, Schwitalla S, Niggemann B, Z&#xe4;nker KS, Dittmar KEJ: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Viscum</span></b></p>
<p style="top:94.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">album extracts Iscador</span></b><sup><b><span style="font-family:DrpfqgGillSans,serif;font-size:5.6pt">&#xae; </span></b></sup><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">P and Iscador</span></b><sup><b><span style="font-family:DrpfqgGillSans,serif;font-size:5.6pt">&#xae; </span></b></sup><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">M counteract the</span></b></p>
<p style="top:102.9pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">growth factor induced effects in human follicular B-HNL</span></b></p>
<p style="top:111.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">cells and breast cancer cells.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Medicina</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2007, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">67:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">90-96.</span></p>
<p style="top:120.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">96.</span></p>
<p style="top:120.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Beuth J, Ko HL, Schneider H, Tawadros S, Kasper HU, Zimst H, Sch-</span></p>
<p style="top:128.4pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">ierholz JM: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Intratumoral application of standardized mistletoe</span></b></p>
<p style="top:137.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">extracts down regulates tumor weight via decreased cell</span></b></p>
<p style="top:145.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">proliferation, increased apoptosis and necrosis in a murine</span></b></p>
<p style="top:153.9pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">model.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Anticancer Res</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2006, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">26:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">4451-4456.</span></p>
<p style="top:162.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">97.</span></p>
<p style="top:162.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Scheffler A, Fiebig HH, Kabelitz D, Metelmann HR: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Zur direkten</span></b></p>
<p style="top:171.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Zytotoxizit&#xe4;t von Mistelpr&#xe4;paraten.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Erfahrungsheilkunde</span></i></p>
<p style="top:179.4pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1993:338-346.</span></p>
<p style="top:188.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">98.</span></p>
<p style="top:188.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Gabius H-J, Darro F, Remmelink M, Andre S, Kopitz J, Danguy A,</span></p>
<p style="top:196.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Gabius S, Salmon I, Kiss R: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Evidence for stimulation of tumor</span></b></p>
<p style="top:204.9pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">proliferation in cell lines and histotypic cultures by clinically</span></b></p>
<p style="top:213.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">relevant low doses of the galactoside-binding mistletoe lec-</span></b></p>
<p style="top:222.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">tin, a component of proprietary extracts.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Cancer Investigation</span></i></p>
<p style="top:230.4pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">2001, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">19:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">114-126.</span></p>
<p style="top:239.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">99.</span></p>
<p style="top:239.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Kopp J, K&#xf6;rner I-J, Pf&#xfc;ller U, G&#xf6;ckeritz W, Eifler R, Pf&#xfc;ller K, Franz</span></p>
<p style="top:247.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">H: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Toxicity of mistletoe lectins I, II and III on normal and</span></b></p>
<p style="top:256.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">malignant cells.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  In </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Lectins: Biology, Biochemistry, Clinical Biochemistry</span></i></p>
<p style="top:264.5pt;left:330.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Volume 8</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">. Edited by: Van Driessche E, Franz H, Beeckmans S, Pf&#xfc;ller</span></p>
<p style="top:273.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">U, Kallikorm A, Bog-Hansen TC. Hellerup (Denmark), Textop;</span></p>
<p style="top:281.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1993:41-47. </span></p>
<p style="top:290.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">100. Wagner H, Jordan E, Z&#xe4;nker KS: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Cell-mediated and direct cyto-</span></b></p>
<p style="top:298.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">toxicity of purified ingredients of </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album</span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">J Cancer Res</span></i></p>
<p style="top:307.0pt;left:330.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Clin Oncol</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1987:53.</span></p>
<p style="top:315.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">101. Abuharbeid S, Apel J, Sander M, Fiedler B, Langer M, Zuzarte ML,</span></p>
<p style="top:324.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Czubayko F, Aigner A: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Cytotoxicity of the novel anti-cancer</span></b></p>
<p style="top:332.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">drug rViscumin depends on HER-2 levels in SKOV-3 cells.</span></b></p>
<p style="top:341.0pt;left:330.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Biochem Biophys Res Commun</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2004, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">321:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">403-412.</span></p>
<p style="top:349.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">102. Kienle GS, Kiene H: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Stellenwert, Dosierung und Gef&#xe4;hrlichkeit</span></b></p>
<p style="top:358.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">(Tumorenhancement) des ML I &#x2013; immunologische Schlu&#xdf;-</span></b></p>
<p style="top:366.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">folgerungen und experimentelle Untersuchungen.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  In </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Die Mis-</span></i></p>
<p style="top:375.0pt;left:330.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">tel in der Onkologie. Fakten und konzeptionelle Grundlagen</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> Stuttgart,</span></p>
<p style="top:383.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">New York, Schattauer Verlag; 2003:301-332. </span></p>
<p style="top:392.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">103. Franz H: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">The in vivo toxicity of toxic lectins is a complex phe-</span></b></p>
<p style="top:400.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">nomenon.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  In </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Lectins: Biology, Biochemistry, Clinical Biochemistry</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Volume</span></i></p>
<p style="top:409.0pt;left:330.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">8</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">. Edited by: Van Driessche E, Franz H, Beeckmans S, Pf&#xfc;ller U, Kal-</span></p>
<p style="top:417.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">likorm A, Bog-Hansen TC. Hellerup (Denmark), Textop; 1993:5-9. </span></p>
<p style="top:426.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">104. Klamerth O, Vester F, Kellner G: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Inhibitory effects of a protein</span></b></p>
<p style="top:434.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">complex from </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">on fibroblasts and HeLa cells.</span></b></p>
<p style="top:443.0pt;left:330.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Hoppe Seylers Z Physiol Chem. </span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1968, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">349(6):</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">863-864.</span></p>
<p style="top:451.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">105. Konopa J, Woynarowski JM, Lewandowska-Gumieniak M: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Isolation</span></b></p>
<p style="top:460.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">of Viscotoxins &#x2013; Cytotoxic basic polypeptides from </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum</span></i></b></p>
<p style="top:468.5pt;left:330.1pt;line-height:8.0pt"><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">album </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">L.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Hoppe Seylers Z Physiol Chem</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1980, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">361(10):</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1525-1533.</span></p>
<p style="top:477.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">106. Ulrich W, Mechelke F: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Reaktion der In-vitro-Kulturen von men-</span></b></p>
<p style="top:485.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">schlichen Fibroblasten, HeLa-Zellen und von murinen L-Zel-</span></b></p>
<p style="top:494.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">len bei Applikationen eines Pr&#xe4;parats aus </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">L.</span></b></p>
<p style="top:502.5pt;left:330.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Arzneim &#x2013; Forsch/Drug Res</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1980, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">30(II):</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1722-1725.</span></p>
<p style="top:511.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">107. Jurin M, Zarkovic N, Hrzenjak M, Ilic Z: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Antitumorous and immu-</span></b></p>
<p style="top:519.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">nomodulatory effects of the </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">L. preparation Iso-</span></b></p>
<p style="top:528.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">rel.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Oncology</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1993, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">50:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">393-398.</span></p>
<p style="top:536.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">108. Zarkovic N, Kalisnik T, Kissel D, Konitzer M, Jurin M, Grainza S:</span></p>
<p style="top:545.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Comparison of the effects of </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">lectin ML-1 and</span></b></p>
<p style="top:553.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">fresh plant extract (Isorel) on the cell growth </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">in vitro </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">and</span></b></p>
<p style="top:562.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">tumorigenicity of melanoma B16F10.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Cancer Biother Radiopharm</span></i></p>
<p style="top:570.5pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1998, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">13:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">121-131.</span></p>
<p style="top:579.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">109. Fritz B, Ulrich W: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Flow cytometric Analysis of human cell lines</span></b></p>
<p style="top:587.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">after exposure to preparations from </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album</span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Planta Med</span></i></p>
<p style="top:596.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1989, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">55:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">100-101.</span></p>
<p style="top:604.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">110. Fritz B: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Einfluss von </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">L. Pr&#xe4;paraten und allopa-</span></b></p>
<p style="top:613.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">thischen Zytostatika auf Proliferation, Zellzyklus und DNA-</span></b></p>
<p style="top:621.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Gehalt menschlicher Zellen in vitro.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  In </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">PhD Thesis</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> Universit&#xe4;t</span></p>
<p style="top:630.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Hohenheim; 1989. </span></p>
<p style="top:638.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">111. Taylor A, McKenna GF, Burlage HM: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Anticancer activity of plant</span></b></p>
<p style="top:647.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">extracts.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Texas reports on Biology and Medicine</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1956, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">14:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">538-556.</span></p>
<p style="top:655.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">112. Franz H: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Mistletoe lectins and their A and B chains.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Oncology</span></i></p>
<p style="top:664.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1986, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">43:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">23-34.</span></p>
<p style="top:672.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">113. Seeger PG: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">&#xdc;ber die Wirkung von Mistelextrakten (Iscador</span></b></p>
<p style="top:681.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">und Plenosol).</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Erfahrungsheilkunde</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1965, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">14:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">149-174.</span></p>
<p style="top:689.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">114. Selawry OS, Schwartz MR, Haar H: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Tumor inhibitory activity of</span></b></p>
<p style="top:698.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">products of Loranthaceae (mistletoe).</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Proceedings of the Ameri-</span></i></p>
<p style="top:706.5pt;left:330.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">can Association for Cancer Research</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1959:62-63.</span></p>


<p style="top:41.9pt;left:54.1pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:41.9pt;left:405.7pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:757.4pt;left:497.1pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 32 of 33</span></p>
<p style="top:770.1pt;left:430.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:86.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">115. Snajberk G: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Die kanzerostatischen Wirkungen spezieller Vis-</span></b></p>
<p style="top:94.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">cum-Proteine &#x2013; Signifikanz und Wirkungsverlust.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  In </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">PhD The-</span></i></p>
<p style="top:102.9pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">sis</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> Ludwig-Maximilians-Universit&#xe4;t, M&#xfc;nchen; 1980. </span></p>
<p style="top:111.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">116. Drees M, Berger DP, Dengler WA, Fiebig GH: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Direct cytotoxicity</span></b></p>
<p style="top:120.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">effects of preparations used as unconventional methods in</span></b></p>
<p style="top:128.4pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">cancer therapy in human tumor xenografts in the clonogenic</span></b></p>
<p style="top:137.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">assay and in nude mice.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  In </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Immunodeficient animals: Models for can-</span></i></p>
<p style="top:145.5pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">cer research</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Volume 51</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">. Edited by: Arnold W, K&#xf6;pf-Maier P, Micheel</span></p>
<p style="top:153.9pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">B. Basel, Karger Verlag; 1996:115-122. </span></p>
<p style="top:162.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">117. Zarkovic N, Vukovic T, Loncaric I, Miletic M, Zarkovic K, Borovic S,</span></p>
<p style="top:171.0pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Cipak A, Sabolovic S, Konitzer M, Mang S: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">An overview on antican-</span></b></p>
<p style="top:179.4pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">cer activities of the </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">extract Isorel</span></b><sup><b><span style="font-family:DrpfqgGillSans,serif;font-size:5.6pt">&#xae;</span></b></sup><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Cancer</span></i></p>
<p style="top:188.0pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Biother Radiopharm</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2001, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">16:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">55-62.</span></p>
<p style="top:196.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">118. Jurin M, Zarkovic N, Borovic S, Kissel D: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Immunomodulation by</span></b></p>
<p style="top:204.9pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">the </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">L. preparation Isorel and its antitumorous</span></b></p>
<p style="top:213.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">effects.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  In </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Grundlagen der Misteltherapie. Aktueller Stand der Forschung</span></i></p>
<p style="top:222.0pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">und klinische Anwendung</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> Edited by: Scheer R, Becker H, Berg PA. Stutt-</span></p>
<p style="top:230.4pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">gart, Hippokrates Verlag GmbH; 1996:315-324. </span></p>
<p style="top:239.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">119. Khwaja TA, Dias CB, Pentecost S: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Recent studies on the antican-</span></b></p>
<p style="top:247.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">cer activities of Mistletoe (</span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album</span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">) and its alcaloids.</span></b></p>
<p style="top:256.0pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Oncology</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1986, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">43:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">42-50.</span></p>
<p style="top:264.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">120. Cebovic T, Spasic S, Popovic M: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Cytotoxic effects of the Viscum</span></b></p>
<p style="top:273.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">album L. extract on Ehrlich tumour cells in vivo.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Phytotherapy</span></i></p>
<p style="top:281.5pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Research</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2008, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">22:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1097-1103.</span></p>
<p style="top:290.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">121. Kuttan G: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Tumoricidal activity of mouse peritoneal macro-</span></b></p>
<p style="top:298.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">phages treated with </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">extract.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Immunological Inves-</span></i></p>
<p style="top:307.0pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">tigations</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1993, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">22:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">431-440.</span></p>
<p style="top:315.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">122. Kuttan G, Kuttan R: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Immunological mechanism of action of the</span></b></p>
<p style="top:324.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">tumor reducing peptide from mistletoe extract (NSC</span></b></p>
<p style="top:332.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">635089) cellular proliferation.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Cancer Lett</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1992:123-130.</span></p>
<p style="top:341.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">123. Kuttan G, Kuttan V, Kuttan R: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Effect of a preparation from </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Vis-</span></i></b></p>
<p style="top:349.5pt;left:72.1pt;line-height:8.0pt"><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">cum album </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">on tumor development in vitro and in mice.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Jour-</span></i></p>
<p style="top:358.0pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">nal of Ethnopharmacology</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1990, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">29:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">35-41.</span></p>
<p style="top:366.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">124. Berger M, Schm&#xe4;hl D: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Studies on the tumor-inhibiting efficacy</span></b></p>
<p style="top:375.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">of Iscador in experimental animal tumors.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">J Cancer Res Clin</span></i></p>
<p style="top:383.5pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Oncol</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1983:262-265.</span></p>
<p style="top:392.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">125. Koch FE: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Experimentelle Untersuchungen &#xfc;ber lokale Beein-</span></b></p>
<p style="top:400.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">flussung von Impfgeschw&#xfc;lsten.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Z Krebsforsch</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1938:325-335.</span></p>
<p style="top:409.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">126. Koch FE: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Experimentelle Untersuchungen &#xfc;ber entz&#xfc;ndung-</span></b></p>
<p style="top:417.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">und nekroseerzeugende Wirkung von </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album</span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Z Ges</span></i></p>
<p style="top:426.0pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Exp Med</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1938, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">103:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">740-749.</span></p>
<p style="top:434.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">127. Linder MC, Murillo C: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Mistletoe preparations prevent changes</span></b></p>
<p style="top:443.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">in copper metabolism which normally occur in rats with</span></b></p>
<p style="top:451.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">implanted tumors. Abstract 18. Proceedings from the 73rd</span></b></p>
<p style="top:460.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Annual Meeting of the American Association for Cancer</span></b></p>
<p style="top:468.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Research &#x2013; April 28&#x2013;May 1, 1982.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  St. Louis, Missouri; 1982:5. </span></p>
<p style="top:477.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">128. Seitz W: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Die Wirkung von Iscador (Viscum praeparatum M.)</span></b></p>
<p style="top:485.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">auf das Walker-Karzinosarkom der Ratte.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Wien Klin Wochen-</span></i></p>
<p style="top:494.0pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">schr</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1975, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">87:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">131-132.</span></p>
<p style="top:502.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">129. Burger AM, Mengs U, Sch&#xfc;ler JB, Zinke H, Lentzen H, Fiebig HH:</span></p>
<p style="top:511.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Recombinant mistletoe lectin (ML) is a potent inhibitor of</span></b></p>
<p style="top:519.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">tumor cell growth in vitro and in vivo.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Proceedings of the Ameri-</span></i></p>
<p style="top:528.0pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">can Association for Cancer Research</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1999, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">40:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">399.</span></p>
<p style="top:536.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">130. Timoshenko AV, Lan Y, Gabius H-J, Lala PK: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Immunotherapy of</span></b></p>
<p style="top:545.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">C3H/HeJ mammary adenocarcinoma with interleukin-2,</span></b></p>
<p style="top:553.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">mistletoe lectin or their combination. effects on tumour</span></b></p>
<p style="top:562.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">growth, capillary leakage and nitric oxide (NO) production.</span></b></p>
<p style="top:570.5pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Eur J Cancer</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2001, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">37:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1910-1920.</span></p>
<p style="top:579.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">131. Franz H: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Viscaceae lectins.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  In </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Advances in lectin research</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Volume 2</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">.</span></p>
<p style="top:587.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Edited by: Franz H. Berlin, Volk und Gesundheit; 1989:28-59. </span></p>
<p style="top:596.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">132. Vester F: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">&#xdc;ber die kanzerostatischen und immunogenen</span></b></p>
<p style="top:604.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Eigenschaften von Mistelproteinen.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Krebsgeschehen</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1977,</span></p>
<p style="top:613.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">5:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">106-114.</span></p>
<p style="top:621.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">133. M&#xfc;ller J: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Verfahren zur Gewinnung eines Arzneimittels.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">(C</span></i></p>
<p style="top:630.0pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">24971 IVa/30h), 1&#x2013;12. 24-5-1962. Bundesrepublik Deutschland</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> .</span></p>
<p style="top:638.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">134. Schumacher U, Feldhaus S, Mengs U: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Recombinant mistletoe lec-</span></b></p>
<p style="top:647.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">tin (rML) is successful in treating human ovarian cancer cells</span></b></p>
<p style="top:655.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">transplanted into severe combined immunodeficient (SCID)</span></b></p>
<p style="top:664.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">mice.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Cancer Lett</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2000, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">150:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">171-175.</span></p>
<p style="top:672.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">135. Ziegler R, Grossarth-Maticek R: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Individual Patient Data Meta-</span></b></p>
<p style="top:681.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">analysis of Survival and Psychosomatic Self-regulation from</span></b></p>
<p style="top:689.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Published Prospective Controlled Cohort Studies for Long-</span></b></p>
<p style="top:698.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">term Therapy of Breast Cancer Patients with a Mistletoe</span></b></p>
<p style="top:706.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Preparation (Iscador).</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">eCam</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2008.</span></p>
<p style="top:715.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">136. B&#xfc;ssing A, Girke M, Heckmann C, Schad F, Ostermann T, Kr&#xf6;z M:</span></p>
<p style="top:723.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Validation of the self-regulation questionnaire as a measure</span></b></p>
<p style="top:86.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">of health in quality of life research.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Eur J Med Res</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2009,</span></p>
<p style="top:94.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">14(5):</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">223-227.</span></p>
<p style="top:102.9pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">137. Rostock M, Huber R: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Randomized and double-blind studies &#x2013;</span></b></p>
<p style="top:111.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">demands and reality as demonstrated by two examples of</span></b></p>
<p style="top:120.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">mistletoe research.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Forsch Komplementarmed Klass Naturheilkd.</span></i></p>
<p style="top:128.4pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">2004, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">11 Suppl:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">18-22.</span></p>
<p style="top:137.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">138. Chvetzoff G, Tannock I: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Placebo Effects in Oncology.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">J Natl Can-</span></i></p>
<p style="top:145.5pt;left:330.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">cer Inst</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2003, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">95:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">19-29.</span></p>
<p style="top:153.9pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">139. Kienle GS, Kiene H: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">The powerful placebo effect. Fact or fic-</span></b></p>
<p style="top:162.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">tion?</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">J Clin Epidemiol</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1997, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">50:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1311-1318.</span></p>
<p style="top:171.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">140. Hr&#xf3;bjartsson A, G&#xf8;tzsche P: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Is the placebo powerless? An anal-</span></b></p>
<p style="top:179.4pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">ysis of clinical trials comparing placebo with no treatment.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">N</span></i></p>
<p style="top:188.0pt;left:330.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Engl J Med</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2001, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">344:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1594-1602.</span></p>
<p style="top:196.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">141. Wode K, Schneider T, Lundberg I, Kienle GS: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Mistletoe treatment</span></b></p>
<p style="top:204.9pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">in cancer-related fatigue: a case report.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Cases Journal</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2009,</span></p>
<p style="top:213.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">2:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">77.</span></p>
<p style="top:222.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">142. Stone R, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Can-</span></b></p>
<p style="top:230.4pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">cer-related fatigue: Inevitable, unimportant and untreata-</span></b></p>
<p style="top:239.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">ble? Results of a multi-centre patient survey.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Ann Oncol</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2000,</span></p>
<p style="top:247.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">11:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">971-975.</span></p>
<p style="top:256.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">143. Carroll JK, Kohli S, Mustian KM, Roscoe JA, Morrow GR: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Pharma-</span></b></p>
<p style="top:264.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">cologic treatment of cancer-related fatigue.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Oncologist</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2007,</span></p>
<p style="top:273.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">12:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">43-51.</span></p>
<p style="top:281.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">144. Mustian KM, Morrow GR, Carroll JK, Figueroa-Moseley CD, Jean-</span></p>
<p style="top:290.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Pierre P, Williams GC: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Integrative nonpharmacologic behavio-</span></b></p>
<p style="top:298.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">ral interventions for the management of cancer-related</span></b></p>
<p style="top:307.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">fatigue.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Oncologist</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2007, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">12:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">51-67.</span></p>
<p style="top:315.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">145. Sheiner LB, Rubin DB: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Intention-to-treat analysis and the goals</span></b></p>
<p style="top:324.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">of clinical trials.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Clin Pharmacol Ther</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1995, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">57:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">6-15.</span></p>
<p style="top:332.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">146. Pampallona S, von Rohr E, van Wegberg B, Bernhard J, Helwig S,</span></p>
<p style="top:341.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Heusser P, Huerny C, Schaad H, Cerny T: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Socio-demographic and</span></b></p>
<p style="top:349.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">medical characteristics of advanced cancer patients using</span></b></p>
<p style="top:358.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">conventional or complementary medicine.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Onkologie</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2002,</span></p>
<p style="top:366.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">25:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">165-170.</span></p>
<p style="top:375.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">147. Concato J, Shah N, Horwitz RI: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Randomized, controlled trials,</span></b></p>
<p style="top:383.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">observational studies, and the hierarchy of research designs.</span></b></p>
<p style="top:392.0pt;left:330.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">N Engl J Med</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2000, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">342:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1887-1892.</span></p>
<p style="top:400.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">148. Benson K, Hartz AJ: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">A comparison of observational studies and</span></b></p>
<p style="top:409.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">randomized, controlled trials.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">N Engl J Med</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2000, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">342:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1886.</span></p>
<p style="top:417.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">149. Kunz R, Oxman AD: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">The unpredictability paradox: review of</span></b></p>
<p style="top:426.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">empirical comparisons of randomised and non-randomised</span></b></p>
<p style="top:434.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">clinical trials.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">BMJ. </span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1998, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">317(167):</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1185-1190.</span></p>
<p style="top:443.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">150. Rothwell PM: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">External validity of randomised controlled trials:</span></b></p>
<p style="top:451.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">&quot;To whom do the results of this trials apply?&quot;.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Lancet</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2005,</span></p>
<p style="top:460.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">365:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">82-93.</span></p>
<p style="top:468.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">151. Fritz P, Dippon J, Kierschke T, Siegle I, Mohring A, Moisa A, Murdter</span></p>
<p style="top:477.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">TE: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Impact of mistletoe lectin binding in breast cancer.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Anti-</span></i></p>
<p style="top:485.5pt;left:330.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">cancer Res</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2004, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">24:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1187-1192.</span></p>
<p style="top:494.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">152. Frantz M, Jung M-L, Rib&#xe9;reau-Gayon G, Anton R: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Modulation of</span></b></p>
<p style="top:502.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">mistletoe (</span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">L.) lectins cytotoxicity by carbohy-</span></b></p>
<p style="top:511.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">drates and serum glycoproteins.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Arzneimittelforschung. </span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2000,</span></p>
<p style="top:519.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">50(5):</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">471-478.</span></p>
<p style="top:528.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">153. Olsnes S, Stripe F, Sandvig K, Pihl A: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Isolation and characteriza-</span></b></p>
<p style="top:536.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">tion of Viscumin, a toxic lectin from </span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">L. (mistle-</span></b></p>
<p style="top:545.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">toe).</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">The Journal of Biological Chemistry</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1982, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">257:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">13263-13270.</span></p>
<p style="top:553.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">154. Seifert G, Jesse P, L&#xe4;ngler A, Reindl T, L&#xfc;th M, Lobitz S, Henze G,</span></p>
<p style="top:562.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Prokop A, Lode HN: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Molecular mechanisms of mistletoe plant</span></b></p>
<p style="top:570.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">extract-induced apoptosis in acute lymphoblastic leukemia</span></b></p>
<p style="top:579.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">in vivo and in vitro.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Cancer Lett</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2008, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">264:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">218-228.</span></p>
<p style="top:587.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">155. Thies A, Dautel P, Meyer A, Pfuller U, Schumacher U: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Low-dose</span></b></p>
<p style="top:596.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">mistletoe lectin-I reduces melanoma growth and spread in a</span></b></p>
<p style="top:604.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">scid mouse xenograft model.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Br J Cancer</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2008, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">98:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">106-112.</span></p>
<p style="top:613.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">156. Pryme IF, Bardocz S, Pusztai A, Ewen SW: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Suppression of growth</span></b></p>
<p style="top:621.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">of tumour cell lines in vitro and tumours in vivo by mistletoe</span></b></p>
<p style="top:630.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">lectins.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Histol Histopathol</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2006, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">21:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">285-299.</span></p>
<p style="top:638.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">157. Rostock M, Huber R, Greiner T, Fritz P, Scheer R, Schueler J, Fiebig</span></p>
<p style="top:647.0pt;left:330.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">HH: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Anticancer activity of a lectin-rich mistletoe extract</span></b></p>
<p style="top:655.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">injected intratumorally into human pancreatic cancer</span></b></p>
<p style="top:664.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">xenografts.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Anticancer Res</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2005, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">25:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1969-1975.</span></p>
<p style="top:672.5pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">158. Antony S, Kuttan R, Kuttan G: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Inhibition of lung metastasis by</span></b></p>
<p style="top:681.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">adoptive immunotherapy using Iscador.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Immunological Investiga-</span></i></p>
<p style="top:689.5pt;left:330.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">tions</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 1999, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">28:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">1-8.</span></p>
<p style="top:698.0pt;left:312.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">159. Antony S, Kuttan R, Kuttan G: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Role of natural killer cells in</span></b></p>
<p style="top:706.5pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Iscador mediated inhibition of metastasis by apoptive immu-</span></b></p>
<p style="top:715.0pt;left:330.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">notherapy.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Immunological Investigations</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2000, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">29:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">219-231.</span></p>


<p style="top:597.3pt;left:340.7pt;line-height:9.5pt"><span style="font-family:DtjmlfFrutiger,serif;font-size:9.5pt">Publish with </span><span style="font-family:RyfdclFrutiger,serif;font-size:9.5pt;color:#186d9d">Bio</span><span style="font-family:RyfdclFrutiger,serif;font-size:9.5pt;color:#006e6a">Med</span><span style="font-family:RyfdclFrutiger,serif;font-size:9.5pt;color:#72797f"> Central  </span><span style="font-family:DtjmlfFrutiger,serif;font-size:9.5pt"> and  every </span></p>
<p style="top:607.9pt;left:338.6pt;line-height:9.5pt"><span style="font-family:DtjmlfFrutiger,serif;font-size:9.5pt">scientist can read your work free of charge</span></p>
<p style="top:624.0pt;left:329.6pt;line-height:7.0pt"><i><span style="font-family:KnxpcmFrutiger,serif;font-size:7.0pt">&quot;BioMed Central will be the most significant development for </span></i></p>
<p style="top:633.9pt;left:328.6pt;line-height:7.0pt"><i><span style="font-family:KnxpcmFrutiger,serif;font-size:7.0pt">disseminating the results of biomedical research in our lifetime.&quot;</span></i></p>
<p style="top:645.4pt;left:342.6pt;line-height:6.5pt"><span style="font-family:DtjmlfFrutiger,serif;font-size:6.5pt">Sir Paul Nurse, Cancer Research UK</span></p>
<p style="top:658.6pt;left:336.5pt;line-height:8.0pt"><span style="font-family:DtjmlfFrutiger,serif;font-size:8.0pt">Your research papers will be:</span></p>
<p style="top:671.7pt;left:342.1pt;line-height:7.0pt"><span style="font-family:DtjmlfFrutiger,serif;font-size:7.0pt">available free of charge to the entire biomedical community</span></p>
<p style="top:684.2pt;left:341.9pt;line-height:7.0pt"><span style="font-family:DtjmlfFrutiger,serif;font-size:7.0pt">peer reviewed and published immediately upon acceptance</span></p>
<p style="top:697.0pt;left:341.9pt;line-height:7.0pt"><span style="font-family:DtjmlfFrutiger,serif;font-size:7.0pt">cited in PubMed and archived on PubMed Central </span></p>
<p style="top:709.4pt;left:341.6pt;line-height:7.0pt"><span style="font-family:DtjmlfFrutiger,serif;font-size:7.0pt">yours &#x2014; you keep the copyright</span></p>
<p style="top:724.8pt;left:316.1pt;line-height:6.0pt"><span style="font-family:DtjmlfFrutiger,serif;font-size:6.0pt">Submit your manuscript here:</span></p>
<p style="top:732.7pt;left:315.9pt;line-height:5.5pt"><span style="font-family:DtjmlfFrutiger,serif;font-size:5.5pt">http://www.biomedcentral.com/info/publishing_adv.asp</span></p>
<p style="top:721.9pt;left:488.4pt;line-height:8.5pt"><b><span style="font-family:HkmjxyFrutiger,serif;font-size:8.5pt;color:#186d9d">Bio</span></b><b><span style="font-family:HkmjxyFrutiger,serif;font-size:8.5pt;color:#006e6a">Med</span></b><span style="font-family:DtjmlfFrutiger,serif;font-size:8.5pt;color:#434b4c">central</span></p>
<p style="top:41.9pt;left:54.1pt;line-height:9.0pt"><i><span style="font-family:Arial,serif;font-size:9.0pt">Journal of Experimental &amp; Clinical Cancer Research</span></i><span style="font-family:Arial,sans-serif;font-size:9.0pt"> 2009, </span><b><span style="font-family:Arial,serif;font-size:9.0pt">28</span></b><span style="font-family:Arial,sans-serif;font-size:9.0pt">:79</span></p>
<p style="top:41.9pt;left:405.7pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">http://www.jeccr.com/content/28/1/79</span></p>
<p style="top:757.4pt;left:497.1pt;line-height:9.0pt"><span style="font-family:Arial,sans-serif;font-size:9.0pt">Page 33 of 33</span></p>
<p style="top:770.1pt;left:430.7pt;line-height:7.0pt"><i><span style="font-family:Arial,serif;font-size:7.0pt">(page number not for citation purposes)</span></i></p>
<p style="top:86.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">160. Teicher BA, ed: </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Tumor models in cancer research</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> Totowa, New Jersey:</span></p>
<p style="top:94.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Humana Press; 2001. </span></p>
<p style="top:102.9pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">161. Srivastava PK: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Immunotherapy of human cancer: lessons from</span></b></p>
<p style="top:111.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">mice.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Nature Immunology</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2000, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">1:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">363-366.</span></p>
<p style="top:120.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">162. C&#xe9;spedes MV, Casanova I, Parre&#xf1;o M, Mangues R: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Mouse models</span></b></p>
<p style="top:128.4pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">in oncogenesis and cancer therapy.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Clin Transl Oncol</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2006,</span></p>
<p style="top:137.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">8:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">318-329.</span></p>
<p style="top:145.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">163. Stein GM, Berg PA: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Adverse effects during therapy with mistle-</span></b></p>
<p style="top:153.9pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">toe extracts.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  In </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Mistletoe. The Genus Viscum</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> Edited by: B&#xfc;ssing A.</span></p>
<p style="top:162.5pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">Amsterdam, Hardwood Academic Publishers; 2000:195-208. </span></p>
<p style="top:171.0pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">164. Bauer C, Oppel T, Rueff F, Przybilla B: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Anaphylaxis to viscotoxins</span></b></p>
<p style="top:179.4pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">of mistletoe (Viscum album) extracts.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Ann Allergy Asthma Immu-</span></i></p>
<p style="top:188.0pt;left:72.1pt;line-height:8.0pt"><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">nol</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2005, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">94:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">86-89.</span></p>
<p style="top:196.5pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">165. Hutt N, Kopferschmitt-Kubler M, Cabalion J, Purohit A, Alt M, Pauli</span></p>
<p style="top:204.9pt;left:72.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">G: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Anaphylactic reactions after therapeutic injection of mis-</span></b></p>
<p style="top:213.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">tletoe (</span></b><b><i><span style="font-family:FslmpdGillSans,serif;font-size:8.0pt">Viscum album </span></i></b><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">L.).</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Allergol Immunopathol (Madr)</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2001,</span></p>
<p style="top:222.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">29:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">201-203.</span></p>
<p style="top:230.4pt;left:54.1pt;line-height:8.0pt"><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">166. Grossarth-Maticek R, Ziegler R: </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">Randomised and non-ran-</span></b></p>
<p style="top:239.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">domised prospective controlled cohort studies in matched-</span></b></p>
<p style="top:247.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">pair design for the long-term therapy of breast cancer</span></b></p>
<p style="top:256.0pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">patients with a mistletoe preparation (Iscador): a re-analy-</span></b></p>
<p style="top:264.5pt;left:72.1pt;line-height:8.0pt"><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">sis.</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">  </span><i><span style="font-family:TqhvmgGillSans,serif;font-size:8.0pt">Eur J Med Res</span></i><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt"> 2006, </span><b><span style="font-family:DrpfqgGillSans,serif;font-size:8.0pt">11:</span></b><span style="font-family:DdhngrGillSans,serif;font-size:8.0pt">485-495.</span></p>

</div>
